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The importance of reactive oxygen species (ROS) is illustrated by their crucial roles in 
immunology and disease pathologies. ROS can activate redox-dependent transcription factors, 
promoting a host of proinflammatory immune responses that are exacerbated during oxidative 
stress. The aim of this thesis is to determine how redox modulation impairs self-reactivity and 
aberrant inflammation in diabetes. Prevention of CD4+ TH1 T cell activation is critical for 
restricting autoreactive immune responses and maintaining pancreatic β cell integrity in type 1 
diabetes. Moreover, decreasing the inflammatory milieu and subsequent complications is 
necessary for restoring insulin sensitivity in type 2 diabetes. Although current 
immunosuppressive therapies are invaluable for transplantations, small molecule inhibitors with 
low toxicity are necessary for stopping autoreactivity and treating inflammatory-driven 
metabolic diseases. We utilized a catalytic antioxidant (CA) in diabetogenic models based on 
previous work demonstrating that redox modulation promotes T cell hyporesponsivness and 
impairs innate cell cytokine secretion by blocking NF-κB activation. Additionally, CA sustains 
health of isolated islets, delays islet allograft rejection, and inhibits transfer of diabetes into 
young NOD.scid mice. 
First, the mechanisms behind CA-mediated CD4+ TH1 T cell hyporesponsivness were 
investigated in vitro and in vivo using diabetogenic murine experiments with a focus on the 
redox-dependent sheddase TACE and one of its substrate, LAG-3, a negative regulator of T cell 
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activation. Ability to track type 1 diabetes progression through a serum biomarker, soluble LAG-
3, was also assessed from both murine and human samples. Next, CA-mediated alteration(s) of 
immune cell metabolism was characterized. Effects on glycolysis and oxidative phosphorylation 
were assessed to determine additional mechanisms of regulation and where treatment efficiency 
wanes. Lastly, redox modulation was evaluated in treatment of high-fat diet-induced type 2 
diabetes. Markers of inflammation and diabetic complications were measured to ascertain the 
severity of insulin resistance. 
 Collectively, this work is a distinct contribution to the knowledge of CA treatment and its 
ability to 1) inhibit diabetogenic TH1 responses through regulation of a redox-dependent 
metalloprotease and subsequent cleavage of a negative T cell surface marker; 2) prevent self-
reactivity through metabolic regulation; and 3) reduce inflammation and complications in high-
fat diet-induced type 2 diabetes. 
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1.0  INTRODUCTION 
1.1 TYPE 1 DIABETES 
Type 1 diabetes or insulin-dependent diabetes mellitus is an autoimmune disorder involving 
immune-mediated recognition of islet beta cells by autoreactive T cells. The self-reactive T cell 
response leads to the liberation of ROS and proinflammatory cytokines, resulting in the 
destruction of pancreatic beta cells in the islets of Langerhans and loss of insulin secretion. 
Insulin deficiency causes increased blood glucose levels and hyperglycemic side effects. Patients 
with type 1 diabetes must constantly prevent hyperglycemia by administering exogenous insulin 
or in the situation of severe hyperglycemic unawareness, by undergoing islet transplantation. 
Although the majority of the cases of diabetes affecting children are of the type 1 subset, adults 
are also susceptible. In particular, genetic predisposition based on the human leukocyte antigen 
(HLA) genotype is one of the main risk factors for type 1 diabetes (1-3). Individuals at the 
highest risk for type 1 diabetes development have the DR3/4-DQ8 HLA haplotype, which is 
often screened for in first-degree relatives of patients with diabetes (4; 5). In addition, a host of 
putative environmental triggers such as viral infection, infant diet, and cold weather have been 
hypothesized to contribute to the activation of autoreactive T cells and disease vulnerability.  
Particularly, coxsackie B4 virus (CVB4) has been implicated as one of the viral infections that 
can trigger onset of disease (6). CVB4 is capable of infecting the pancreatic beta cells, which 
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results in local inflammation, damage, and release of islet antigens that could potentially 
stimulate autoreactive T cells (6). Despite the cause, type 1 diabetes is ultimately due to a loss of 
beta cells mediated by autoreactive T cell attack (2). 
Type 1 diabetes affects people in all geographical locations, but has a high incidence rate 
in people living in North America and Europe (7). The worldwide frequency of type 1 diabetes is 
expected to double within the next 15 years (8). Childhood incidence is of special interest, since 
the majority of type 1 diabetes patients are juveniles. In a study conducted in 2000, Finland, 
Sardinia, Portalegre, Puerto Rico, and Canterbury were found to have the highest numbers of 
type 1 diabetes cases, particularly in the 10-14 age range (7), and the global distribution patterns 
had not changed significantly since the 1970s. These results illustrate that certain locations have 
a higher susceptibility of developing type 1 diabetes, as further supported by a map arranged by 
the International Diabetes Federation (Figure 1). Together, type 1 and type 2 diabetes, which is 
characterized by a loss of insulin sensitivity mainly occurring in obese individuals (8) (discussed 
in Chapter 4), afflicts more than 194 million people all over the world, with at least 10% of the 
U.S. cases being type 1 (9). With epidemiological advances enabling better disease monitoring, 
the prevalence of cases around the globe justifies type 1 diabetes as a true chronic epidemic. 
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Figure 1: New cases of type 1 diabetes (0-14 years per 100,000 children per year), 2011. Used 
with permission from the International Diabetes Federation (10).  
1.2 OXIDATIVE STRESS 
Oxidation-reduction or redox reactions are pivotal to maintaining life through respiration, 
metabolism, and energy supply. Mitochondria, which are known to be the powerhouses of the 
cell, possess the ability to utilize nutrients to generate energy (redox potential) via the electron 
transport chain, which donates electrons to oxygen to yield adenosine triphosphate (ATP) and 
H2O (11; 12). Consequently, oxygen free radicals, beginning with superoxide (O2
-
), are non-
enzymatically leaked from the mitochondria and react with other molecules to create other 
reactive oxygen species (ROS) such as hydrogen peroxide (H2O2), peryoxynitrite (ONOO-), and 
hydroxyl radical (OH-), all of which can alter DNA, proteins, carbohydrates, and nucleic acids 
(13-15) and may eventually lead to irreversible damage. The inability of a cell’s antioxidant 
defenses to prevent oxidative injury and accretion of severe ROS-mediated damage over time 
will eventually lead to cell death (15-17).  In order to maintain a reducing environment, several 
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cellular antioxidant defenses are in place, including glutathione, glutathione peroxidase (GPX), 
catalase, and three different superoxide dismutase (18) enzymes: SOD1, 2, and 3, located in 
different sub-cellular and extracellular locations. A basal level of “accidental” superoxide is 
accumulated in healthy individuals (11; 19), which has been widely hypothesized to be 
responsible for aging and the associated pathologies (20-22). Redox reactions are imperative to 
preserving cellular metabolism yet must be strictly regulated. Imbalances between ROS and 
antioxidants can initiate oxidative stress, which without proper resolve, can manifest into 
disease. During chronic oxidative stress caused by environmental factors (i.e. UV light, ionizing 
radiation, toxic substances), infections, or lack of dietary antioxidants, an inequity of cellular 
reducing equivalents capable of detoxifying the increased burden of ROS has marked effects on 
normal cellular processes. However, in times of oxidative stress, normal cellular respiration is 
also still functioning, resulting in dsyregulated mitochondrial free radical production and 
disparity between ROS generation and antioxidant defenses (16; 23). The combination of stress-
induced and conventional mitochondrial dysfunction can manifest into disease states, including 
cancer (24-26), rheumatoid arthritis (27; 28), neurological disorders (29-32), pulmonary diseases 
(33), and type 1 diabetes (34-37).    
Once was thought to be solely derived from the mitochondria, reactive oxygen species 
have now been shown to be produced by an important family of enzymes that play a role in the 
immune system (38-40). The NADPH oxidase (NOX) enzymes are designed to combine 
NADPH and oxygen to actively generate superoxide. Activated phagocytes, such as 
macrophages, monocytes, and dendritic cells (DCs), as well as neutrophils, form ROS within the 
phagosomal membrane for efficient killing of a wide array of invading pathogens (41). The 
protection afforded by the phagocytes is crucial, but not without side effects. Production of 
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highly permeable reactive oxygen species (i.e. H2O2) causes leakage of these molecules from 
phagocytes and therefore, unwanted effects on bystander cells (42; 43). In an environment high 
in oxidative stress, these bystander reactions drive increased activation of the immune system, 
cell damage, and progression to disease. For example, NOX-derived ROS have been shown to 
stimulate mitogenic signaling and proliferation (44; 45), which can have potentially deleterious 
consequences on the promotion of tumorigenesis (46; 47) and in the context of autoimmunity, 
can lead to T cell expansion (48). Additionally, H2O2 can augment monocyte chemokine receptor 
surface expression critical for migration to sites of infection and inducing inflammation (49), and 
can promote VEGF signaling to trigger angiogenesis, with implications in cancer metastasis and 
tumor progression (50). Furthermore, ROS generated from both mitochondria and NADPH 
oxidase complexes can act intra-cellularly as well as inter-cellularly as signal transduction 
molecules. Hydrogen peroxide has been shown to inactivate protein phosphatases (51), as well as 
to activate protein tyrosine kinases (52; 53) and metalloproteases, through the oxidation of 
critical cysteine residues (54; 55). Phosphatases such as SHP-1 serve to decrease inflammation 
by inhibiting tyrosine kinase activity, yet this type of regulation is lost upon cysteine oxidation 
(56-59). Similarly, latent metalloproteases require oxidation for activation and, in the presence of 
hypochlorous acid (HOCL) and H2O2, secretion of chemotactic mediators (L-selectin and 
proinflammatory TNFα) is highly increased (60), thus enhancing inflammation. In addition, 
H2O2 has been demonstrated to freely cross the plasma membrane and activate NF-κB, a redox-
dependent transcription factor (61; 62). NF-κB plays a major role in immunity by promoting 
proinflammatory cytokine production, cell proliferation, and inflammation. In general, receptor-
ligand interactions are known to generate ROS (63; 64). LPS can facilitate the binding of toll-
like receptor 4 (TLR4) to NADPH oxidase 4 (Nox4), causing a subsequent release of ROS (65), 
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resulting in the activation of NF-κB and generation of proinflammatory cytokines IL-1β and 
TNFα (64).  In a highly oxidized environment, the binding of pathogens to innate cell receptors 
can lead to hyperresponsiveness (66), suggesting that inflammation is secondary to oxidative 
stress (36; 67).  Not only are phagocytic cells critical for early pathogen recognition through 
receptor-ligand interaction, they are also necessary for activation of the adaptive immune 
response.  Following antigen recognition by phagocytic antigen-presenting cells (APC), an 
adaptive immune response develops in secondary lymphoid organs, through synapse formation 
of APCs with lymphocytes, as well as from critical innate-derived ROS and third signal 
proinflammatory cytokines (TNFα, IL-1β) enhancing T cell activation, proliferation, and effector 
function (48; 68). APC engagement with T cells first occurs between MHC-peptide and the TCR, 
known as the first signal. Second signal is a costimulatory signal, including T cell CD28 
interaction with CD80/CD86 molecules on the APC surface. The soluble ‘third’ signal is made 
up of cytokines and ROS, critical for the differentiation of T cells into specific lineages and for 
promoting effector functions (69; 70). Within this interaction, the H2O2 made by the phagocytes 
is able to traverse the synapse and act upon the T cells, at concentrations ranging from 10-100 
µM (71; 72), resulting in a feed-forward mechanism stimulating T cell-specific NF-κB activity 
and subsequent proinflammatory cytokine production. Similar effects of ROS are also seen on B 
cells (73). Moreover, antigen stimulation of the T cell receptor (74) also drives endogenous 
production of H2O2 through the T cell’s own NOX enzyme (39; 75). Intracellular H2O2, 
depending on the abundance and the context, can then signal and lead to T cell proliferation (75; 
76), T cell effector function (48; 63; 77) or at high doses, cause apoptosis (75; 76).  Therefore, in 
the presence of oxidative stress, an inability to balance oxidation with antioxidant enzymes can 
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drive chronic inflammation from both the innate and adaptive arms of the immune response (78), 
manifesting into many clinically-relevant diseases, such as type 1 diabetes. 
1.3 OXIDATIVE STRESS IN TYPE 1 DIABETES 
Despite a multitude of efforts in trying to specify the exact etiology, the cause of type 1 diabetes 
is still not fully elucidated. The combinatorial effects of genetic susceptibility, environmental 
factors, and dietary deficiencies are known to contribute to disease origin; however, the impact 
of oxidative stress in a genetically susceptible individual is of particular interest.  Oxidative 
stress, as stated above, occurs when the generation of ROS overcomes the scavenging abilities of 
antioxidants. Such instances may be mediated by genetic lack of antioxidant enzymes as well as 
environmental triggers like viral infections. Overall, oxidative stress has been linked to beta cell 
cytotoxicity (79-81) and has been suggested to play a role in type 1 diabetes pathology (82-85). 
Several studies show that the total serum antioxidant status, as measured by urate, Vitamin C, 
and total plasma antioxidant levels, of prediabetic and type 1 diabetes patients is lower in 
comparison to age-matched controls (86; 87), which inevitably leads to greater oxidative 
modification of proteins and lipids (88). Other literature illustrates a connection between viruses, 
ROS production, and type 1 diabetes onset. ROS are made following viral infection from 
activated phagocytes (89; 90), as mentioned previously, and work to not only cause cellular 
injury but also can activate inflammatory, redox-dependent transcription factors, such as NF-κB, 
perpetuating inflammation. Viral-mediated ROS production or a reduction in antioxidants can 
have severe consequences, as beta cells are more prone to oxidative damage than most other 
tissues. The beta cell mitochondria have exceptionally low levels of the phase II enzymes 
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glutathione peroxidase, superoxide dismutase, and catalase (35; 91-93). Because of this low 
antioxidant defense, beta cells can be clearly disrupted by oxidative stress, and in genetically 
predisposed individuals, result in easy targets for a subsequent cytokine-mediated autoimmune 
attack.   Mitochondrial and NOX-derived ROS both have implications in beta cell 
destruction and type 1 diabetes. Increased glucose causes rapid induction of the tricarboxylic 
acid (TCA) cycle within the beta cell mitochondria, which not only causes greater energy 
production but also leads to augmented ROS generation (94). The superoxide leaked from 
mitochondria can then form H2O2 and work to uncouple glucose metabolism from insulin 
secretion (95). Ultimately, high levels of mitochondrial ROS can cause beta cell death (96; 97).  
Intriguingly, models of type 1 diabetes induce disease by generating toxic amounts of ROS 
within the islets (i.e. streptozotocin and alloxan) (98). Alloxan is easily taken up by beta cells 
(99), where it is reduced into dialuric acid and subsequently reoxidized to establish a redox cycle 
(100). ROS generated by alloxan treatment have been shown to promote islet beta cell DNA 
fragmentation, culminating in cell death (101). In contrast, an alloxan-resistant strain of mice, the 
ALR mouse, shows increased ROS dissipation and resistance to islet destruction (34; 102; 103), 
further implicating the importance of oxidative stress in type 1 diabetes. Streptozotocin (STZ), 
on the other hand, causes beta cell DNA alkylation and eventually drains the cellular 
nicotinamide adenine dinucleotide (NAD+) and ATP source in an effort to repair the DNA (104). 
Xanthine oxidase is then able to utilize dephosphorylated ATP as a substrate for superoxide 
production (105). Additionally, STZ metabolism increases the levels of islet cell nitric oxide 
(NO) (106), which together with superoxide can generate ONOO-. Detection of ONOO- in 
prediabetic nonobese diabetic (NOD) mouse islets (107) suggests the importance of this source 
of ROS in beta cell death (85). Similarly, NOX enzymes have been detected within the 
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pancreatic beta cells (108; 109). Hyperglycemia can increase the assembly of NOX enzymes 
through its p47phox subunit, and therefore, enhance superoxide generation (110) and facilitate 
beta cell death. 
1.3.1 General immunology of type 1 diabetes 
Autoimmune diseases manifest from a complex immune response involving players of both 
innate and adaptive immunity, leading to loss of self tolerance. In type 1 diabetes, the exact 
mechanism(s) by which each arm of the response initiates and furthers the disease is still not 
entirely clear. Genetic predisposition is a susceptibility factor in type 1 diabetes, yet the 
reactivity towards an autoantigen is the critical immunological trigger that eventually elicits 
disease (1; 3). 
Autoantigens are self-molecules present in the host that under the right circumstances 
have the ability to stimulate an immune response. Innate cells process and present self antigens 
to members of the adaptive immune system. Autoantibodies and autoreactive T cells interact 
with autoantigens to drive type 1 diabetes pathogenesis. In type 1 diabetes, the presence of 
autoantibodies was discovered by detecting the reaction of serum with sections of human 
pancreas (111). The exact molecules recognized by the antibodies are islet cell surface and 
cytoplasmic autoantigens. Such antigens associated with type 1 diabetes include glutamic acid 
decarboxylase 65 (GAD65), protein tyrosine phosphatase (IA2), and insulin (IAA) (111; 112). 
GAD65 is an enzyme present in human beta, alpha, and delta cells that mediates GABA 
synthesis and in conjunction with another islet expressed protein, IA2, is accountable for the 
strongest autoantibody recognition of pancreatic islets (111). Insulin, along with its precursor 
proinsulin, are the only known autoantigens specifically to the beta cells (113). Other molecules 
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demonstrated as potential autoantigens include: ICA12, osteopontin, nephrin, CD38, heat shock 
protein 65, rat-specific ICA69, chromogranin-A and the zinc solute carrier, ZnT8 (111; 114; 
115). 
1.3.2 Contribution of the innate immune system in type 1 diabetes pathology 
The innate immune system is responsible for providing the initial defense and regulation when 
the host encounters a foreign antigen (116). Its function, in turn, is to eventually stimulate the 
adaptive response for a more specified and powerful protection. However, if the innate system is 
unable to properly engage and activate the adaptive cells, it may be the first breach in a cascade 
of normally appropriate events that will lead to subsequent failures and autoimmunity.  
NOD mice spontaneously develop type 1 diabetes, characterized by an early infiltration 
of dendritic cells and macrophages into the islets, prior to lymphocytic infiltrate. This infiltrate of 
accessory cells is the first sign of autoimmunity (117; 118) Since dendritic cells are thought to be 
the only APC able to activate naïve T cells, their function in autoimmunity is as important as 
their adaptive immune counterparts (116; 119). Like typical T cell activation, autoreactive T 
cells are also primed by DCs that migrate to the thymus after antigen uptake (120). The specific 
antigen recognized by and mechanism of activation of DCs that mediate type 1 diabetes are still 
only speculative. DCs may be activated by environmental factors, the recognition of islet-
associated proteins, or through interactions with already activated resident macrophages (6; 116). 
As mentioned previously, CVB4 infection has been linked to type 1 diabetes onset (6).  One such 
scenario could involve viral infection of the beta cells where the damage that occurs influences 
the production of proinflammatory cytokines and a local immune response. Usually, the 
cytokines promote a response against the virus and in non-predisposed individuals, clearance of 
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infection without exacerbated incident. However, in genetically susceptible individuals, this 
cytokine burst can be the trigger point that initiates an autoimmune response. The cytokines 
produced can cause the mobilization of endogenous antigen, referred to as cryptic epitopes, 
which can be taken up by resident DCs to activate autoreactive T cells via a bystander approach, 
or to elicit an initial strong response that eventually subsides and reveals other epitope targets, a 
process known as epitope spreading (6; 121-123). Following viral recognition by DCs in 
susceptible individuals, there is an upregulation of costimulatory molecules that can actually 
lower the threshold for the activation of autoreactive T cells (116). Primed T cells can then home 
to the pancreas and cause greater damage of the beta cells. In addition to viral-mediated 
autoreactive mechanisms, pancreatic DCs have also been shown to recognize CD154 (CD40 
ligand) molecules transgenically expressed on beta cells followed by migration to the lymph 
nodes to stimulate autoreactive T cells and cause insulitis (120). Hsp60, which is a heat shock 
protein expressed on the surface of beta cells during islet inflammation, is another molecule that 
can be seen as a danger signal for the DCs (116; 124). These data demonstrate that the presence 
of certain molecules on the surface of pancreatic cells, and not just those that are liberated after 
inflammatory damage, can also activate the DCs. Besides direct recognition of islet-associated 
molecules, DCs can be induced to better present self-antigens as well (116; 119). Despite their 
role in tolerance and the stimulation of Tregs in protecting against type 1 diabetes (125), 
plasmacytoid DCs that phagocytose apoptotic cells have been shown to release IFN-α (126), 
which can enhance the ability of conventional DCs to present self-antigens (119).  
Although resident macrophages are present in the pancreas at all times, acquisition of 
antigen is required for macrophage activation and the production of cytokines. As described 
above, genetic and environmental factors can lead to cell destruction, releasing beta cell-specific 
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antigens as well as ROS (127). The ROS created by the initial insult to the islets are able to 
stimulate the activation of redox-dependent NF-κB and other transcription factors within the 
macrophages (128). Activated macrophages secrete a mixture of proinflammatory cytokines such 
as TNFα, IL-6, IL-1β, and more ROS, which can initiate damage of the pancreatic beta cells 
(129-131). IL-1β can cause extensive cytolysis of beta cells (132) through the upregulation of 
iNOS and subsequent generation of NO (133; 134). By contrast, TNFα enhances IL-1β-mediated 
islet destruction through activation of APCs and T cells (135-137), but does not cause direct beta 
cell apoptosis in vivo (137).  Like DCs, macrophages will also phagocytose dying beta cells and 
present antigen in the context of their MHC molecules. Subsequent to antigen presentation, 
macrophages will release cytokines and ROS that can help to direct the innate response in 
activating other cells such as DCs, αβ T cells, natural killer (NK), natural killer T (NKT), and γδ 
T cells (116). In addition, the combination of NO, IL-1β, and TNF-α produced by recruited 
macrophages can have detrimental effects by mediating islet cytotoxicity and  beta-cell death 
(138). Macrophages from NOD mice have also been described as being deficient in 
phagocytosis, especially in the uptake of apoptotic cells (116). Phagocytosis, in this regard, helps 
to limit inflammation caused by the presence of recently killed cells. If macrophages are unable 
to engulf the anti-inflammatory apoptotic cells, these cells could progress to a necrotic state and 
elicit greater inflammation near the islets, leading to even more beta cell death (139).  
NK and NKT cells are also implicated in type 1 diabetes. NK cells are one of the first 
cells, along with DCs and macrophages, to migrate into the pancreas prior to disease onset (119). 
These cells themselves do not cause disease, but can interact with autoreactive conventional T 
cells to stimulate their proliferation and activation (119). However, NK cells can also carry out 
regulatory functions in the pancreatic infiltrate. For instance, NK cells can directly lyse immature 
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DCs (116), since DCs present at the pancreas before antigen recognition have low levels of MHC 
class I expression. Oxidative stress has been linked to reduced NK cell numbers and expression 
of their activation receptor (140; 141). Similarly, NKT cells, which bridge the gap between 
innate and adaptive immune cells, also have important regulatory functions in autoimmunity. 
NKT cells are reactive to CD1d (142), a rare antigen-presenting molecule. A decrease in CD1d-
restricted NKT cells correlates with an increase in diabetes expression in both NOD mice and 
humans (116; 119). CD1d-NKT cells play regulatory roles in immunity, based on their ability to 
produce large amounts of IL-4, which skews T cells to a TH2 subset (116). Cytokines released 
from TH2 cells inhibit the development of the TH1 subset, which is the major population of CD4+ 
cells involved in type 1 diabetes, as discussed below (143-146). After CD1d-NKT cell transfer, 
diabetes risk is partially reduced in NOD mice (147). Notably, NOD mice have deficiencies in 
both NK and NKT cells (148; 149) 
Overall, DCs, macrophages, NK, and NKT cells have all been identified as having some 
abnormalities in patients with type 1 diabetes (116; 119). Therefore, if people are genetically 
susceptible to disease, modulation of the innate immune system could be valuable in prevention 
and treatment of disease. Although necessary for an initial defense, the innate immune system 
does not elicit as potent a response as the adaptive immune system. ROS and cytokines released 
by APCs not only promote beta cell damage, but also help to generate an adaptive immune 
response, which in type 1 diabetes, is the crucial step in autoimmune destruction. It is well 
established that chronic exposure of antigens to innate immune cells in a highly oxidized 
environment will lead to MHC-peptide presentation, perpetuating an adaptive immune response 
(150; 151) (Figure 2) The adaptive B cell-produced antibodies in type 1 diabetes are responsible 
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for disease prediction and can act in combination with innate molecules to cause even more 
damage that leads to beta cell loss (116; 144-147; 152; 153). 
 
 
Figure 2: Role of redox in the immunopathology of type 1 diabetes.  An initial genetic 
predisposition or environmental insult to the beta cell triggers the release of beta cell antigens as 
well as the production of ROS. Beta cell antigens are phagocytosed, and ROS are able to 
stimulate redox-dependent transcription factors such as NF-κB, which leads to APC activation 
and cytokine secretion. ROS and proinflammatory cytokines secreted by APCs act as the third 
signal within the T cell-APC immunological synapse, which occurs in the pancreatic lymph 
node. ROS play a critical role in the progression of naïve TH0 cells to cytokine-secreting TH1 
cells. Release of IFNγ by TH1 cells then works directly on the beta cells as well as activates more 
APCs and CD8+ cells, all of which can impart deleterious effects on the islets (154). 
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1.3.3 Role of the adaptive immune system in type 1 diabetes pathology 
The adaptive response is primarily made up of B and T cells. Each of these cells produces a 
surface and/or soluble receptor that are specific for the antigen presented by the innate immune 
cells. B cells first produce a B cell receptor (BCR) and then later differentiate into antibody-
secreting plasma cells, whereas T cells only generate a membrane-bound TCR (74). In type 1 
diabetes, B cells have relatively unclear mechanisms for contributing to disease. Prior to diabetes 
onset, autoantibodies formed against islet autoantigens can be detected at high levels in the 
serum (111; 155). Antibodies against more than one autoantigen, along with HLA genotyping, 
can reliably predict diabetes susceptibility (111). Despite their formation, however, if mouse 
antibodies are transferred into a naïve murine host, they do not cause disease (111; 155). 
Therefore, the autoantibodies themselves are not sufficient to trigger disease onset, which is a 
paradox to passive immunity. However, more in depth studies have linked the autoantibodies to 
other possible pathogenic mechanisms. Soluble autoantibodies can activate the innate immune 
response through either Fc receptors or complement receptors and further drive the activation of 
NKT cells, mast cells, macrophages, or γδ T cells that drive the inflammatory response (156; 
157). The membrane-bound forms of antibodies, or the BCR itself, also have mechanisms 
attributing to disease. Autoantibodies that remain attached to B cell surfaces can help to improve 
antigen capture and presentation through MHC class II, characterizing B cells as APCs for CD4+ 
T cell activation (158). Along with DCs and macrophages, B cells have also been detected in the 
infiltrate of the pancreatic islets preceding insulitis (155). Depleting B cells through the use of an 
anti-CD20 monoclonal antibody, rituximab, decreases diabetes incidence in NOD mice and most 
likely acts to generate regulatory B cell populations that help control disease, especially in an 
adoptive transfer model (155). Rituximab clinical trials in recent onset patients show a reduction 
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in the amount of insulin needed after one year of treatments; however, differences between 
control and treated groups are absent after two years, making the therapy only temporarily 
efficacious (159). Although the exact mechanisms by which B cells contribute to type 1 diabetes 
are unclear, antibody formation and the ability of B cells to present antigens are helpful in 
predicting diabetes and priming the autoreactive T cells, respectively. 
Autoreactive T cells are the main effectors of the beta cell damage and apoptosis that 
eventually lead to the onset of type 1 diabetes. Unlike B cells, T cells can directly promote 
apoptosis through cell lysis and the production of proinflammatory cytokines that induce stress 
upon the highly sensitive beta cells (116; 144-147; 152; 153). In the context of continuous beta 
cell ablation in the beginning stages of type 1 diabetes, APCs phagocytose dying cells and 
migrate to the pancreatic lymph node to interact with naïve T cells via the immunological 
synapse. It is this interaction that enables T cell proliferation and effector function to occur. In 
the presence of all three necessary signals: 1) MHC-peptide, 2) costimulation, and 3) soluble 
third signal (in this case consisting of ROS, IL-1β and TNFα), T cells become activated via 
NFAT and NF-κB (160-164). Furthermore, IL-12 released from APCs can differentiate CD4+ T 
cells into the TH1 lineage via signaling through STAT4 (165-168). The specific cytokines 
produced depend on the subset of CD4+ helper T cells involved in the pathogenesis. T helper 
cells can be divided into several populations: TH1, TH2, TH17, and T follicular helper (TFh) cells. 
TH1 cells are involved in cellular immunity, which increases the killing abilities of both 
macrophages and cytotoxic T lymphocytes (CTL), and produce cytokines such as IFN-γ, TNF-α, 
IL-1β and IL-2 (145; 146). TH2 cells help to increase B cell proliferation, antibody production, 
and produce cytokines such as IL-4, IL-5, IL-6, IL-10, and IL-13 (146). TH17 cells produce IL-
21, IL-22, and IL-17, and TFh cells generate IL-2, IL-10, and IL-21 (169). An imbalance of 
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TH1/TH2 is known to be involved in the pathogenesis of type 1 diabetes (146). Several instances 
have been discovered in which promoting TH2 subsets through overexpression of IL-4 (170), 
blocking IL-12-induced TH1 differentiation (146), using an anti-IFN-γ antibody (171) or 
negatively vaccinating (172) in an effort to skew the immune response can actually reduce the 
incidence of disease. TH17 cells are thought to play harmful roles in mouse models of multiple 
sclerosis and collagen-induced arthritis (173). Despite early controversial studies (174-177), 
TH17 cells have also demonstrated pathogenic roles in type 1 diabetes, with increased levels in 
pancreatic islets (178) and the ability to enhance proinflammatory cytokine-induced apoptosis of 
human islets (179). A relatively new T helper cell subset, TFh cells, is important for helping B 
cells to produce antibodies within the germinal centers (180). In the context of type 1 diabetes, 
excessive TFh activity caused a breakdown of tolerance, the development of anti-islet antibodies 
and fast progression to diabetes (181). Additionally, IL-21, which is produced from TFh, is 
critical for pancreatic infiltration (182), making TFh a relevant population of T cells in type 1 
diabetes development. 
In classic type 1 diabetes pathology, CD4+ TH1 cells home to the site of antigen 
production, the beta cells, and recruit other T cells and more APCs through the secretion of 
IFNγ. IFNγ has some indirect effects on beta cells, including potentiating the maturation of 
pancreatic APCs, which can then elicit an even greater T cell response (183). Additionally, 
neutralization of IFNγ in NOD mice has been shown to reduce both diabetes and insulitis (171), 
whereas a null mutation in the IFNγR gene in NOD mice leads to delayed insulitis and inhibition 
of spontaneous diabetes (184). Proinflammatory cytokines TNFα, IL-1β, and IFNγ all play a role 
in beta cell death primarily through activation of redox-regulated transcription factors NF-κB and 
STAT1 (145; 185; 186). Combinations of TNFα with IFNγ or IL-1β are necessary for primary 
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murine beta cell death (187), and TNFα/IFNγ act synergistically to activate the stress-activated 
pro-apoptotic JNK/SAPK pathway, which promotes beta cell apoptosis via p53 and intracellular 
ROS (188). The activation of NF-κB can also increase iNOS and Fas expression, potential 
inducers of cell death, while downregulating the anti-apoptotic protein Bcl-2 (189). Apoptosis of 
beta cells is also mediated partially by T cell expression of Fas ligand, TNFα, and 
perforin/granzyme (137; 189). Specifically, CD4+ T cells are thought to be sufficient for type 1 
diabetes onset (144; 190), whereas CD8+ T cells seem to play in later stages of diabetes, being 
responsible for direct beta cell killing (191). CD4+ cells help to coordinate beta cell antigen-
specific damage indirectly through enhancing effector function of cytotoxic T lymphocytes 
(CTLs) (152; 153). It is known that synergy between both diabetogenic CD4+ and CD8+ T cells 
results in absolute transfer of diabetes in rodent models (192; 193).  Although specific to the 
model of autoimmune diabetes, TNFα secretion from CD4+ T cells can bind to TNFR1 on beta 
cells and cause apoptosis (194), while CD8+ T cells can kill NOD beta cells by a Fas-dependent 
mechanism (195) or by perforin release (196). CD8+ T cells can elicit an antigen-specific killing 
response via lysis of beta cells (152; 153) in much the same fashion as the lysis of virally 
infected cells. Ultimately, T cell exacerbation of beta cell death comes from endogenous 
generation of ROS and cytokines following APC activation (197) that can perpetuate islet 
destruction through a feed forward mechanism.  
 Regulatory T cells (Treg) are another adaptive cell subset important in type 1 diabetes 
resolution of pathogenesis. Tregs are specialized cells that suppress activation of effector T cells 
and preserve tolerance to self-antigens (198), making them highly important in controlling 
autoimmunity. Regulatory T cells are predominately CD4+Foxp3+ and curb activation and 
function of self-reactive T cells in the periphery. In type 1 diabetes, CD4+CD25+Foxp3+ Tregs 
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have been shown to play a role in disease inhibition (198), including the prevention of diabetes 
development in NOD mice (199-203). The suppression itself can be due to a number of different 
surface cell molecules present on Tregs (CTLA-4, LAG-3, and PD-1) as well as 
immunosuppressive cytokine release (IL-10, TGF-β) (204). CD8+ Tregs are also important in 
regulating autoimmune responses. CD8+CD25+Foxp3+ Tregs measured in a collagen-induced 
murine model of arthritis can reduce disease severity and suppress T cell effector function (205). 
Furthermore, CD8+CD122+ Tregs can localize to the central nervous system, decreasing 
inflammation in the experimental autoimmune encephalomyelitis murine model of multiple 
sclerosis (206). In the NOD mouse, CD8+ Tregs are important for GAD-induced transferred 
tolerance (207) and for reversal of autoimmunity (208). Another cell capable of immune 
suppression of type 1 diabetes is the αβ-TCR+CD3+CD4−CD8− double negative (DN) Treg cell. 
DN T cells mediate the inhibition of self-peptide reactive CD8+ T cells (209). DN T cells are 
considered unconventional regulatory cells because they are activated in an antigen-specific 
manner to directly kill effector T cells. DN Tregs first acquire peptide-MHC from APCs and then 
interact with effectors via Fas/FasL, which causes apoptosis of the autoreactive T cells. Human 
studies have identified a clear deficiency in Treg functionality in type 1 diabetes patients (210). 
The mechanism(s) behind this inadequacy has not been fully elucidated; however, no current 
evidence suggests an overabundance of ROS to be the culprit. In the context of an oxidative 
stress environment, Treg abilities are actually preserved. Instead, it is likely that the significant 
ROS-mediated TH1 inflammation plays a role in preventing sustained Treg suppression against 
self-antigen (211-213), resulting in hyperactivation and autoreactive T cell attack of the beta 
cells.   
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Despite the differences between the innate and the adaptive immune system, interplay 
between the two makes autoimmune diabetes an extremely complicated and contentious disease.  
Overall, ROS are crucial in not only activating the initial infiltrating macrophages and DCs (214) 
via the common denominator NF-κB, but also for subsequently driving an adaptive TH1 immune 
response that is necessary for total ablation of beta cells and progression to type 1 diabetes (189; 
190) (Figure 3). Therefore, therapies would be most beneficial if there was not only protection 
of the beta cells from ROS, but also inhibition of the ROS-mediated autoimmune attack, possibly 
by preventing NF-κB activation, the ensuing inflammation, and the initiation of the adaptive 
immune response. 
 
Figure 3: Islet infiltration in type 1 diabetes. Pancreata from NOD mice were taken at 
hyperglycemia (18 wks) or during euglycemia as a control. Sections stained with hematoxylin 
and eosin. 
1.4 TYPE 1 DIABETES THERAPY AND EFFORTS FOR PREVENTION 
Currently, the only mainstream treatment for type 1 diabetes is daily insulin injection. Because of 
the loss of insulin and impairment in blood glucose tolerance, several severe side effects may 
occur in type 1 diabetes patients if insulin levels are not exogenously and consistently 
maintained. Acute illnesses include ketoacidosis and hypoglycemia, whereas long term 
complications may include heart attack, stroke, poor wound healing, retinopathy, and 
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nephropathy (9), all of which are a burden on countries with limited healthcare systems. In the 
United States, people diagnosed with diabetes spend 2.3 times more on medical costs than those 
individuals without diabetes (215). With the costs of chronic disease treatment increasing 
annually (8), insulin, needles, and other diabetes testing supplies will only become more 
expensive. In addition, dysregulated glycemic control occurs in patients failing to manage their 
daily insulin levels (216). New studies are being conducted in order to eradicate costs and 
compliance issues of patients. One such study proposed the effectiveness of inhaled insulin 
(216); but upon establishment by Pfizer, the inhaler did not allow for precise insulin dosing 
delivery and was discontinued (217).  Beta cell and pancreas transplantations have also been 
implemented over the years; although like any transplant, immunosuppressive drugs must be 
taken long-term in order for the host not to reject the tissue (9) and several islet donors are 
typically needed per transplant (218). Unfortunately, only 44% of islet transplantation recipients 
remain insulin independent at 3 years post-transplant (219). Another highly promising area of 
research is the use of exogenous stem cell sources for reconstitution of insulin-producing beta 
cells (9; 220). Autologous inducible pluripotent stem cells may be a potential source of new beta 
cells, with studies in NOD mice proving successful for reversing diabetes (221; 222). However, 
the underlying issue with stem cells is effectively stopping the autoimmunity so as not to provide 
another source of antigen to already endogenously activated autoreactive T cells. Other means of 
treatment, preferably before onset, are thus a necessary consideration.  
With improvements in detecting susceptibility, type 1 diabetes is becoming a predictable 
disease. In addition, better immunological understanding of diabetes can help to identify 
autoantigens and clarify the mechanisms behind beta cell destruction. The window of time for 
preventative therapy, however, dwindles as prediction accuracy increases and beta cell mass 
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decreases (113) (Figure 4). Therefore, prophylactic treatments or diabetes vaccination are 
challenging but not entirely inconceivable. Different pharmacological agents or antibody 
administrations, such as mycophenolate mofetil (MMF) and anti-CD3, respectively, have the 
ability to translate into preventative treatments in humans and animal models (223; 224). Both of 
these therapeutics help in suppressing the autoimmune response. MMF has been shown to block 
activated T and B cell proliferation and antibody formation with enhanced specificity (223). 
Anti-CD3 treatment acts as a partial activating signal, inducing tolerance in T cells and skewing 
the response to more of a TH2 phenotype, increasing anti-inflammatory cytokines and inducing 
CD8+ regulatory T cell production (224; 225). A clinical trial was conducted in 2006 utilizing 
MMF alone or in combination with Daclizumab, which is a monoclonal antibody specific for IL-
2 receptor alpha (CD25), to patients recently diagnosed with type 1 diabetes. Both drugs should 
theoretically inhibit the activation of autoreactive T cells, thus possibly preserving any remaining 
beta cells. Although the hypothesis had support from previous animal studies (226; 227), the trial 
failed to limit the destruction of residual beta cells and was concluded in 2008 (228). Similarly, 
Teplizumab, an anti-CD3 antibody, showed promise in preclinical studies in recent onset 
diabetics (229), yet also failed to reach efficacy endpoints in a clinical trial, where no differences 
existed in insulin dependency between Teplizumab and placebo-treated patients (230).  TrialNet, 
the international network of clinical centers, is currently recruiting high-risk individuals for a 
Teplizumab trial as well as other first-degree relatives and recent onset patients for various other 
therapeutic procedures (231). However, the high prevalence of failures in the clinic has sparked 
the necessity for alternative approaches as well as combinatorial treatments, as reviewed by 
Phillips et al (232).  
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Vaccination against type 1 diabetes might seem quite paradoxical in the typical sense of 
an immunization. For protection against autoimmunity, a vaccine would have to promote 
tolerance to an antigen (a ‘negative’ vaccination) or drive the system towards a different 
immunological subset. In a multivalent vaccine strategy described by our group, immunization of 
NOD mice with islet lysate drove a more TH2-type response, skewing the autoreactive T cell 
pool away from autoantigen recognition, effectively preventing and reversing type 1 diabetes 
(172). Conversely, a clinical trial of autoantigen immunization in recent onset patients showed 
no effect in preserving insulin production (233). A recent and more hopeful clinical trial utilizing 
the Bacillus-Calmette-Guerin (BCG) vaccine, currently administered for tuberculosis, showed 
reversibility of disease in long-term type 1 diabetes patients following immunization (234). 
Reversal of disease was attributed to the killing of insulin-specific autoreactive T cells, induction 
of regulatory T cells, and the regeneration of new beta cells. Despite the indirect procedure with 
the BCG vaccine, such findings are clearly worth more in-depth trials, especially in recent onset 
patients. In light of all of these trials, we are testing a different kind of treatment targeting an 
important aspect of type 1 diabetes pathology – oxidative stress. While investigations are 
ongoing regarding catalytic antioxidant usage as a stand-alone therapy or in combination with 
other drugs, prophylactic treatments targeting redox modulation may be particularly promising, 
as will be discussed in detail below and in the upcoming chapters. 
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Figure 4: The ability to predict type 1 diabetes increases as beta cell mass decreases, resulting in 
less effective methods for preventative strategies. Used with permission from The Lancet (113). 
1.5 REDOX MODULATION 
GPX, SOD, and catalase are categorized as the most crucial antioxidant enzymes; however, islets 
inherently contain only a fraction of these enzymes in comparison to liver, which possesses the 
highest percentage of antioxidant gene expression (235). Because of the low antioxidant defenses 
present in pancreatic islets, therapeutic strategies to enhance antioxidants are potentially of 
greater therapeutic benefit. Overexpression of GPX1, SOD1 (Cu/Zn SOD), SOD2 (MnSOD), or 
SOD mimetic, an enzyme mimicking superoxide dismutase activity, administration in 
insulinoma cell lines afforded protection from ROS and reactive nitrogen species (145) in vitro 
(36; 236; 237). Usage of SOD mimetics in other inflammatory models has also demonstrated 
decreases in proinflammatory cytokines (238; 239). Furthermore, stable transfection of insulin-
producing RINm5F cells with GPX, catalase, and Cu/Zn SOD resulted in protection from 
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cytokine toxicity induced by the combination of IL-1β, TNFα, and IFNγ (240).  Antioxidant 
overexpression has been linked to not only protection against ROS and cytokines, but also to 
enhanced cell proliferation and decreased death. PDX1, a transcription factor necessary for beta 
cell differentiation, survival and insulin gene transcription (241), is also very responsive to ROS 
(242). Oxidative stress causes cytoplasmic relocation of PDX1, increased degradation of the 
protein, and subsequent dysfunction of beta cells (243; 244). Upon GPX1 overexpression within 
the islets, PDX1 protein exhibits stability and enhanced function in type 2 diabetes models , 
which can also have implications in type 1 diabetes for stabilizing beta cell survival. Other 
experiments have utilized transgene or adenoviral technology to overexpress antioxidant genes 
within the beta cells to specifically show islet-intrinsic, as opposed to autoimmune protection 
from type 1 diabetes. These studies have yielded conflicting results. For example, overexpression 
of metallothionein and catalase in beta cells was unable to delay or inhibit spontaneous diabetes 
onset in NOD mice and reduced activation of the PDX1 survival pathway (245). Metallothionein 
proteins are intracellular, cysteine-rich molecules with potent redox capabilities (246). Similarly, 
transgenic expression of extracellular SOD under control of the insulin promoter in beta cells 
does not confer any difference in type 1 diabetes incidence in comparison to control NOD mice 
(247). These results suggest that basal levels of ROS production are necessary for beta cell 
function, possibly by triggering appropriate insulin signaling and regulating cell survival (248). 
In contrast, overexpression of thioredoxin, a redox-regulated protein which helps repair ROS-
damaged proteins and DNA, affords protection of beta cells from autoimmune and STZ-induced 
diabetes (249). Beta cell-specific transgenic expression of catalase and metallothionein is also 
able to protect isolated islets from hydrogen peroxide, which induces beta cell mitochondrial 
damage (95) and cytotoxicity (250), and reduce the effects of STZ treatment (250-252). 
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Transgenic expression of heme oxygenase-1, which has crucial cytoprotective functions against 
oxidative stress and inflammation, can reduce insulitis severity and delay spontaneous diabetes 
in NOD mice (253), and alloxan-induced diabetes is also decreased following overexpression of 
Cu/Zn SOD in beta cells (254). Moreover, precedence for the importance of enhancing islet-
associated antioxidant levels has been demonstrated at the genetic level, in which mice resistant 
to alloxan treatment (ALR mice) exhibit protection from diabetes (103; 255). This finding 
provides further justification for the need for necessary experiments to determine “druggable” 
targets based upon modulation of antioxidant function.  
 Because of global reductions in ROS, systemic administration of antioxidants, in 
comparison to overexpression studies, shows more consistency in ameliorating type 1 diabetes. 
Administration of 16 mg/kg/day of a potent antioxidant, Lazaroid, which inhibits lipid 
peroxidation, to young NOD mice resulted in a reduction of diabetes incidence from 89% in 
controls to 44% in the treated animals (256). Furthermore, after multiple low-dose administration 
of STZ, addition of zinc sulphate to the drinking water was able to increase islet metallothionein 
levels in mice, inhibiting the onset of type 1 diabetes (257). Also, intraperitoneal injection of 
butylated hydroxyanisole antioxidant was able to attenuate the production of proinflammatory 
cytokines by islets and macrophages (258), thereby lowering insulitis and hyperglycemia (259). 
Such uniformity in these results, versus the transgenic expression of multiple antioxidants, as 
discussed above, may relate to the ability of systemic therapies to not only protect the beta cells 
but to also inhibit immune system activation and inflammation. Adenoviral delivery of systemic 
heme oxygenase to NOD mice decreased insulitis and type 1 diabetes incidence; however, this 
alleviation was associated with a decrease in mature DCs and TH1 effector function (260). 
Additionally, ALR mice resistant to alloxan-induced diabetes contain specific genetic 
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modifications conferring systemic elevation of antioxidants, resulting in neutrophils with 
reduced superoxide bursts (261). In an in vitro system using the antioxidant probucol, which can 
delay alloxan-induced (262) and spontaneous diabetes in rats (263), macrophages exhibit 
decreased H2O2 production, thus maintaining islet viability (264). 
1.6 CATALYTIC ANTIOXIDANT 
Further reports on the effects of systemic antioxidants on innate immunity include studies from 
our lab utilizing manganese metalloporphyrin-based catalytic antioxidants (CA) with bone 
marrow-derived macrophages. In particular, manganese metalloporphyrins are a class of 
superoxide dismutase (18) mimics, constructed with a manganese center, 4 quaternized cationic 
pyridyl nitrogens, and varying side chain alkyl groups imparting lipophilicity differences (265) 
(Figure 5). CA display extreme stability, efficacious bioavailability, localizing to the nucleus, 
cytosol, and mitochondria, and low toxicity (TD50=91.5 mg/kg), maximizing their therapeutic 
potential (266-268). The metal center within the CA catalyzes superoxide dismutation, 
mimicking SOD activity (269; 270), and affords scavenging capabilities of a broad range of  
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Figure 5: MnTE-2-PyP5+. Structure of the catalytic antioxidant used in our studies. Used with 
permission from JBC (271). 
 
Following treatment with CA, LPS-induced production of nitrite (NO2-), O2- TNFα, and IL-1β 
by macrophages was significantly reduced, in comparison to control (36; 64) (Figure 6). This 
effect was mediated in part by the ability of CA to oxidize the p50 subunit of NF-κB within the 
nucleus, inhibiting its binding to DNA and subsequent transcription of proinflammatory 
cytokines (64). CA, therefore, acts as an oxidioreductase, with pro-oxidative capabilities within 
the negatively-charged nucleus and antioxidant abilities throughout the rest of the cell (268; 
272). Redox modulation of transcription factor DNA binding has previously been demonstrated 
for NF-κB, as well as for other eukaryotic transcription factors such as AP-1 and AP-2 (273; 
274). Inhibition of NF-κB has been well established as an effective method of thwarting the 
immune response and resolving inflammation to maintain beta cell integrity (275; 276); 
however, we are the first to illustrate a link between metalloporphyrin catalytic antioxidants, 
blockade of NF-κB activation, and delayed autoimmune diabetes, as described below. 
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Figure 6: Catalytic antioxidants decrease proinflammatory cytokine synthesis in LPS-
stimulated NOD bone marrow-derived macrophages. Culture supernatants from LPS-
stimulated macrophages were harvested at 24-72h and analyzed for (A) TNF-α and (B) IL-1β by 
ELISA. (C) Superoxide levels were measured by cytochrome c reduction. Results are 
representative of the means (±SEM) of at least four independent experiments, each performed in 
triplicate. **p < .001 versus LPS-challenged macrophages. Used with permission from FRBM 
(64).  
1.6.1 Prevention of type 1 diabetes 
The activation of macrophages and T cells relies on oxidative stress, which ultimately leads to 
the progression of type 1 diabetes. Based upon this fact, CA was also investigated in the context 
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of CD4+ and CD8+ T cells. The BDC-2.5 TCR-Tg TH1 cell clone, specific for the protein 
chromogranin A (ChgA), a member of the granin family of neuroendocrine secretory proteins 
(115), causes rapid onset of diabetes upon transfer into NOD.scid recipients (277). Pretreatment 
of NOD.scid mice with CA prior to adoptive transfer of the BDC-2.5 clone inhibits infiltration of 
T cells into the pancreas, significantly delaying type 1 diabetes onset. To further delineate the 
mechanism of diminished T cell effector function, in vivo treatment of NOD and BDC-2.5 TCR-
Tg mice with CA was able to decrease innate-derived third signal synthesis, primarily consisting 
of TNFα, resulting in antigen-specific T cell hyporesponsiveness (48). Similar results were found 
upon CA treatment in the context of CD8+ T cells, reducing proliferation, cytokine production, 
and cytolytic effector molecules (278). Interestingly, by inhibiting NADPH oxidase in NOD 
animals (NOD.Ncf1
m1J
) in an effort to genetically mimic systemic CA administration, NOX-
derived superoxide production is not only eliminated, but T cells also show reduced TH1 
responses, with protection from type 1 diabetes onset (163). Earlier studies by Chaudhri et al. 
supported our findings by demonstrating attenuation of T cell proliferation and IL-2R expression 
following antioxidant treatment (279; 280). These results point to the possible importance of 
redox modulation in not only regulating the innate immune cells, but also impacting the T cells, 
which formulate an adaptive immune response crucial for the autoimmune attack in type 1 
diabetes (Figure 7). 
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Figure 7:  Role of redox modulation in controlling ROS-mediated beta cell destruction.  
Redox modulation has shown promise in blocking the production of ROS and its ability to 
activate APCs, resulting in diminished TH1 cell activation and effector function, which 
ultimately may help regulate beta cell destruction (154). 
1.6.2 Potential for alleviation of ER stress 
In addition to decreasing oxidative stress imposed on the islets, which can directly damage beta 
cells or indirectly stimulate the autoreactive immune response to become activated, redox 
modulation may also be useful for decreasing deleterious ER stress within the beta cells. Because 
the beta cells are constantly making insulin and insulin must be folded properly for secretion, the 
importance of balancing a high protein-folding load with survival of the cells increases 
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substantially in comparison to other non-secretory cells (281). An overload of misfolded proteins 
may eventually result in cell death, if not properly resolved. An early study by Lo et al. 
highlighted the susceptibility of beta cells to ER stress by overexpressing MHC class II proteins 
in islets, essentially overwhelming the protein folding machinery and leading to apoptosis (282). 
Other more recent studies show biochemical connections between ER stress-induced apoptosis 
and beta cell death, through both calcium-dependent and independent molecules (283-285). To 
reconcile protein misfolding within the ER, the unfolded protein response, or UPR is 
consequently triggered (286; 287). The UPR acts as a backup mechanism to protect cells from 
accumulating unfolded proteins and to restore the balance between the protein folding machinery 
and the secretory pathway (288). However, an accumulation of unfolded proteins during severe 
ER stress is sometimes unable to be resolved by the UPR, as characterized in the Akita mouse 
which contains a mutation in the proinsulin 2 gene. This mutation disrupts insulin folding, retains 
it within the ER, activates UPR, yet still eventually leads to beta cell death (289; 290). Moreover, 
ROS have been suggested to support the UPR towards a more proapoptotic than proadaptive 
level (291) further illustrating the importance of regulating oxidative stress to maintain beta cell 
survival. Although the UPR paradoxically utilizes an oxidative environment within the ER to 
correctly fold proteins (i.e. disulfide bond formation), sustained oxidative stress can drive the 
UPR to a level that promotes apoptosis (291; 292). Additionally, the abundance of ROS present 
during continued unabated ER stress can trigger apoptosis in neighboring cells as well. This is 
especially critical in islet beta cells, where the ability to handle oxidative stress is already 
reduced because of low levels of antioxidants (35; 91-93). More pertinent is when unresolved ER 
stress leads to dying beta cells containing the misfolded proteins. These cells can be taken up by 
resident pancreatic APCs and presented to autoreactive T cells within the pancreatic lymph 
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nodes. This type of event may stimulate the reactivity of T cells to formerly tolerated ‘neo-
autoantigens’, which can ultimately promote more beta cell destruction and eventual 
development of autoimmune diabetes (293; 294). A study conducted by Malhotra, et. al shows 
that antioxidant treatment of CHO cells results in not only decreased oxidative stress, but also 
decreased misfolded proteins, reduced activation of the UPR, and enhanced secretion of proteins 
(281). Thus, it appears that a temporal or redox balance is essential for optimal beta cell function. 
In situations where the beta cell may experience environmental stressors that lead to disruption 
of the ER-machinery, the results may set in motion both ER-stress-induced UPR and the 
expression of misfolded proteins in an oxidative environment, further providing an optimal 
milieu for driving autoreactive T cells to become activated. Therefore, redox modulation may 
serve yet another purpose: to help reduce ER stress and subsequently maintain beta cell viability.   
1.6.3 Promise of CA in transplantation 
The ability to predict susceptibility to type 1 diabetes is becoming increasingly accurate (295), 
and therefore, prophylactic treatment of patients with antioxidant therapeutics is not out of the 
realm of possibilities. However, a more feasible option for individuals with chronic 
hyperglycemia is islet transplantation. Islets, like any other transplantable organ, are in short 
supply; however, maintaining function and viability of transplanted islets is the major drawback 
of the procedure (251). Not only are islets susceptible to immune rejection, but hypoxia during 
isolation and transplantation is the primary cause of beta cell death (296). Because of their low 
resistance to ROS (35; 91-93), beta cells are especially vulnerable to oxidative damage and 
ischemia-reperfusion injury (297; 298). In order to combat this weakness, the application of 
antioxidants seems a suitable alternative, as they have shown promise in liver and kidney 
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transplantations (258; 299). Longer allograft survival times have been demonstrated with mouse 
islets soaked with hydroxyl-radical inhibitors prior to transplantation (300) and with multiple in 
vivo administrations of SOD and catalase prior to and after islet transplantation (301). Likewise, 
transduction of islets with heme oxygenase-1 or SOD2 genes improved viability and insulin 
secretion in vitro (302), with greater functionality upon transplantation, in comparison to controls 
(303), respectively. Furthermore, we have also demonstrated benefit using the catalytic 
antioxidant approach, whereby adding CA during and after human islet isolation enhanced cell 
survival and function, allowing for normalization of STZ-induced diabetic NOD.scid mice (304). 
Additionally, CA is not only able to protect human islets from STZ cell damage, but can also 
protect murine islets from both antigen-independent, innate-mediated inflammation, and antigen-
dependent T cell-mediated allograft rejection (297). Overall, unlike common anti-rejection 
drugs, which are outstanding at suppressing the adaptive immune response but fail to shield islets 
from ROS/inflammation (305; 306), our CA treatment is non-toxic to islets and can alleviate 
both the alloimmune (297) and autoimmune response (36; 48; 64; 278).  
1.6.4 Other potential avenues for CA usage 
Although redox has been extensively studied in the context of both type 1 diabetes and type 2 
diabetes (94; 307), the plethora of literature discussed above shows the implications of ROS in 
all stages of autoimmune type 1 diabetes, including the primary “trigger”, the initiation of 
insulitis by the innate immune system, and the acquisition of T cell-mediated autoreactivity. 
These studies open the door to novel ideas of redox modulation, such as targeting ROS-
dependent immunological metalloproteases (54; 55; 60) or disrupting the autoreactive T cell 
pool, as described (48; 163; 278). Moreover, a study evaluating self-antigen-primed T cells 
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demonstrates how NO is able to reduce FOXP3 expression and subsequently decrease Tregs in 
autoimmune disorders (308), illustrating how intricate and vast the role of redox is on the 
immune response and where future studies may focus. In addition to effects on the target 
organ(s) and the immune system, autoimmunity also gives rise to systemic problems, and in the 
context of diabetes, ROS have been characterized as crucial elements promoting hyperglycemia-
induced diabetic complications, especially those involving the vasculature (16; 309). One 
important study conducted by Ling, et. al provided evidence of oxidative stress-mediated 
vascular complications in prediabetic NOD mice (310), which exemplifies the importance of 
ROS in not only exacerbation of disease, but also on initiation of type 1 diabetes and non-
hyperglycemic associated pathologies. Furthermore, antioxidants, such as Vitamin E, can not 
only dampen vascular activation (311), but can also grant protection from the loss of secondary 
target organ function, such as the kidneys (312). Therefore, oxidative stress affects every aspect 
of type 1 diabetes and the benefit of redox modulation may be more significant than once 
thought. 
1.7 SUMMARY 
Although optimal treatments must take into consideration the limitations associated with current 
antioxidant therapies, including bioavailability, immunogenicity-limited cellular accessibility, 
and cost of production, the advent of newer non-peptidyl small compounds may allow for better 
alleviation of oxidative stress. Antioxidant therapy should restore balance between oxidation and 
reduction, leading to resolution of inflammation, thus decreasing the autoimmune destruction of 
the islet beta cells. The following chapters will discuss how CA treatment, specifically, (1) 
promotes autoreactive T cell hyporesponsiveness; (2) reduces immune cell metabolism, in mouse 
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models of type 1 diabetes; and (3) modulates inflammation and diabetic complications in a high-
fat diet model of type 2 diabetes. 
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2.0  MODULATION OF REDOX BALANCE LEAVES MURINE DIABETOGENIC 
TH1 T CELLS “LAG-3-ING” BEHIND 
2.1 ABSTRACT 
Preventing activation of diabetogenic T cells is critical for delaying type 1 diabetes onset. 
The inhibitory molecule LAG-3 and metalloprotease TACE work together to regulate TH1 
responses. The aim of this study was to determine if regulating redox using a catalytic 
antioxidant (CA) could modulate TACE-mediated LAG-3 shedding as a way to impede 
diabetogenic T cell activation and progression to disease. A combination of in vitro experiments 
as well as in vivo analyses using NOD mouse strains was conducted to test the effect of  redox 
modulation on LAG-3 shedding, TACE enzymatic function, and disease onset. Systemic 
treatment of NOD mice significantly delayed type 1 diabetes onset. Disease prevention 
correlated with decreased activation, proliferation, and effector function of diabetogenic T cells, 
reduced insulin-specific T cell frequency, and enhanced numbers of LAG-3+ cells. Redox 
modulation also affected TACE activation, diminishing LAG-3 cleavage. Furthermore, disease 
progression was monitored by measuring serum soluble LAG-3, which was decreased in CA-
treated mice. Therefore, affecting redox balance by CA treatment reduces the activation of 
diabetogenic T cells and impedes type 1 diabetes onset via decreasing T cell effector function 
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and LAG-3 cleavage. Moreover, soluble LAG-3 can serve as an early T cell-specific biomarker 
for type 1 diabetes onset and immunomodulation. 
2.2 INTRODUCTION 
In addition to direct cell-mediated killing of beta cells in type 1 diabetes, soluble 
inflammatory mediators, including cytokines and ROS, often precede the later stages of 
fulminant beta cell destruction. Regulation of local and systemic redox affects activation and 
proliferation of a variety of immune cells and  protects tissues/cells from innate and cell-
mediated damage (154). Based on previous studies showing the importance of ROS in chronic 
inflammation, our lab has utilized a CA to modulate both innate and adaptive immunity in type 1 
diabetes. CA is a manganese metalloporphyrin (Mn(III) mesotetrakis (N-alkylpyiridinium-2-yl) 
porphyrin; MnTE-2-PyP
5+
) that catalyzes superoxide dismutation, mimicking superoxide 
dismutase activity (269). CA also scavenges a broad range of ROS, including superoxide, 
hydrogen peroxide, peroxynitrite, and lipid peroxyl radicals (64; 269; 313). The importance of 
blocking ROS to hinder autoreactive immune responses and type 1 diabetes has been 
demonstrated within the NOD.Ncf1 mouse model, where the p47phox mutation in NADPH 
oxidase leads to protection from spontaneous diabetes onset in 70% of the females (163). CA 
treatment mimics this mutation, yet serves as a physiologically relevant possibility for disease 
intervention and clinical use. CA activity regulates proinflammatory immune processes by 
decreasing TNFα, IL-1β, and ROS synthesis from activated antigen-presenting cells (48), likely 
by inhibition of NF-κB-dependent gene transcription and efficient innate immune activation (64). 
CA can translocate to the nucleus and inhibit the binding of the p50 NF-κB subunit to the DNA 
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via oxidation of the critical cysteine at position 62, resulting in significantly reduced 
proinflammatory cytokine production (64; 314). Additionally, CA induces CD4+ T cell antigen-
specific hyporesponsiveness (48) and decreases the cytolytic activity of CD8+ T cells (278), 
delaying islet allograft rejection (297). In the context of type 1 diabetes, diabetogenic BDC-2.5 T 
cell clones exhibit impaired diabetes transfer in CA-treated NOD.scid recipient mice (36).  
Although the effects of modulating the redox balance are profound, the mechanism of 
CD4+ antigen-specific hyporesponsiveness and decrease in proinflammatory cytokine 
production after CA treatment is still poorly understood. Our previously published work showed 
that TNFα secretion is reduced in CA-treated macrophages (48). A Disintegrin and 
Metalloproteinase-17 (ADAM17), or Tumor Necrosis Alpha Converting Enzyme (TACE), is a 
metalloprotease responsible for cleaving pro-TNFα from the cell surface. Many 
metalloproteases, such as TACE, are redox-dependent enzymes, initially formed as latent 
zymogens that become active upon oxidation of specific cysteine residues (Cys522 and Cys600) 
in their disintegrin/cysteine-rich region, releasing the prodomain from their catalytic subunit 
(Figure 8) (54; 55; 315; 316). TACE is synthesized in the rough ER, matured in the Golgi, and is 
then expressed as a transmembrane protein on the cell surface (317). We hypothesize that CA 
treatment may not only scavenge ROS, decrease proinflammatory cytokine production, and 
inhibit NF-κB activation, but may also inhibit TACE, altering the cleavage kinetics of T cell 
surface proteins. Support for this hypothesis derives from studies demonstrating that TACE is 
responsible for the shedding of key transmembrane proteins, such as TNFα, Notch, epidermal 
growth factor receptor ligands, L-selectin (CD62L), and CD223 (LAG-3), making it an essential 
enzyme in normal immune function (318-323). The inhibition of TACE activation via specific 
TACE inhibitors, such as TAPI-1, has recently gained popularity in the clinic, with vast 
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increases in the production of these agents (323; 324). Diseases that are targeted by this type of 
therapy include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, Sjögrens 
syndrome, and atopic dermatitis (323; 324). The most promising TACE inhibitors, however, 
failed phase II trials as a result of mechanism-based hepatotoxicity and/or lack of efficacy (325). 
Therefore, small molecules that can afford the same type of protection with a better toxicity 
profile would be beneficial. 
Figure 8: The TACE metalloprotease is redox-dependent. TACE is formed initially as a 
latent zymogen, with a thiol interaction between a cysteine and zinc residue keeping the enzyme 
inactive. Upon oxidation of the critical cysteine switch, sulfonic acid is formed, breaking the 
thiol bond with zinc. An autocatalytic cleavage event then occurs to release the active TACE 
enzyme from its prodomain. Used with permission from FRBM (54). 
 
 
Lymphocyte Activation Gene 3 (LAG-3) is a negative regulator of immune cell 
activation expressed on activated CD4+ and CD8+ T cells and plasmacytoid dendritic cells (326; 
327). Upon TCR binding with MHC class II, LAG-3 levels increase on the surface of T cells, 
resulting in attenuated TCR-dependent T cell activation and eventual clonal exhaustion (Figure 
Prodomain Active 
TACE 
 41 
9) (328), possibly by physical competition with CD4 for MHC interaction (329). LAG-3 tempers 
the immune response, prevents any aberrant activation, and controls the expansion of the T cell 
pool (328). IL-12 is thought to upregulate human LAG-3, possibly indicating overlapping 
regulatory elements with CD4 (326; 330); however, the transcription factor(s) responsible for 
LAG-3 expression have yet to be identified. To allow CD4 to bind efficiently to class II, LAG-3 
is cleaved by TACE (315; 321). LAG-3 follows cyclical kinetics, in which its upregulation and 
cleavage is eventually followed by a re-upregulation to promote immune response contraction 
and homeostasis (Figure 10).  
Figure 9: LAG-3 is a negative T cell regulator. Following TCR interaction with MHC-peptide, 
LAG-3 is upregulated and binds to class II MHC to prevent T cell activation. Upon TACE-
mediated cleavage of LAG-3, CD4 is then able to bind to class II MHC and promote T cell 
activation and effector function. 
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Figure 10: LAG-3 protein expression displays cyclical kinetics. LAG-3 is initially upregulated 
upon antigen stimulation in order to inhibit aberrant T cell activation. Once LAG-3 is shed by 
TACE, CD4 binds efficiently to MHC class II and progresses the immune response to complete 
T cell activation. After the cells have effectively cleared the pathogen, LAG-3 is re-upregulated 
to promote contraction and immune response homeostasis. 
 
 
LAG-3 knockout
 
mice demonstrate increased T cell proliferation and IFN-γ cytokine 
production (328), and antibody-mediated LAG-3 blockade results in enhanced CD69 expression 
and T cell differentiation (331). Additionally, recent studies report that LAG-3(-/-) NOD mice 
demonstrate accelerated spontaneous diabetes (332; 333), further indicating a potential 
immunoregulatory function of LAG-3. Soluble LAG-3 (sLAG-3) is a surrogate measure of 
TACE activity (315; 321) and an additional marker of T cell activation (334; 335). Indeed, serum 
levels of sLAG-3 are considered a biomarker of T cell activation in breast cancer (334). 
Therefore, in the context of type 1 diabetes, sLAG-3 could serve as a surrogate marker of 
autoreactive T cell activation, a predictive biomarker of diabetes progression from preclinical to 
clinical disease, or a measure of immuno-intervention efficacy.   
In this study, we demonstrate the effects of CA treatment on the TACE redox state, 
coupled with LAG-3 expression and T cell activation, to promote autoreactive T cell 
hyporesponsiveness and reduce type 1 diabetes onset. 
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2.3 RESEARCH DESIGN AND METHODS 
2.3.1 Materials 
NOD.BDC-2.5.TCR.Tg, NOD, NOD.scid, and 6.9TCR/NOD.C6 (C6.6.9) mice were bred and 
housed under specific pathogen-free conditions in the Animal Facility of Rangos Research 
Center at Children’s Hospital of Pittsburgh of UPMC (Pittsburgh, PA). Female mice at 4-10 wks 
of age were used in all experiments. All animal experiments were approved by the Institutional 
Animal Care and Use Committee of the Children’s Hospital of Pittsburgh and were in 
compliance with the laws of the United States of America. LAG-3-PE (C9B7W), CD40L-APC, 
PD-1-FITC (eBioscience, San Diego, CA), CD4-APC, CD69-PE, CD40-PE, CD44-FITC, 
CTLA-4-PE, FasL-PE (BD Biosciences, San Diego, CA), goat anti-mLAG-3 (R&D Systems, 
Minneapolis, MN), anti-mTbet (4B10) (Santa Cruz, CA), and rabbit anti-mTACE (Abcam, 
Cambridge, MA) were used for flow cytometry and Western blots. Antibody pairs for IFN-γ 
ELISAs were purchased from BD Biosciences and mouse DuoSet TNFα and hLAG-3 ELISAs 
were purchased from R&D Systems. MnTE-2 catalytic antioxidant (CA) was a generous gift 
from James Crapo, MD at National Jewish Health. CA was prepared as previously described (48) 
and used at 68 µM in all in vitro experiments. 
2.3.2 CA pellet implantation and spontaneous type 1 diabetes assessment 
NOD female mice were implanted with a 14-day sustain release CA pellet (2.1 mg/kg/day) 
subcutaneously at the nape of the neck. Control animals were left untreated. Animals were 
reimplanted with CA pellets every 2 weeks until 29 weeks of age. Spontaneous type 1 diabetes 
 44 
incidence was monitored by blood glucose starting at 12 weeks of age. Overt diabetes was 
defined as two consecutive readings >300 mg/dl. 
2.3.3 In vitro T cell assay 
BDC-2.5.TCR.Tg, NOD, or C6.6.9 splenocytes from 6-8 wk old mice were seeded in 96-well 
round-bottom plates or 12-well plates with 0.5-1 µM of BDC-2.5 mimotope (M) 
(EKAHRPIWARMDAKK) or 2.5 µg/ml concanavalin A (ConA) (336) in supplemented DMEM 
(48) (Invitrogen Life Technologies). TAPI-1 (Calbiochem, Darmstadt, Germany) was 
supplemented daily at 4 µM as indicated. At 24-96h post-stimulation, cells were collected for 
flow cytometry or for preparation of whole cell lysates. Supernatants were harvested for ELISA. 
2.3.4 Surface staining and flow cytometric analysis 
Cells were stained as previously described (278). Fluorescence was measured on a FACSAria 
(BD Biosciences). Flow cytometric analysis was done using FlowJo Software v6.4 (Tree Star, 
Ashland, OR). All samples were gated on CD4+ cells. Fold change was calculated as 
(Control/No antigen)/(CA/No antigen). 
2.3.5 Cytokine measurements by ELISA 
sLAG-3 ELISAs were performed as described (321). IFN-γ and TNFα ELISAs were performed 
according to manufacturer’s instructions. All ELISAs were read on a SpectraMax M2 microplate 
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reader (Molecular Devices, Sunnyvale, CA), and data was analyzed using SoftMax Pro v5.4.2 
(Molecular Devices).  
2.3.6 Immunization for LAG-3 detection 
One day prior to immunization, 28 NOD mice were treated intraperitoneally (i.p.) with CA (10 
mg/kg) or HBSS. Mice were injected with 50 µg of insulin emulsified in Complete Freund’s 
Adjuvant (CFA) s.c. at the base of the tail and treated i.p. for 7 days. On days 0.5, 1, 2, 3, 4, 6, 
and 8, 2 mice/group were sacrificed, and inguinal lymph nodes (LNs) were harvested for flow 
cytometry of LAG-3. Non-immunized mice served as negative controls. Similar to insulin 
immunizations, NOD mice (n=6/group/experiment) were pretreated with CA or HBSS, 
immunized with hen egg lysozyme (HEL) (100 ug) or NOD.scid islet cells (5000) and treated 
with CA or HBSS for 7 days. On day 8, LNs were harvested and stimulated for an in vitro recall 
assay. Supernatants were collected at 2-3 days post-stimulation and utilized for IFN-γ ELISA. 
2.3.7 Intracellular cytokine staining and ELISPOT assay 
NOD insulin immunization +/- CA was conducted as above. Primary intracellular IFN-γ was 
detected in inguinal LN cells isolated 6 days after insulin immunization. After surface staining 
for CD4, LN cells were prepared as described (278), stained with APC-labeled mouse anti-IFN-γ 
(BD Biosciences) or isotype controls, and analyzed by flow cytometry. Antigen recall ELISPOT 
assays were also conducted 6 days after immunization using LN cells (2.5x10
5
 in triplicate) 
seeded in IFN-γ-precoated strips from Mabtech (Sweden) with 25 µg insulin. After 2 days of 
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incubation at 37°C in a 5% CO2 humid air chamber, plates were developed following the 
manufacturer’s instructions. Frequency = 2.5x105/avg# spots/treatment. 
2.3.8 Preparation of cell lysates and western blotting 
BDC-2.5.TCR.Tg splenocytes were stimulated with M +/- CA. Whole cell lysates from 
splenocytes or from CD4+ T cells, isolated after stimulation via MACS separation using the 
CD4+ T cell Isolation Kit (Miltenyi Biotec, Auburn, CA), were prepared as described (337). 
Membrane lysates were obtained by lysis in 50 mM Tris, pH 7.4, 150 mM NaCl buffer 
supplemented with inhibitor cocktails, centrifugation at 72,000 x g for 30 min, removal of 
supernatants, and sonication with Tris buffer+1% NP-40. Protein concentration of all lysates was 
determined by BCA protein assay (Thermo Fisher, Rockford, IL). Protein lysates were separated 
on 8% or 4-20% (TACE) SDS–PAGE gels. For fluorescein-5-maleimide (F5M) detection 
(Thermo Scientific, Rockford, IL), 25 µg lysates were labeled with 1.5 µM F5M for 10 min on 
ice in the dark. After labeling, the lysate was filtered over 3K centricon filters to remove any 
remaining label, samples were ran on SDS-PAGE gels, and fluorescence was detected. Western 
blots were performed as described (64) with antibodies to LAG-3 (1:1300), Tbet (1:1000), 
TACE (1:2000), and β-actin (1:10,000) in 5% BSA in TBST. Secondary antibodies were from 
Jackson ImmunoResearch, West Grove, PA.  Chemiluminescence was detected using ECL Plus 
reagent (Amersham Pharmacia Biotech, Buckinghamshire, UK). Blots were analyzed using 
Fujifilm LAS-4000 imager and Multi Gauge software (Fujifilm Life Science, Tokyo, Japan). 
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2.3.9 LAG-3 mRNA quantification 
BDC-2.5.TCR.Tg splenocytes were isolated and stimulated with 1 µM M +/- CA for 72-96h. 
Cells were collected, pelleted, and stored at -80°C before RNA isolation. RNA was isolated 
using the RNAeasy Kit (Quiagen, Valencia, CA), followed by cDNA synthesis using the 
SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad, CA). The qRT-PCR was 
performed using the following primer pair: LAG-3 (forward) 5’-
AGTGACTCCCAAATCCTTCGGGTT-3’, (reverse) 5’-
GGGACGCCACACAAATCTTTCCTT-3’; GAPDH (forward) 5’-
TGCATCCTGCACCACCAACT-3’, (reverse) 5’-CTGGCATGGCCTTCCGTGTT-3’. 
Quantitative RT PCR was performed using a Light Cycler 2.0 (Roche, Indianapolis, IN). The 
reaction mixtures containing SYBR Green were generated following the manufacturer’s 
protocol. The cycling program was: initial denaturation at 95°C for 10 min, 40 cycles of 
amplification with a denaturation step at 95°C for 5 sec, an annealing temperature of 60°C for 15 
sec, and an extension step at 72°C for 20 sec. All samples were normalized to GAPDH, and CA-
treated samples were compared to control samples arbitrarily set to 1. 
2.3.10 Soluble LAG-3 (sLAG-3) immunoprecipitation 
Supernatants from BDC-2.5.TCR.Tg splenocyte stimulations were concentrated in 30K Amicon 
Ultra-15 centrifugal filter units (Millipore). Samples >30K were immunoprecipitated using 1 µg 
of LAG-3 antibody as described (337). Western blot was performed as above. 
 48 
2.3.11 In vitro TACE fluorogenic assay 
BDC-2.5.TCR.Tg splenocytes were stimulated for 24h with M +/- CA +/- 200 µM TAPI-1 in 96-
well black fluorescence plates. TACE specific fluorogenic substrate (Mca-P-L-A-Q-A-V-Dpa-R-
S-S-S-R-NH2, Fluorogenic Peptide Substrate III, R&D Systems) diluted to 10 µM in 50 mM Tris 
buffer, pH 9.0 was added for 6h at 37°C. Fluorescence was read at an excitation of 320 nM, 
emission of 405 nM. The average fold change in activity = Stimulated Cells/Unstimulated vs. 
Stim+CA/Unstim vs. Stim+TAPI/Unstim. 
2.3.12 Adoptive transfer of diabetes 
One day prior to adoptive transfer, 6 NOD.scid mice were treated i.p. with CA (10 mg/kg) or left 
untreated. BDC-2.5.TCR.Tg splenocytes were adoptively transferred (10
7
/mouse) intravenously 
(i.v.) into NOD.scid recipients on day 0. Mice were treated daily with CA. Serum was collected 
every 4 days post-transfer for sLAG-3 ELISA. Mice positive for glucosuria after daily urinalysis 
were monitored by blood glucose levels, and overt diabetes was determined as above. Mice were 
monitored for disease onset up to 28 days post-transfer, when splenocytes were isolated for in 
vitro analysis.  
2.3.13 sLAG-3 levels from NOD and human samples 
NOD females and males (n=4/group) were bled for serum every other week starting at 6 weeks 
of age until 14 weeks of age. sLAG-3 was detected by ELISA according to the manufacturer’s 
instructions. Mice positive for glucosuria after daily urinalysis were monitored by blood glucose 
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levels, and overt diabetes was determined as above. Human serum samples (type 1 diabetes, 
healthy controls, first-degree relatives) were graciously provided by: Dorothy Becker (Children’s 
Hospital of Pittsburgh), Clayton Matthews (University of Florida), and Ranjeny Thomas 
(University of Queensland). hLAG-3 ELISAs were blocked and samples/standards were diluted 
in 30% FBS in PBS to minimize background. Autoantibody data was also provided by both the 
Mathews and Thomas groups. 
2.3.14 Statistical analysis 
The difference between mean values was assessed by Student’s t test, with p<0.05 considered 
significant. All experiments were performed at least three times with data ± SEM obtained in 
triplicate in each experiment. For LAG-3 FACS analysis, data are representative of at least three 
independent experiments and fold change of expression is calculated as indicated.  Survival 
analysis
 
was done using the product-limit (Kaplan-Meier) method with the endpoint defined as 
disease. Data on
 
animals that did not develop type 1 diabetes were censored. The p values were 
determined by Log-Rank
 
test. 
2.4 RESULTS 
2.4.1 CA treatment delays spontaneous diabetes 
CA treatment disrupts innate immune-mediated proinflammatory signals (48) and delays islet 
allograft rejection (297), prompting us to determine the effects of its long-term administration on 
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type 1 diabetes onset. NOD females (4 wks old) implanted with CA pellets demonstrated delayed 
diabetes onset compared to control mice (p<0.0001). Furthermore, stopping CA pellet 
implantation at 29 weeks afforded protection against diabetes until 40 weeks of age (Figure 11), 
suggesting that redox modulation imparts inhibition of autoreactive processes and delays end-
organ autoimmunity. 
Figure 11: Spontaneous diabetes is reduced upon systemic CA treatment. NOD females 
(n=7) were implanted with a 14-day sustain release CA pellet (2.1 mg/kg/day) bi-weekly, and 
control NOD mice (n=14) were left untreated. Pellet implantation was stopped at 29 weeks of 
age. Diabetes was monitored by blood glucose, with 2 consecutive readings of >300 mg/dl 
indicating overt disease, ***p<0.0001. 
 
2.4.2 Redox modulation decreases TH1 effector function 
TH1 T cells play a key role in mediating type 1 diabetes (338; 339). To mechanistically 
determine how modulation of the redox state affects diabetogenic CD4+ TH1 adaptive immune 
effector responses, BDC-2.5.TCR.Tg splenocytes were stimulated +/- M +/- CA in vitro. CA 
treatment diminished T cell activation, shown by decreased frequency of CD4+CD69+ cells 
(p<0.05 at 72 and 96h) (Figure 12A) and reduced CD4+ T cell proliferation (p<0.05 at 96h) 
(Figure 12B). In conjunction with previous results (48), redox modulation significantly lowered 
IFN-γ production (p<0.05) and reduced Tbet protein expression (Figure 12C, D). These data 
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indicate that CA diminishes T cell activation and TH1 effector function, likely contributing to the 
diabetes protection observed above (Figure 11). 
 
Figure 12: Redox modulation promotes a reduction in T cell activation and effector 
function. (A) BDC-2.5.TCR.Tg splenocytes were left untreated or stimulated with M +/- CA. At 
24-96h, cells were stained for and gated on CD4+ cells, and CD69 was analyzed by flow 
cytometry, n=3 independent experiments, *p<0.05. (B) CFSE-labeled splenocytes were treated 
with M +/- CA. At 48-96h, cells were stained and gated on CD4+CFSE+ cells. Grey lines = M, 
Black lines = M+CA, Filled histograms = CFSE+ cells at time point 0. % proliferating cells = 
average of 3 independent experiments, *p<0.05 (C) Supernatants from 96h cultures were used in 
an IFN-γ ELISA, n=3 independent experiments performed in triplicate, *p<0.05. (D) Whole cell 
lysates from 96h cultures were probed for Tbet by immunoblot. Actin was probed as a loading 
control. Data are representative of 3 independent experiments.  
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2.4.2.1 BDC-2.5 T cells have reduced activation/memory markers following CA treatment 
 
In addition to CD69+ expression, BDC-2.5.TCR.Tg splenocytes were also analyzed for other 
activation and memory markers upon redox modulation. CD40 interaction with CD40L on T 
cells is known to aid in the activation of APCs and B cells. Furthermore, CD40 has been detected 
on diabetogenic BDC-2.5.TCR.Tg T cells, with putative roles in inducing NF-κB activation and 
binding directly to other T cells in the periphery for faster responses (340). Moreover, adoptive 
transfer of CD40
hi
 diabetogenic T cells rapidly cause type 1 diabetes in a NOD.scid mouse 
model (341). CA treatment of BDC-2.5.TCR.Tg splenocytes stimulated with M reduced the 
amount of CD4+CD40+ cells to almost significance at 96h (Figure 13A), potentially correlating 
with lower diabetogenicity. CD40L expression was also measured after CA treatment. 
CD4+CD40L+ cells, conversely, were increased upon redox modulation (Figure 13B). Although 
this result seems to pose a conundrum for reduced activation, studies have described CD40L as a 
homeostatic surface marker (342) that is downregulated by CD40 ligation (343). If CD40 is 
decreased in vitro, less ligation would occur, resulting in sustained levels of CD40L. Further 
studies would need to be conducted in a more physiological system in vivo or with isolated T 
cells to definitively comprehend the differences in this costimulatory pathway.  
In addition to activation markers, the memory surface molecule CD44 was also analyzed. 
CA treatment decreased the number of CD4+CD44+ cells (Figure 13C), indicating a possible 
reduction in CD4+ effector memory T cells as CD44 is known to be critical for sustaining the 
memory phenotype (344). Another molecule that was analyzed upon redox modulation was Fas 
ligand (FasL), which is important for binding Fas on target cells and inducing apoptosis. In the 
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context of T cell activation, FasL expression is initially low but is increased as stimulation 
continues. Eventually, FasL-Fas interaction will instigate activation-induced cell death, 
ultimately returning the immune response to homeostasis. Upon stimulation of BDC-2.5.TCR.Tg 
splenocytes, CD4+FasL+ cells are lowered after CA treatment (Figure 13D). Such decreases 
may be related to the overall activation delay seen with CD69 expression and proliferation 
(Figure 12); however, reports indicate that memory CD4+ T cells can obtain cytotoxic 
characteristics (345; 346), such as FasL expression, and this mechanism may be used to directly 
lyse beta cells, as was shown for CD8+ T cells (347). Reduced FasL after CA treatment may 
indicate a less cytotoxic phenotype of memory diabetogenic T cells. 
The last set of molecules analyzed after redox modulation were two negative T cell 
regulators, CTLA-4 and PD-1. CTLA-4 is necessary for T cell contraction, and expressed at later 
stages after T cell activation. CA treatment results in slight reduction of CTLA-4 expression, 
especially at 72h post-stimulation (Figure 13E). In reference once again to the general delay in T 
cell activation seen above, this effect may be a kinetic phenomenon. On the other hand, PD-1, 
another molecule implicated in negatively regulating T cells, was not affected by redox 
modulation (Figure 13F). Overall, these data suggest additional facets of redox modulation-
dependent reductions in T cell activation, which would be beneficial in decreasing 
diabetogenicity. More studies are needed to obtain significant conclusions. 
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Figure 13: Redox modulation decreases diabetogenicity of BDC-2.5.TCR.Tg CD4+ T cells 
through various activation and memory markers. BDC-2.5.TCR.Tg splenocytes were left 
untreated or stimulated with M +/- CA. At 24-96h, cells were stained for and gated on CD4+ 
cells, and CD40L, CD40, CD44, CTLA-4 (n=3), FasL (n=2), or PD-1 (n=1) was analyzed by 
flow cytometry. 
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2.4.3 CA treatment limits antigen-specific T cell frequency 
To determine if CA treatment affected the frequency of antigen-specific TH1 cells in vivo, we 
immunized NOD mice (6-8 wks old) with a known autoantigen, insulin, and utilized inguinal LN 
cells on day 6 for primary intracellular IFN-γ detection and recall ELISPOT assay (Figure 14). 
IFN-γ-expressing CD4+ T cells were reduced after CA treatment compared to control animals 
(p<0.005) (Figure 14A). Furthermore, LN cells from CA-treated animals displayed decreased 
IFN-γ secreting cells compared to control animals (p<0.05), with a significant reduction in 
insulin-specific effector function after recall stimulation (Figure 14B). The frequency of antigen-
specific cells in control animals was ~1 in 19,000, whereas in CA-treated animals, the frequency 
diminished to 1 in 46,000.  These results suggest that redox modulation disrupts expansion of 
insulin-specific T cells, which may lead to delays in autoimmune-mediated beta cell destruction 
and in type 1 diabetes onset.  
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Figure 14: CA treatment reduces insulin-specific T cell effector function and frequency. 
NOD mice were treated with CA or HBSS daily. Mice were immunized with insulin in CFA. (A) 
Inguinal LNs were removed at day 6 post-immunization, and surface stained for CD4 as well as 
intracellularly stained for IFN-γ for flow cytometric analysis. Cells were gated on CD4+ cells, 
n=3 independent experiments with 2 mice/group, *p<0.005. (B) Inguinal LNs were also isolated 
on day 6 and stimulated with insulin in a recall IFN-γ ELISPOT. Two days after stimulation, 
ELISPOT plates were developed, and spots were counted using the Zeiss KS Elispot Imaging 
system. Frequency = 2.5x10
5
/avg # of spots per treatment. Graph shows the average of 3 
independent experiments performed in triplicate (*p<0.05). 
 
2.4.3.1 Redox modulation reduces IFN-γ production following stimulation of NOD T cells 
 
Further support for CA-mediated reductions in IFN-γ was obtained through both in vitro 
stimulation and in vivo immunization experiments using the open TCR repertoire NOD mouse 
model. NOD splenocytes stimulated with the mitogen ConA in the presence of CA showed 
significant reductions in IFN-γ production at 48h (Figure 15A). Moreover, immunizing NOD 
mice with whole islet cells or the non-autoantigen HEL demonstrated similar reductions in IFN-γ 
secretion after 7 days of in vivo CA treatment followed by 2-3 days of recall antigen stimulation 
of LN cells in vitro (Figure 15B, C). Unlike insulin immunization, however, the levels of IFN-γ 
were not significantly reduced, although the trend is apparent. 
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Figure 15: CA treatment decreases IFN-γ production following stimulation of NOD T cells. 
(A) NOD splenocytes were left unstimulated or stimulated with ConA +/- CA for 96h. 
Supernatants from 48-96h cultures were used in an IFN-γ ELISA, n=4 independent experiments 
performed in triplicate, **p<0.005. (B-C) NOD mice were treated with CA or HBSS daily. Mice 
were immunized with 5000 NOD.scid islet cells or 50 µg HEL in CFA. Inguinal LNs were 
removed at day 8 post-immunization and stimulated with (B) 5000 or 2500 NOD.scid islet cells 
for 3 days or (C) 62.5 or 125 µg/mL HEL for 2 days. Supernatants were used in an IFN-γ 
ELISA, n=3 independent experiments.  
2.4.4 CD4+LAG-3+ T cell frequency is enhanced following CA treatment 
LAG-3 is important in negatively regulating T cell responses, and thus, may play a role in 
mediating decreased T cell activation following CA administration (328; 348; 349). We first 
measured LAG-3+ T cell frequency following M +/- CA stimulation of BDC-2.5.TCR.Tg 
splenocytes in vitro. M+CA treatment resulted in a higher frequency of LAG-3+ T cells 
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compared to M-alone stimulated samples (Figure 16A). The MFI of LAG-3 did not differ 
between groups. Because LAG-3 is not constitutively expressed (350; 351), unstimulated cells 
+/- CA treatment expectedly demonstrated low LAG-3+ T cell frequencies. Upon quantification 
of the in vitro results, the fold change in LAG-3+ T cell frequency reached significance at 24h 
and 48h (p<0.05) post-stimulation (Figure 16B), indicating kinetically-delayed T cell activation.  
We next looked in vivo for LAG-3 kinetics following insulin immunization and CA 
administration of NOD mice (6-8 wks old). As shown by others (321; 352-355) and similar to 
our in vitro results (Figure 16A, B), control-treated animals exhibited a lower peak of LAG-3+ 
cells by day 3 post-immunization in comparison to CA-treated mice; however, redox modulation 
resulted in an enhanced trend toward LAG-3+ cells at day 3 post-immunization (p=0.07) (Figure 
16C). No difference in LAG-3 MFI was seen between the groups (data not shown). These data 
demonstrate that CA treatment can affect LAG-3+CD4+ T cell frequency in vivo, albeit not to 
significance, suggesting slight obstruction of T cell activation following autoantigen 
immunization in the presence of redox modulation. 
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Figure 16: LAG-3+ T cell frequency is enhanced upon stimulation plus CA. BDC-
2.5.TCR.Tg splenocytes were left untreated or stimulated with M +/- CA in vitro. (A) At 24-96h, 
cells were stained and gated on CD4+, and LAG-3 expression was analyzed by flow cytometry. 
Graph is representative of 4 independent experiments. Dot blots representative of 72h 
stimulation. (B) Fold change in % CD4+LAG-3+ cells and LAG-3 MFI was calculated as Ag/No 
Ag vs. Ag+CA/No Ag and averaged from the 4 in vitro independent experiments represented in 
A, *p<0.05. (C) NOD mice were split into two groups (n=14/group) and treated daily with CA 
or HBSS as a control. On day 0, mice were immunized with insulin in CFA. Inguinal LNs were 
removed and pooled at the indicated days post-immunization (days 0.5, 1, 2, 3, 4, 6, 8) from 2 
mice/group, stained for and gated on CD4+ cells, and LAG-3 was analyzed by flow cytometry. 
Graph shows the average of 3 independent experiments. 
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2.4.4.1 Autoantigen stimulation plus CA increases the frequency of LAG-3+ T cells 
 
In addition to cognate mimotope stimulation, BDC-2.5.TCR.Tg splenocytes were stimulated 
with more physiological autoantigens, whole islet cells and beta-membrane, which is an isolated 
preparation of the insulin-containing secreted beta granules. Following redox modulation, 
splenocytes stimulated with either antigen demonstrated significant increases in the frequency of 
LAG-3+ cells compared to splenocytes stimulated without CA (Figure 17A).  
BDC-2.5.TCR.Tg T cells are considered primed autoreactive cells, as they mature in vivo 
in the presence of their cognate antigen (277), chromogranin A, which is part of the beta granule 
membrane (115). Redox modulation was additionally tested in a naïve, autoreactive strain called 
the 6.9TCR/NOD.C6 mouse. The T cells in the C6.6.9 model express the BDC-6.9 transgenic 
TCR, which is specific for an unknown beta granule membrane antigen. Antigen for the BDC-
6.9 TCR is encoded on chromosome 6 in the NOD mouse; however, in the NOD.C6 model, this 
chromosomal region is replaced by the BALB/c locus, making the T cells naïve autoreactive 
since they are not matured in vivo in the presence of their cognate antigen (356). In this system, 
redox modulation during stimulation with beta-membrane significantly enhanced the numbers of 
LAG-3+ T cells (Figure 17B). These data demonstrate the ability of CA to affect LAG-3 in both 
a primed and naïve T autoreactive cell state.  
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Figure 17: LAG-3+ T cell frequency is enhanced following autoantigen stimulation plus 
CA. (A) BDC-2.5.TCR.Tg splenocytes or (B) C6.6.9 splenocytes were stimulated with 
NOD.scid islet cells or beta-membrane +/- CA in vitro.  At 24-96h, cells were stained and gated 
on CD4+, and LAG-3 expression was analyzed by flow cytometry. Fold change in % 
CD4+LAG-3+ cells was calculated as Ag/No Ag vs. Ag+CA/No Ag and averaged from 3 in 
vitro independent experiments. *p<0.05, **p<0.005, ***p<0.0005. 
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2.4.5 LAG-3 shedding is reduced upon CA treatment 
In addition to surface levels, sLAG-3 was also analyzed following M stimulation of BDC-
2.5.TCR.Tg splenocytes. LAG-3 contains four extracellular domains (D1-D4), a connecting 
peptide region (CP), a transmembrane domain (321), and a cytoplasmic tail (335). Within the 
immunological synapse, an antigen-mediated respiratory burst activates TACE by oxidizing 
Cys522 and Cys600 to release the TACE prodomain (54; 55). Active TACE then cleaves the 70 
kDa full-length LAG-3 within the CP, shedding D1 through D4 domains, a 54 kDa fragment 
(321). sLAG-3 shed into the serum can be measured as a marker of T cell activation (334) 
(Figure 18).  
Figure 18: LAG-3 cleavage schematic. LAG-3 is expressed on the cell as a 70 kDa molecule. 
TACE cleavage occurs within the CP region, releasing a 54 kDa subunit that transiently 
dimerizes with other full-length LAG-3 left on the cell surface. Eventually, the cleaved portion is 
shed into the serum as sLAG-3 and eventually excreted out of the body (321). 
 
 
Immunoprecipitation and subsequent western blotting of BDC-2.5.TCR.Tg splenocyte 
culture supernatants demonstrated reduced sLAG-3 after CA treatment compared to control 
samples (Figure 19A), illustrating decreased LAG-3 cleavage upon redox modulation. Notably, 
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sLAG-3 was undetectable in the ‘No Ag’ sample, which did not undergo antigenic stimulation. 
From these results, we postulate that CA can reduce LAG-3 shedding by modulating TACE 
enzymatic function. 
2.4.6 CA exposure decreases sLAG-3 in a TACE-dependent manner 
We next wanted to test the dependence, as a result of T cell activation, of redox-mediated TACE 
modifications on LAG-3 cleavage.  In order to attribute the reduction of LAG-3 shedding to CA-
regulated TACE, we compared M vs. M+CA vs. M+TAPI, a known TACE inhibitor. M+CA 
decreased sLAG-3 levels in comparison to M alone (p<0.05) as detected by ELISA (Figure 19B) 
and consistent with Figure 19A. Both CA and TAPI reduced the amount of detectable sLAG-3 
to a similar extent (p<0.05) in comparison to M alone. Furthermore, a comparison between 
M+TAPI and M+CA+TAPI demonstrated no significant difference in reducing sLAG-3 levels. 
These data suggest that CA treatment is likely inhibiting TACE-dependent LAG-3 cleavage.  
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Figure 19: Soluble LAG-3 protein is decreased following CA treatment. (A) Supernatants 
from BDC-2.5.TCR.Tg splenocytes stimulated +/- M +/- CA for 48h were concentrated using 
Amicon Ultra Centrifugal Filters at a 30K cutoff. The >30K portion was then 
immunoprecipitated with anti-LAG-3 Ab, separated on an SDS-PAGE gel, and probed for LAG-
3 by western blot. Data representative of 3 independent experiments. (B) BDC-2.5.TCR.Tg 
splenocytes were stimulated with M +/- CA +/- TAPI-1 for 72h. Supernatants were collected and 
used in sLAG-3 ELISAs. N.D.= none detected. Graph shows the average of 4 independent 
experiments performed in triplicate. *p<0.05. 
2.4.6.1 LAG-3 transcription and protein levels are reduced following CA treatment 
 
 
In addition to reductions in sLAG-3 detected in supernatants after stimulation plus CA, LAG-3 
transcription and translation were also measured in whole splenocytes and isolated CD4+ T cells. 
At 72h post-stimulation, LAG-3 mRNA is significantly reduced in BDC-2.5.TCR.Tg splenocytes 
activated with M+CA (Figure 20A). Likewise, both full-length and cleaved LAG-3 protein 
levels are also reduced in CA-treated splenocytes and isolated CD4+ T cells (Figure 20B, C). 
These data may seem to contradict the flow cytometric results which show no detectable 
differences in the amount of LAG-3 per cell (MFI) after redox modulation (Figure 20C). 
However, the flow cytometric studies only measured the amount of LAG-3 on the cell surface, 
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not what was contained inside the cell. Previous reports have suggested the storage of preformed 
LAG-3 in intracellular vesicles (353), which could be the source of the differences detected in 
whole cell lysates by western blot. Overall, the reductions in LAG-3 mRNA and protein would 
likely contribute to the significant decrease in cleaved sLAG-3. This outcome, together with the 
effects of CA on TACE activity, would further delay diabetogenic T cell activation. 
Figure 20: LAG-3 transcription and protein levels are reduced upon redox modulation. (A) 
BDC-2.5.TCR.Tg splenocytes were stimulated with M +/- CA for 72-96h. mRNA was isolated, 
cDNA was transcribed, and relative lag3 mRNA levels were measured by qRT-PCR. The fold 
change of M samples were set arbitrarily to 1 and compared to M + CA treatment. All samples 
were normalized to the endogenous GAPDH control. n=3 independent experiments. **p<0.005. 
(B-C) BDC-2.5.TCR.Tg splenocytes were treated with M +/- CA for 48-96h. (B) Whole cell 
lysates were made and probed for LAG-3. Actin was used as a loading control. Graph 
representative of n=3 independent experiments. (C) CD4+ T cells were isolated via MACS 
separation after 72h stimulation. Whole cell lysates were made and probed for LAG-3. Actin was 
used as a loading control. Densitometry was determined by normalizing M and M+CA to actin 
and then dividing M/M+CA for 3 independent experiments. 
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2.4.7 Redox modulation reduces TACE levels and enzymatic activity 
We also wanted to determine if CA treatment specifically decreased TACE enzymatic activity. 
Utilizing BDC-2.5.TCR.Tg splenocytes in an in vitro TACE-specific fluorogenic assay, 
enzymatic activity in CA-treated cells was significantly decreased compared to M-stimulated 
cells (p<0.005) (Figure 21A). As a positive control, TAPI-treated cells also demonstrated a 
significant reduction in TACE activity (p<0.0005). To delineate whether the difference in 
enzymatic activity corresponded with decreased levels of TACE protein, we performed western 
blots for the TACE prodomain and active isoforms. TACE is formed as a latent/inactive enzyme 
containing a disulfide linkage, whereby oxidation of the bond promotes autocatalytic cleavage of 
the prodomain (20 kDa) from the active subunit (80 kDa) (54; 55). Under CA exposure, cleavage 
of the TACE prodomain was reduced compared to control samples (Figure 21B), indicating less 
oxidation of the critical cysteine switch and likely resulting in decreased enzymatic activity. 
Membrane lysates also exhibited diminished levels of active TACE following CA treatment 
(Figure 21C). Interestingly, immature TACE was also reduced upon redox modulation, 
suggesting less overall activation-induced expression of TACE (54; 357).   
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Figure 21: Redox modulation diminishes active TACE levels and enzymatic function. (A) 
BDC-2.5.TCR.Tg splenocytes were stimulated with M +/- CA +/- TAPI for 24h and 
supplemented with TACE-specific fluorogenic substrate. Fluorescence was measured at 6h post 
substrate addition. The fold change in activity was calculated by Stimulated Cells/Unstimulated 
vs. Stim + CA/Unstimulated vs. Stim + TAPI/Unstimulated Cells. Graph shows the average of 3 
independent experiments performed in triplicate. p<*0.05,**0.005, ***0.0005. (B-C) BDC-
2.5.TCR.Tg splenocytes were stimulated with M +/- CA for 72h and probed for TACE by 
western blot. (B) Whole cell lysates were used. Actin was probed as a loading control. (C) 
Membrane lysates were utilized. Data are representative of 3 independent experiments.  
2.4.7.1 CA is able to inhibit protein oxidation, leading to less TACE activity 
 
As a proof of principle, BDC-2.5.TCR.Tg splenocytes were stimulated +/- CA to test the overall 
oxidation of proteins as well as the ability of TACE to cleave pro-TNFα, its canonical shedding 
target. Membrane lysates were isolated and stained with F5M, which labels sulfhydryl-
containing reduced proteins. Redox modulation showed a general decrease in protein oxidation, 
contributing to reduced TACE activation (Figure 22A). Furthermore, BDC-2.5.TCR.Tg 
splenocytes stimulated with islet cells + CA demonstrated significant reductions in TNFα 
secretion, once again indicating effects on TACE enzymatic activity (Figure 22B).  
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Figure 22: Redox modulation reduces protein oxidation and TNFα shedding. BDC-
2.5.TCR.Tg splenocytes were stimulated with (A) M +/- CA or (B) NOD.scid islet cells +/- CA. 
(A) Membrane lysates were labeled with F5M, run on an SDS-PAGE gel, and visualized by 
fluorescence. Gel representative of 3 independent experiments. (B) Supernatants were collected 
after 72h stimulation and utilized in a TNFα ELISA. n=3 independent experiments, *p<0.05. 
2.4.8 CA treatment prevents diabetes transfer in correlation with reduced sLAG-3 serum 
 levels 
We next monitored LAG-3 in conjunction with diabetes progression upon adoptive transfer of 
disease-causing T cells. Measurement of sLAG-3 has been used as an index of breast cancer 
prognosis, with greater levels corresponding to better anti-tumor CTL responses and patient 
survival (334). Underlying these observations is an increase in T cell activation, and we therefore 
propose that diabetogenic T cell activation can be indirectly ascertained by serum sLAG-3. To 
assess this possibility, NOD.scid mice (10 wks old) were adoptively transferred with BDC-
2.5.TCR.Tg splenocytes and treated daily with CA. Control animals all developed diabetes by 
day 15 post-transfer, whereas CA-treated mice remained disease-free until the end of the study at 
day 28 (p<0.0001) (Figure 23A). Furthermore, serum levels of sLAG-3 steadily increased in 
control animals over time, yet sLAG-3 from CA-treated mice was significantly lower at days 12 
and 16 post-transfer (p<0.05) (Figure 23B). Splenocytes were isolated either at diabetes onset 
(day 16) or at the end of the experiment (day 28) and stained for LAG-3. CA-treated animals had 
a higher frequency of LAG-3+CD4+T cells versus control animals (p<0.05) (Figure 23C). 
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Additionally, in vivo CA treatment decreased active TACE protein levels compared to control 
animals (Figure 23D). sLAG-3, therefore, serves as a biomarker of type 1 diabetes progression 
in this model and correlates with enhanced LAG-3+ T cells, decreased active TACE levels, and 
inhibition of disease following CA treatment. 
 
Figure 23: Redox modulation delays diabetes onset, which correlates with decreased sLAG-
3 and enhanced LAG-3+ cells. NOD.scid mice (n=3/group) were treated on day -1 through day 
28 i.p. with or without CA. BDC-2.5.TCR.Tg splenocytes were i.v. transferred on day 0. (A) 
Mice were monitored by glucosuria for the onset of type 1 diabetes and considered diabetic after 
two consecutive blood glucose readings of >300 mg/dl,***p<0.0001. (B) Blood was collected 
retroorbitally every 4 days to day 16, and serum was isolated for sLAG-3 ELISA. Open squares 
= control, filled diamonds = CA-treated.*p<0.05. (C) On day 16 and 28 post-transfer, 
splenocytes were stained for and gated on CD4+ cells. LAG-3 was detected by flow cytometry. 
Graph shows the average of 3 mice/group, *p<0.05. (D) Lysates were made from splenocytes 
and run on an SDS-PAGE gel. Western blots were performed to measure TACE expression. 
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2.4.9 sLAG-3 levels correlate with diabetes incidence in NOD mice 
 
Historically, NOD females are known to have an earlier onset and greater diabetes incidence 
than NOD males. Therefore, sLAG-3 was measured over several weeks of age to determine if it 
correlated with diabetes onset. In Figure 24A, sLAG-3 is significantly increased in NOD 
females early in life (6-8 weeks of age) in comparison to NOD males. After 10 weeks of age, the 
differences in sLAG-3 between genders are less pronounced. NOD female mice in this particular 
cohort succumbed to disease starting at 13 weeks of age, significantly earlier than male disease 
onset and 7 weeks following the significant differences in sLAG-3 observed between female and 
male mice (Figure 24B). This delay in disease after T cell activation between the sexes may be 
attributed to differences in the development of autoantibodies, which are known to precede 
diabetes onset (358) and to depend on T cells for their formation. This possibility was further 
investigated utilizing human serum samples. 
 
Figure 24: Early detection of sLAG-3 correlates with greater type 1 diabetes incidence in 
NOD females. (A) NOD females and males were bled for serum every 2 weeks starting at 6 
weeks of age. Sera were quantified using a sLAG-3 ELISA. **p<0.005. (B) NOD mice were 
monitored for diabetes onset weekly, starting at 12 weeks of age. Two subsequent blood glucose 
readings >300 mg/dl were considered diabetic. n=4 mice/group, *p<0.05. 
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2.4.10 First-degree relative sLAG-3 levels inversely correlate with the number of 
 autoantibodies 
Upon T cell activation, sLAG-3 is shed from the cell surface, enabling the measurement of 
serum levels prior to disease onset, as depicted in Figures 23 and 24. sLAG-3 was first 
quantified from the serum of type 1 diabetes patients ranging from bleeds at onset to bleeds 
almost 6 years after onset (Figure 25). No differences in sLAG-3 were detected regardless of the 
date of collection, suggesting the time point of serum evaluation may be too late and 
heterologous immunity may have masked any distinction.  
 
Figure 25: sLAG-3 levels do not vary between healthy controls and type 1 diabetes patients 
at onset or beyond. Sera from different bleed collection times (A: at onset, B: recent onset, C: 
+/- 2 years post-onset, D: +/- 5.9 years post-onset) were utilized in a hLAG-3 ELISA. The 
number of serum samples per collection time is indicated on the graphs. 
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The autoantigens identified in type 1 diabetes are T cell-dependent antigens, which 
require antigen presentation and TCR binding. T cell help through MHC-peptide interaction with 
the B cell and costimulation via CD40L-CD40 is necessary for plasma cell activation and 
antibody secretion (359). Consequently, autoantibody production is secondary to T cell 
activation. The kinetics of sLAG-3 would most likely precede the secretion of autoantibodies for 
type 1 diabetes prediction and onset. As a genetic disease, first-degree relatives of type 1 
diabetes patients have a high susceptibility to disease (4; 5; 358). In this population, HLA testing 
can be performed to predict onset; additionally, autoantibodies are often measured to determine 
risk. The number of autoantibodies is a reliable predictor of type 1 diabetes, with 3 being the 
highest (GAD, IAA, IA2) and 0 being the lowest risk (360). Therefore, sLAG-3 was measured in 
first-degree relatives who contained various numbers of autoantibodies. In comparison to type 1 
diabetes patients, sLAG-3 levels in antibody-negative (Ab-) first-degree relatives were almost 
significantly higher (Figure 26A), indicating the beginning stages of T cell activation and 
possibly predicting progression to disease. Furthermore, the number of autoantibodies was 
determined compared to sLAG-3; 0-1 autoantibody correlates with greater sLAG-3 levels, 
whereas 2-3 autoantibodies correlates with very low levels of sLAG-3 (Figure 26B). This 
phenomenon demonstrates an inverse correlation of sLAG-3 with the number of autoantibodies, 
both contributing to type 1 diabetes risk. 
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Figure 26: sLAG-3 inversely correlates with autoantibody levels. Sera were utilized in a 
hLAG-3 ELISA. (A) Sera were collected at +/- 5.9 years post-onset (reanalyzed from Figure 25), 
from first-degree relatives that were antibody-negative or positive, or from healthy controls. n=1-
8 samples/group. (B) sLAG-3 from first-degree relatives was compared to the number of 
autoantibodies present. n=20. 
2.5 DISCUSSION 
Because CA treatment directly affects innate immune cells and proinflammatory third signal 
synthesis (48) as well as NF-κB and NF-κB-dependent gene transcription (64), we sought to 
understand how modulating redox balance could influence activation and function of 
diabetogenic TH1 cells. In particular, we hypothesized that CA administration would decrease 
TACE-dependent LAG-3 shedding, leading to autoreactive T cell hyporesponsiveness and 
reduced type 1 diabetes.  
In this study, long-term modulation of the redox state resulted in significantly delayed 
type 1 diabetes onset, illustrating the importance of ROS in promoting autoreactive immune 
responses. With the correlation of 1 mouse year = 34 human years (361), CA was able to extend 
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diabetes onset for about 10 years, and if the mouse model truly depicts human type 1 diabetes, 
CA treatment would result in a human onset time of 22 years old instead of 12 years old in the 
controls. However, stopping the CA treatment at 29 weeks does not seem to afford absolute 
enduring protection against disease onset. This may be due to blood clearance of the modulator 
as a result of troughing of the CA level below the effective concentration and consequently, loss 
of therapeutic efficacy. Under this circumstance, CA treatment alone may require chronic 
administration to inhibit diabetes onset; however, CA administration in combination with an 
antigen-specific therapeutic approach targeting self-reactive T cells might afford long-lasting 
protection by inducing T cell-specific ignorance or tolerance. Nonetheless, CA treatment has 
marked effects on early T cell responses, resulting in a delay in diabetes onset. BDC-2.5.TCR.Tg 
T cells demonstrated decreased activation, proliferation, and effector function upon CA 
treatment, which correlated with enhanced LAG-3+CD4+ T cells in vitro and a trend towards 
significant increases in vivo. The effect of CA on LAG-3 is T cell specific in our system, as 
double-staining for CD3 and CD4 overlapped 100%, excluding the possibility of pDC expression 
of LAG-3 (data not shown). Absence of T cell activation, coupled with greater LAG-3+CD4+ T 
cell frequency, indicates two possible consequences of redox modulation: (1) less 
activation/progression to effector function of antigen-specific autoreactive T cells and/or (2) 
obstruction of LAG-3 shedding. Notably, T cells from insulin immunized mice exhibited reduced 
TH1 effector responses (decreased IFN-γ synthesis and a lower frequency of antigen-specific T 
cells), suggesting that regulation of LAG-3 may be responsible for this phenomenon. With recent 
reports demonstrating accelerated diabetes in LAG-3(-/-) NOD mice (332; 333), our redox 
modulation results may be reflective of T cell ignorance (362; 363). Diabetogenic T cells in 
NOD mice already have an advantage of efficiently expanding from a greatly reduced precursor 
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pool (364). If CA delays or prevents the autoantigen-specific T cell pool necessary for reaching 
the threshold at which a break in tolerance to self-antigen occurs, disease onset should be 
reduced. 
Collectively, our results also suggest that an overall delay in T cell activation kinetics 
may be the main cause of redox modulation anomalies. Impaired TACE activity, via LAG-3, 
offers new insights into a novel mechanism of autoreactive T cell activation thus far unknown, 
and redox-dependent modifications together can contribute and feed-forward to prevent 
diabetogenic immune responses. 
Redox modulation also reduced the transcription and translation of LAG-3. We have 
previously identified NF-κB as another target of redox modulation (64). Notably, redox-
dependent NF-κB is a predicted transcription factor responsible for LAG-3 expression 
(SABiosciences' Text Mining Application). Therefore, it is tempting to speculate that new LAG-
3 protein synthesis is retarded as a result of CA-mediated NF-κB inhibition, contributing to the 
reduction in sLAG-3 observed. CA was also able to affect TACE activation and enzymatic 
activity, further contributing to decreased sLAG-3. Immature TACE levels were also reduced 
after treatment. Because oxidants activate signaling kinases and GTPases to drive the expression 
of metalloproteases (54; 357), scavenging of oxidants by CA (64; 269; 313) may inhibit proper 
signal transduction and cause decreased expression of immature TACE. Another 
metalloprotease, ADAM10, unlike TACE, is responsible for constitutive LAG-3 shedding (321) 
and may also be partially inhibited by CA treatment (54; 315; 316; 320). However, our 
experiments using TAPI blocked LAG-3 shedding by both metalloproteases, ruling out enzyme-
specific differences (365). Both TAPI and CA demonstrated similar reductions in sLAG-3 versus 
M alone, supporting the notion that CA can directly modify TACE-dependent cleavage.  
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Based on the current data, redox-modulated LAG-3+ cells may have altered signal 
transduction pathways and/or are functioning as suppressive T cells (355; 366; 367).  Upon TCR 
recognition of peptide-MHC, LAG-3 colocalizes with the TCR in the lipid raft and binds with 
greater affinity to MHC class II molecules than does CD4 (331; 368; 369). However, the mere 
blockade of CD4 binding to MHC class II is not sufficient to decrease TH1 activation; therefore, 
LAG-3 may signal in a negative manner to downregulate T cell activation (351; 370). Although 
LAG-3-MHC class II ligation stimulates SHP-1 and ERK activation in the DC, signaling through 
LAG-3 into the T cell is currently undefined (371). The cytoplasmic tail of LAG-3 contains a 
KIEELE motif (351) and an EP motif which binds to the protein LAP (LAG-3-associated 
protein) as determined by yeast two-hybrid system, though the function of LAP is unidentified 
(372). By mutating the cytoplasmic KIEELE motif of LAG-3, proliferation is increased, 
indicating the importance of inhibitory downstream signaling in control of expansion (354). 
Therefore, the KIEELE motif is thought to mediate negative signaling, whereas the EP motif 
may prevent LAG-3 from acting as a coreceptor (349). Nonetheless, the EP motif is rare in 
human proteins, and since LAG-3 lacks an immunoreceptor tyrosine-based inhibitory motif 
(ITIM), this unique EP motif may be critical for full LAG-3 function (372). LAG-3-TCR 
cocapping studies performed by Hannier et al. show inhibition of calcium fluxes, induction of 
CD25, but lack of apoptosis, following LAG-3 cross-linking (368). These results provide 
evidence that LAG-3 is necessary for immune response control, yet inhibits cell death and 
induces IL-2R, most likely for eventual proliferation or the maintenance of regulatory T cells.  
Retention of LAG-3 on CD4+ T cells could potentially decrease the frequency of activated 
autoreactive T cells and, based on recent findings, may act as regulatory T cells. Natural 
CD4+CD25+ Tregs have been shown to express LAG-3 upon activation (355), and 
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CD4+CD25+FOXP3+LAG-3+ adaptive Tregs have been detected in tumor draining lymph 
nodes, requiring cell-to-cell contact for suppression (373). Furthermore, IL-10 secreting 
CD4+CD25-FOXP3-LAG-3+ Tregs have been isolated from the Peyer’s Patches and express 
Egr2, a transcription factor necessary for anergy (366). Contrary to kinetics in effector cells, 
regulatory T cells retain the expression of LAG-3 despite activation status, and require LAG-3, 
as their suppressive activity is decreased upon antibody blockade of the molecule (367). 
Additionally, ectopic expression of LAG-3 is able to bestow suppressor activity upon CD4+ T 
cells (321; 355), illustrating the possible effects of non-physiological manipulation and 
preservation of functional LAG-3. Ultimately, the conservation of cell surface LAG-3 may lead 
to early contraction of T cell activation, either by directly affecting the T cell on which it is 
expressed, or by imparting regulation via modulation of accessory cells (371). Both signal 
transduction and regulatory potential will be determined in future studies.   
 sLAG-3 shedding coincides with in vivo SEB-mediated T cell activation (335) as well as 
T cell activation in breast cancer screens (334). At present, there is a paucity of serum 
biomarkers that measure T cell activation prior to overt diabetes (374), and little is known about 
the endogenous role of LAG-3 in autoimmune settings. We therefore, wanted to determine if we 
could monitor diabetes progression via serum sLAG-3. Redox modulation prevented type 1 
diabetes onset in the rapid adoptive transfer model, similar to previous reports (36), but more 
importantly, sLAG-3 directly correlated with T cell activation and autoimmunity. Serum sLAG-3 
was enhanced in control animals before and upon disease onset, suggesting greater activation of 
diabetogenic T cells. sLAG-3 may, therefore, serve as a T cell-specific diagnostic marker for 
initiation of beta cell destruction, and along with surface LAG-3 expression, may additionally 
function as surrogates of immunomodulation. Furthermore, sLAG-3 was higher in NOD females 
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than males at early time points, which tracks with diabetes risk and indicates a delay between T 
cell activation and disease onset. However, human sLAG-3 did not differ between type 1 
diabetes patients and healthy controls; instead, sLAG-3 inversely correlated with the number of 
autoantibodies present in first-degree relatives highly susceptible to disease. This suggests that 
sLAG-3 may be a potential biomarker for the early progression of at-risk individuals to help 
predict disease manifestation a priori autoantibody appearance, but larger first-degree relative 
studies need to be conducted in order to definitively make this conclusion.  Additionally, 
therapies that utilize prophylactic drugs, as well as attempts at reversal of autoimmunity, may 
result in the modification of adaptive immune responses, and measurement of sLAG-3 would 
allow for determination of treatment efficacy on autoreactive T cells in a noninvasive manner.  
Taken together, our data suggest that redox modulation arrests LAG-3 shedding by 
impeding expression kinetics and decreasing TACE activity. Through redox manipulation, LAG-
3 surface expression is maintained at levels adequate to attenuate TCR-mediated TH1 cell 
activation and effector function. This would be beneficial for maintaining diabetogenic effector 
cells in a quiescent state or in preventing their activation entirely. In concert with the recently 
reported mechanisms of direct and indirect actions of CA on immune cells and diabetes 
progression (36; 48; 64; 154; 278; 297), the identification of LAG-3-mediated immunoregulation 
adds another layer to the control of autoimmunity. Our discovery also supports the use of sLAG-
3 as a novel surrogate marker of type 1 diabetes progression in preclinical situations and possibly 
as a means to monitor the effectiveness of T cell-directed immunotherapy. 
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3.0  REDOX MODULATION PROMOTES METABOLIC QUIESCENCE AND 
REGULATION OF IMMUNE CELLS 
3.1 REVIEW: CHANGING THE ENERGY OF AN IMMUNE RESPONSE 
The breakdown of nutrients into the critical energy source ATP is the general purpose of cellular 
metabolism and is essential for sustaining life. Similarly, the immune system is composed of 
different cell subsets that are indispensable for defending the host against pathogens and disease. 
The interplay between metabolic pathways and immune cells leads to a plethora of different 
signaling pathways as well as cellular activities. The activation of T cells via glycolysis-mediated 
upregulation of surface markers, for example, is necessary for an appropriate effector response 
against an infection. However, tight regulation of immune cell metabolism is required for 
protecting the host and resuming homeostasis. An imbalance of immunological metabolic 
function and/or metabolic byproducts (reactive oxygen species) can oftentimes lead to diseases. 
In the case of cancer, overactive glucose metabolism can lead to hyperproliferation of cells and 
subsequent decreases in cytotoxic T cell activity, which attack and destroy the tumor. For this 
reason and many more, targeting metabolism in immune cells may be a novel therapeutic 
strategy for treatment of disease. The metabolic pathways of immune cells and the possibilities 
of immunometabolic therapies will be discussed.   
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3.1.1 Aerobic respiration 
Cellular metabolism is necessary for generating energy and sustaining life. Through a series of 
steps involved in glycolysis (glucose), fatty acid (fat) oxidation, and amino acid (protein) 
oxidation, cells can break down ingested products into critical energy sources. This energy, 
better known as adenosine triphosphate or ATP, is synthesized as a result of the degradation of 
nutrients. Oxygen (O2) plays a key role in enabling reactions required for the formation of ATP. 
In human cells, oxidative phosphorylation is the main process leading to the generation of ATP 
(375). The degradation of nutrients through the glucose oxidation, fatty acid oxidation, or amino 
acid oxidation pathways converge to all produce acetyl-CoA, a key molecule that provides a 
carbon source for fueling the TCA cycle. The oxidation of acetyl-CoA to carbon dioxide (aerobic 
respiration) then allows for the subsequent reduction of nicotinamide adenine dinucleotide 
(NAD+) and flavin adenine dinucleotide (FAD) via the TCA cycle. The intermediate products, 
NADH and FADH2, serve as electron transport chain coenzymes for oxidative phosphorylation. 
For efficient respiration, electrons must be transferred from NADH and FADH2 to oxygen via the 
mitochondrial complexes along the electron transport chain within the inner mitochondrial 
membrane. To ensure proper oxidative phosphorylation, electrons must be strictly allocated 
down the electron transport chain while protons must be pumped across the mitochondrial 
membrane.  This movement of electrons not only facilitates the production of H2O, but also 
drives a proton gradient that causes the phosphorylation of adenosine diphosphate to adenosine 
triphosphate (Figure 27). ATP can then be utilized for a number of events including 
DNA/RNA/protein synthesis, cell signaling, cytoskeletal rearrangement, cell proliferation, and 
metabolic pathways. In addition to its necessity for energy production, the electron transport 
chain is also responsible for the formation of mitochondrial reactive oxygen species (ROS) 
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through continuous ‘leakage’ of electrons, causing partial reduction of O2 molecules (376). Such 
events lead to the generation of superoxide (O2
-
), hydrogen peroxide (H2O2), and hydroxyl 
radical (OH
-
), which can both stimulate physiological actions as well as damage important 
molecules in the body (377), depending on the quantity. At low levels, ROS help control normal 
cellular functions, as demonstrated by the immune system’s reliance on this type of signaling for 
regulation, activation, T cell proliferation (378; 379), NF-κB activation (380), and signal 
transduction (381-383). Conversely, high levels of ROS lead to oxidative stress, which has been 
linked to a variety of diseases, aging, and cell death (22; 384-386). ROS production is, thus, a 
necessary evil for functional aerobic metabolism.  
 
 
Figure 27: Energy generation in mitochondria. Mitochondria generate energy by oxidative 
phosphorylation. Alternatively, energy may be generated by glycolysis alone, where pyruvate is 
converted to lactate. Used with permission from Sex Transm. Infect. (387). 
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3.1.2 Aerobic glycolysis 
Although aerobic respiration is the main source of ATP in most mammalian cells, an alternative 
form of metabolism, glycolysis, is crucial in both immunity and disease states. Glycolysis 
enables the conversion of one glucose molecule to 2 pyruvate molecules, with subsequent 
production of lactate, NAD+, and ATP. The utilization of glycolysis is a less efficient form of 
metabolism. During mitochondrial respiration, a cell is able to produce 38 ATP molecules; 
however, during glycolysis, only 2 molecules of ATP are generated. Obviously, the 19-fold 
increase in ATP via oxidative phosphorylation seems more advantageous to the cell, especially 
since both metabolic pathways can use glucose as the starting material. However, glycolysis is 
especially important in times of hypoxia (anaerobic) and can occur even in the presence of 
oxygen (aerobic), such as with tumors and immune cells. Both anaerobic and aerobic glycolysis 
are crucial for the maintenance of tumor cells (388-390). Tumor cells switch their energy 
production from oxidative phosphorylation to glycolysis upon transformation to malignancy 
(391; 392). This enables the tumor to rapidly grow in hypoxic environments and evade host 
immune cell defense mechanisms (393-395). In oxygenated environments, tumor cells display 
augmented glucose transport and glycolysis (396; 397). This counterintuitive metabolic 
programming has been attributed to over-adaptation to hypoxic environments, a greater need for 
macromolecules during unrestrained proliferation (glycolysis affords better protein/nucleotide 
synthesis), and elevated expression of the glycolytic enzyme hexokinase (398; 399). This high 
aerobic glycolysis seen in cancer cells is called the Warburg effect (388; 400) and has led to the 
development of anti-glycolytic drugs for cancer treatment (401-403). During proliferation, T 
cells and cancer cells show similar metabolic programming. Thus T cells, even in the presence of 
sufficient oxygen, also choose to ferment glucose, as further discussed below.  
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3.1.3 Immune cell metabolism 
The immune system is made up of two different arms: the innate and adaptive immune system. 
The innate system is a first-line of defense against pathogens and foreign substances. Unlike the 
adaptive arm, the innate response is non-specific and is mediated by antigen-presenting cells and 
granulocytes. Examples of innate cells include dendritic cells, macrophages, and neutrophils. 
After successful priming by the innate cells, the adaptive immune response, made up primarily of 
T and B cells, provide antigen-specific protection against the insult, either through the release of 
cytotoxic granules, cytokines, or antibodies. Immune cells, like most other cells in the body, 
utilize nutrients via cellular metabolism. At rest, immune cell metabolism is able to regulate cell 
volume, ion integrity and growth (404). However, in addition to housekeeping proliferation and 
sustenance, ATP within the immune cells must be ready to carry out various functional activities 
such as phagocytosis, activation, antigen presentation/processing, migration, phosphorylation, 
differentiation, and effector responses (404; 405). Most of these actions are thermodynamically 
taxing, requiring notable and rapid changes in metabolism (404; 406). Furthermore, immune 
cells must facilitate cytoskeletal changes, increased ion signaling, enhanced phospholipid 
turnover, and greater macromolecule synthesis in a very short time during rapid energy 
consumption (407). Importantly, resting immune cells, especially those of the adaptive arm, 
contain little glycogen stores, resulting in the dependence of imported glucose to uphold 
metabolic needs (408-410).  
Because of the diverse functionality of immune cells, several important differences exist 
between their metabolism and that of other cells within the body. Alveolar cells, for example, are 
reliant primarily on oxidative phosphorylation for the generation of sufficient ATP (411). Those 
cells which are in constant contact with oxygenated blood are especially formulated for 
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mitochondrial respiration. On the other hand, immune cells travel through the body to monitor 
the peripheral tissues. Once a foreign antigen is detected, APCs migrate to the draining 
secondary lymphoid organs where they can process and present the antigen to lymphocytes. 
APCs are present in strategic areas of the body as resident phagocytes. These cells, therefore, are 
not necessarily exposed to normoxic conditions at all times. For instance epidermal dendritic 
cells reside within the deep tissue layers of the skin (412), where oxygen tension is lower than 
the dermis (413). Such conditions create a slightly hypoxic environment in which key immune 
cells must be able to utilize alternate forms of metabolism in order to survive and function 
properly (414). Similarly, lymphocytes, upon activation within the secondary lymphoid organs, 
travel to the site of inflammation by traversing the endothelial cell wall into the target area (415). 
Once again, the migration of lymphocytes away from the source of oxygen causes slight hypoxia 
and a resultant loss of dependence on oxidative phosphorylation. Most sites of inflammation are 
also areas of lowered oxygen, with innate phagocytes clogging the blood vessels (416-418). 
Localization of immune cells thus requires adaptation to different oxygen levels and promotes 
more glycolytic pathways (419; 420). 
Although influential, the environment is not the only element dictating the metabolic 
choices within immune cells. The activation of both innate and adaptive immune cells is 
absolutely critical for protecting the body from pathogens and insults. Consequently, the cells 
cannot afford to be inefficient in their nutrient metabolism. With this being said, it would seem 
likely that immune cells should generate ATP via oxidative phosphorylation, fostering the most 
energy from the nutrients provided. However, this is not entirely the case. Although some 
mitochondrial respiration does occur in immune cells, the level at which it is used depends 
significantly on the cell’s specificity and state of reactivity. Activated (and some inactive) 
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immune cells prefer to utilize glycolysis, as it is 100-times faster than oxidative phosphorylation 
for macromolecule synthesis and proliferation (421) (Figure 28). 
Figure 28: Metabolic pathways of resting vs. activated immune cells. In quiescent cells, 
glucose is oxidized within mitochondria generating high levels of CO2, ATP, and ROS. 
Conversely, proliferating cells partially oxidize glucose by the glycolytic pathway to generate 
lactate, ATP, and metabolic intermediates for biosynthesis of macromolecules. Used with 
permission from Biochim. Biophys. Acta (422).  
 
 As mentioned, naïve APCs monitor the body for foreign substances. In this resting state, 
myeloid cells and granulocytes favor glycolysis (423; 424). Homeostatic protein turnover, 
degradation, and synthesis all occur via growth factor utilization (425; 426). Once antigen is 
phagocytosed, APCs immediately upregulate costimulatory molecules and process and present 
antigen on their cell surface. Such events require greater ATP; however, APCs retain their 
dependence upon glycolysis (423; 424). Dendritic cells, for example, are known to undergo 
metabolic changes towards greater glycolysis upon toll-like receptor (TLR) stimulation (427). 
Moreover, classically activated macrophages (known as M1), which promote proinflammatory 
cytokines are known to be regulated by glycolysis; however, alternatively activated macrophages 
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(M2), which are anti-inflammatory, rely more so on mitochondrial respiration (428; 429). 
Glycolysis is, therefore, important for inflammatory responses and can be detrimental in the face 
of chronic inflammatory diseases. Granulocytes, such as neutrophils, also favor glycolysis (423; 
430). Neutrophils are the first mediators at the site of foreign entry. Their immediate 
degranulation and pyrogenic secretion lead to subsequent cell death (431). In accordance with 
the glycolytic reliability of APCs, quick responses are needed by neutrophils, but survival via 
greater ATP production is not necessary. Fast reactivity and turnover rates of both APCs and 
granulocytes, therefore, make sense with their choice to generate ATP through the more rapid 
glycolytic pathway. 
Lymphocytes, on the other hand, rely heavily on oxidative phosphorylation during resting 
states but switch their metabolic needs to glycolysis during activation. Subsequently, some 
lymphocytes return to oxidative phosphorylation after clearance of an antigen to generate 
memory (432-434). Therefore, there is a cyclical pattern of metabolic pathways, fluctuating 
between anabolism and catabolism, as reviewed by Pearce et al. (435). At rest, T cells need a 
constant supply of nutrients as well as TCR stimulation (436). The idea of TCR ‘tickling’ has 
long been thought to prevent deletion of mature T cells (437). The active metabolism behind the 
quiescent state is a relatively novel idea. Circulating naïve lymphocytes undergo oxidative 
phosphorylation to generate a surplus of ATP reserves via catabolic metabolism, the breakdown 
of nutrients (410). In a sense, quiescent immune cells remain ‘at attention’ in order to quickly 
mobilize following antigen stimulation (438). Preservation of quiescence is mediated by turnover 
of cell cycle proteins, a very active event which requires a lot of ATP (425; 426), and by 
upregulation of cyclin-dependent kinase inhibitors (439). Quiescent cells not only utilize 
glucose, amino acids, and lipids for ATP generation, but can also extract nutrients from those 
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proteins which are degraded, via autophagy or self-eating (404; 440; 441). Engagement of the 
TCR as well as growth factors and homeostatic cytokines, like IL-4, IL-5, IL-7, and IL-3 (442-
444), also all play roles in keeping naïve cells alive. Cytokine-receptor signaling, specifically, 
can activate protein kinases that are necessary for the uptake of adequate ATP to preserve 
homeostatic processes (410), whereas a lack of TCR interaction will downregulate glucose 
transport, ATP, and mitochondrial potential (436). Insufficiencies in glucose uptake by T cells 
will lead to BAX induction and apoptosis (445); however, this stringency serves to control the 
naïve T cell population, ensuring the turnover of existing cells as new cells are produced to avoid 
over accretion (436). 
Lymphocytes also need to become activated upon antigen stimulation, albeit more rapidly 
than innate immune cells. Such changes in metabolism are well-documented in the case of 
mitogen-stimulated lymphocytes (435; 438; 446). Within the first 24h post-mitogen stimulation, 
lymphocytes considerably enlarge their size (435). During this time, new macromolecules are 
being synthesized, including nucleotides and proteins. Following the growth, T cells then divide 
every 4-6 hours (446) and eventually will differentiate into effector cells. Effector functions such 
as cytokine production and cytotoxic granule release then enable the cell to attack the infected 
target tissue. This quick change in cell size and function relies primarily on obtaining nutrients 
from the environment and driving glycolysis (410). Instead of initiating the long process of 
oxidative phosphorylation, T cells convert glucose to pyruvate via the more rapid glycolysis 
(421), and in the process, generate ATP and lactate, which allows for the conversion of NADH 
back to NAD+ to retain glycolysis. The dependence of T cells on glucose is so great, that even in 
the presence of excess glutamine, which is another carbon source that can be metabolized by 
lymphocytes, proliferation is stunted (442). T cells are not able to enhance mitochondrial 
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respiration to a level that meets their energy needs. Moreover, T cells require high levels of 
NADH as macromolecular precursors; therefore, greater lactate production equals more NAD 
generation (406). Notably, following mitogen-stimulation, an excess of lactate can be measured 
from T cells (447; 448). Aerobic glycolysis ensures that enough energy is made to propel 
macromolecule synthesis (anabolic metabolism), which is ultimately crucial for clearance of a 
pathogen, as well as to keep the cells alive and functional (410; 449; 450). Some oxygen 
consumption does still occur (451), yet is typically only utilized in situations where glucose is 
limited (452; 453). Mitogenic-stimulation of peripheral blood mononuclear cells, for example, 
causes oxygen consumption attributed to ATPase activity, protein synthesis, and nucleic acid 
synthesis (405; 438). Moreover, activation of lymphocytes promotes a calcium flux, which will 
also drive the upregulation of mitochondrial enzyme activity for sufficient oxidative 
phosphorylation (454; 455). In the case of infection, T effector cells promote clearance of the 
pathogen and primarily utilize glycolysis for rapid growth. By the time pathogen has been 
cleared, the mitochondrial capacity of effector cells is reduced in such a way that they can only 
sustain viability through glycolysis. In the absence of adequate nutrients and IL-2 present during 
infection, effector cells are unstable and eventually will undergo apoptosis. Certain clones, 
nonetheless, will retain their ability to switch back to oxidative phosphorylation. Such cells will 
contain greater mitochondrial mass, either through differences in biogenesis or asymmetric 
division (432). In autoreactivity (456) as well as graft-versus-host disease (457), chronically 
stimulated T cells rely on oxidative phosphorylation in contrast to acutely activated cells (those 
discussed above) which depend on glycolysis. Oftentimes, such illnesses and metabolic 
outcomes correlate with mitochondrial dysfunction and/or increased mitochondrial mass present 
during the disease (458). Lipid oxidation, specifically, is important for the generation of both 
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regulatory T cells (Tregs) (459) and memory CD8+ T cells (460), countering glycolytic effector 
CD4+ and CD8+ T cells. Following T cell activation, not only will the clearance of antigen help 
generate memory, but remaining T effector cells will die via apoptosis due to decreased growth 
factors and metabolism (389). Memory T cell metabolism is similar to naïve, in that both 
populations require oxidative phosphorylation; however, some critical changes occur over the 
course of an immune response to ensure memory T cell survival. Those that become memory 
cells will have higher TCR affinities, which allows for advantageous survival in conditions of 
nutrient limitation and low homeostatic engagement (436). Furthermore, CD8 T cells, described 
to have substantial spare respiratory capacity after clearance of infection, will be long-lived 
memory cells (434). Spare respiratory capacity is especially critical for producing sufficient ATP 
under times of stress and for boosting long-term cell survival (461; 462), which would be 
necessary for memory response. Similarly, CD4 T cell memory is enhanced via blockade of a 
gene called Noxa that is responsible for driving apoptosis under conditions of limiting glucose 
(463; 464). 
3.1.4 Connecting immune signaling and metabolism 
Stimulation of T cells via the TCR requires proper engagement by MHC-peptide on the APC. 
Additionally, costimulation during T cell activation is critical for downstream signaling and 
effector function. Conversely, a lack of costimulation can lead to T cell anergy and deletion 
(465; 466). Appropriate T cell activation is not only governed by mere mechanistic interaction 
and a cascade of signaling molecules, but there are important links to metabolism. CD28 is the 
quintessential costimulatory molecule for T cell activation. Its ability to bind CD80/CD86 on 
APCs enables downstream signaling and promotes T cell differentiation (467; 468). Analogous 
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to insulin-receptor signaling, CD28 has been shown to enhance glucose metabolism by triggering 
an accumulation of glycolytic intermediates (409), stimulating glycolysis, and increasing glucose 
transporter expression (469). CTLA-4, on the other hand, offsets the effects of CD28, reducing 
glycolysis and rendering cells quiescent (470). One of the most essential downstream signaling 
cascades bridging the gap between T cell activation and metabolism is the PI3K-Akt-mTOR 
pathway. CD28, IL-2 and TCR engagement leads to PI3K-dependent Akt activation, which in 
turn increases the amount of glucose transporters on the plasma membrane as well as elevates 
activities of glycolytic enzymes i.e. hexokinase and phosphofructokinase (406; 410; 444). PI3K 
as well as MAPK and NF-κB can all activate Myc, which is responsible for inducing glucose 
transporters as well as glycolytic enzymes (471; 472). Akt, in conjunction with STAT5, also 
plays a role in glucose uptake in resting T cells (473). Unlike other cell types, lymphocytes only 
express the Glut1 glucose transporter (406; 436). In the absence of adequate TCR and/or 
cytokine stimulation during both the resting and activated states, Glut1 will be internalized, 
leading to downregulation of surface expression, reduced transport of glucose across the plasma 
membrane, and decreased viability of the cell (474). CD28-mediated Akt signaling is especially 
important for glucose uptake as it is necessary for expression and trafficking of Glut1 to the cell 
surface (409; 475). Comparable to T cells, B cells also increase Glut1 expression following BCR 
engagement (408). PI3K similarly plays a critical role in B cell proliferation and 
immunoglobulin synthesis through regulation of glycolysis and Glut1 (476). Although Glut1 
expression is critical for lymphocyte activation, a balance must exist; otherwise, overexpression 
of Glut1 can manifest into hyperactive lymphocytes and pathologies (475). 
mTOR is another critical regulator of metabolism in immune cells (477). The ability of 
mTOR to sense nutrient availability (478; 479) leads to the induction of mRNA translation and 
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protein synthesis (480). Without proper mTOR signaling, T cell proliferation will be blocked 
(481) and anabolic storage processes will be decreased (482; 483). Inhibition of the PI3K-Akt-
mTOR pathway can also lead to T cell anergy (484; 485), whereas mTOR-deficient T cells do 
not differentiate into effector T cells, but instead regulatory T cells (486). Additionally, mTOR 
has been linked to chemokine-dependent signaling, resulting in T cell migration (487-489) and 
cancer metastasis (490; 491). These data highlight the importance of proper metabolic signaling 
in initiating an effective adaptive immune response and reveal possible targets for therapeutic 
intervention.  
Cytokine binding and cytokine receptor expression have also been connected with 
metabolism. Although immune cells primarily utilize glycolysis, some oxidative phosphorylation 
still occurs and is necessary for functionality. If mitochondrial respiration is blocked at different 
complexes of the electron transport chain, both TNF binding to its receptor on cells (492) and IL-
2R expression on lymphocytes are reduced (379). Interestingly, TNFα-deficient mice are actually 
protected from obesity-induced insulin resistance, highlighting the importance of 
proinflammatory cytokines in metabolic signaling (493), (494). Other innate immune cytokines, 
such as IL-1, IL-6, IL-3 and IL-7, also contribute to metabolism. IL-1 can prevent fatty acid 
synthesis (495), whereas IL-6 can both increase the levels of lipid and glucose metabolism (496). 
IL-3, which is known to support the growth of myeloid and lymphoid cells, is important for 
sustaining Glut1 on the surface of lymphocytes (444) and has been directly shown to shift 
metabolism from oxidative phosphorylation to glycolysis (497). In order for activated Akt to 
sustain glucose uptake in both resting and activated T cells, IL-7 must be present (442). Overall, 
each cytokine binds a specific receptor and coordinates T cell function with metabolic needs. 
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Similar to macrophages, adipocytes can also release cytokines/chemokines (i.e. IL-1, IL-
6, IFNγ, TNFα, MCP1) to bridge the gap between immunity and metabolism (469; 498; 499). 
Adipokines can recruit monocytes and lymphocytes into the adipose and promote 
proinflammatory and anti-inflammatory functions. Overnutrition can induce adipocyte 
hypertrophy, creating a hypoxic core and MCP-1 production, which facilitates macrophage entry 
into the adipose (500). Lymphocytes associated with adipose tissue are oftentimes modulators of 
the infiltrating macrophages (501). For example, Tregs are present in greater abundance in the 
adipose of lean mice, correlating with an anti-inflammatory macrophage phenotype (502). 
Furthermore, proinflammatory effector T cells have been detected in the fat of obese mice, 
leading to the recruitment of even more proinflammatory macrophages (503) and contributing to 
insulin resistance (504; 505).  
Hormone secretion, from adipose as well as other tissues, is also important in regulating 
lymphocyte function. Leptin, a hormone released from the adipose, along with insulin, which is 
secreted from the pancreatic beta cells, both play critical roles in connecting metabolism to the 
immune system. Leptin, which regulates food intake by inhibiting appetite, is low in times of 
starvation, resulting in decreased metabolism to maintain vital organs. Consequently, low leptin 
levels lead to immunosuppression (469). In a well-nourished environment, leptin can modulate 
both the innate and adaptive arms of the immune system to promote greater cytokine production 
(506), decreased apoptosis (507) and skew T cells towards the TH1 lineage (508; 509). The 
effects of leptin on TH1 responses have been especially documented in the context of 
autoimmunity. Leptin has been shown to accelerate type 1 diabetes onset in NOD mice via 
enhancement of IFNγ-producing T cells (510). Furthermore, higher leptin levels have been 
detected in female animals that are susceptible to EAE induction versus resistant males, 
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positively correlating with an increase in TH1 responses (511). Heightened immune responses 
following leptin signaling may be damaging in autoimmunity; however, in obesity, failure of 
proper immunity, resulting in increased infections, has been linked to greater leptin insensitivity 
in severely overweight individuals (512). In general, the immune system cannot function 
properly in times of over- or under-nutrition (513), revealing the many intricacies between 
metabolism and immunity. Similarly, insulin, which promotes cellular metabolism by 
stimulating the uptake of glucose and storage as glycogen, can play a role in modulating the T 
cell response. Beyond acting as a lymphocyte-specific antigen in type 1 diabetes, insulin helps 
shape T cell growth and function. Upon activation, insulin receptor is expressed on T cells. 
Insulin signaling then facilitates glucose uptake, amino acid transport, lipid metabolism, and 
protein synthesis (514).  Stimulating CD4+ and CD8+ T cells in the presence of insulin can 
induce more TH2-type cells and cytokines (515), leading to a more anti-inflammatory 
environment. These data strongly suggest why lack of insulin signaling in both type 1 and type 2 
diabetes can lead to both enhanced TH1 cells and uncontrolled inflammation (516).   
3.1.5 Modulators of metabolism and potential immunometabolic therapeutic implications 
Mitochondrial activity has been implicated as a cause of aging, and metabolic dysfunction and 
ROS production have been linked to neurodegeneration, cancer, and autoimmunity (22; 384-
386). An accumulation of ROS and redox-damaged byproducts eventually leads to cell 
dysfunction and death. (517). Indeed, mutations of the electron transport chain can diminish ROS 
production and thus elongate life (518; 519). Although immune cells contain higher levels of 
antioxidants than other cells (520) and rely on both glycolysis and respiration, aging immune 
cells show accrued impairment, causing reduced lymphocyte proliferation. Functional decline of 
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immune cells, or senescence, often correlates with age, as free radical production overwhelms 
antioxidant defenses and the risk of infections/tumors is enhanced (521-523). During a normal 
mammalian lifetime, metabolic pathways are kept in check via a number of endogenous 
mediators such as hypoxia-inducible factor-1 and uncoupling proteins, which prevent oxidative 
phosphorylation by partially dissipating the mitochondrial proton gradient. Pertaining to aerobic 
respiration, the existence of antioxidants particularly protects against oxidative stress and 
damage. Additionally, endogenous mechanisms do exist to restrict ROS production so as not to 
damage neighboring tissues. For example, Kupffer cells, macrophages residing within the liver, 
do not undergo respiratory bursts, thus protecting the surrounding parenchyma from any ROS-
mediated destruction (524; 525). Conversely, peritoneal macrophages, which are more involved 
in clearance of infection, can experience an oxidative burst, with less threat of damage to 
surrounding tissue (526). Despite these many mechanisms, improper metabolism of immune 
cells can result in disease. The strict dependence of immune cells on glucose for survival and 
activation, however, may make them good targets for metabolic therapeutics (435). Such 
therapeutics could potentially better control autoimmunity, transplantation rejection, 
neurodegeneration and cancer. 
3.1.5.1 Hypoxia-inducible factor 1 
 
Hypoxia-inducible factor-1 (HIF-1) is especially important for modulating metabolism under low 
oxygen conditions. HIF-1 inhibits the progression of pyruvate into the TCA cycle by redirecting 
it to lactate production, via activation of pyruvate dehydrogenase kinase (527-529). Furthermore, 
HIF-1 can induce glycolytic enzymes while reducing mitochondrial oxygen consumption (529). 
Such a switch exists to preserve the viability of cells in times of hypoxia. Interestingly, a similar 
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change occurs in activated lymphocytes, as discussed above. The metabolic similarity between 
hypoxic cells and lymphocytes begs the question of whether or not HIF-1 plays a role in 
modulating T cell activation. Hypoxic areas within the body create a need for immune cells to 
survive and function properly in all environments, hence the importance of HIF-1 activation 
(414). Under hypoxic conditions and anaerobic glycolysis, specifically during wound healing, T 
cells will shift from TH1 to TH2 type responses, directing less inflammatory function in the 
absence of oxygen (530). In mice prone to type 2 diabetes, decreased levels of HIF-1 indeed lead 
to impaired wound healing (531). 
Besides hypoxic conditions, HIF-1 is able to induce expression of genes that improve 
immune cell viability during aerobic glycolysis (449). The expression of HIF-1 is initially 
provoked by insulin, IGF1 (insulin-like growth factor 1), and angiotensin, all of which play roles 
in growth and survival (532; 533). HIF-1 is increased in activated T cells and promotes 
expression of Glut1, aiding in T cell survival (414; 534). In addition to its importance in 
maintaining T cell viability, HIF-1 also helps regulate T cell subset differentiation. TH17 cell 
differentiation requires enhanced glycolysis and expression of the transcription factor RORγT, 
both of which are increased via HIF-1 activation (535; 536). Furthermore, HIF-1 is known to 
directly repress Foxp3, the transcription factor critical for Treg induction (535). Tregs, unlike 
other T cell subsets, are primarily powered through lipid oxidation (459). Likewise, lipid 
metabolism, which would mainly utilize oxidative phosphorylation, can inhibit glycolytic-
dependent TH17 differentiation (537).  
HIF-1 also plays important roles in controlling innate cell functions (527). ATP, 
glycolytic enzymes and Glut1 expression are all regulated by HIF-1 in macrophages and 
neutrophils. Under hypoxic conditions, APC phagocytosis and antigen presentation as well as 
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granulocyte responses are weakened (538; 539). Upon HIF-1-deficiency, innate cell motility, 
invasiveness, pathogen killing and T cell-stimulating abilities decrease further (424; 540). 
Without effective HIF-1 expression, APCs and granulocytes suffer dysfunctional host defenses. 
On the contrary, chronic inflammation and HIF-1 may together instigate tissue fibrosis, 
autoimmunity and tumor progression by affecting both innate and adaptive immune cells.  
In chronic kidney disease and obesity, HIF-1 can switch from its proangiogenic function 
to promote fibrosis (541; 542). Relevant to HIF-1’s ability to modulate TH17 differentiation, 
mice deficient for HIF-1 are resistant to inducible experimental autoimmune encephalomyelitis 
(EAE) (535; 536), a rodent model of multiple sclerosis in which disease is largely mediated by 
TH17 cells. Furthermore, HIF-1 has been shown to play major negative roles in prostate cancer 
tumorigenesis (543), breast cancer prognosis (544), and many other cancer outcomes (545), 
through induction of genes responsible for cell proliferation, angiogenesis, survival, migration, 
and glucose metabolism (546). Immune cells play crucial roles in mediating appropriate wound 
healing, tolerating self-antigens, and cytotoxic killing of tumor cells. Therefore, blocking HIF-1 
may allow for appropriate immunity and alleviation of disease. The list of HIF-1 inhibitors is 
expanding (545). For example, digoxin, which inhibits HIF-1 gene and protein expression, can 
block tumor growth (547) as well as RORγt-dependent TH17 differentiation (548), yet does not 
affect other T cell lineages. It is tempting then to speculate that while blockade of HIF-1 may 
stunt proliferation and development of TH17 cells, cytotoxic CD8 T cells may still be active to 
allow for killing of tumors. Conversely, since HIF-1 is known to repress Treg differentiation, 
inhibition of this molecule may augment suppressive T cells. In the context of autoimmunity, this 
side effect may be beneficial in protecting against self-antigen recognition. However, in the case 
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of cancer, combinatorial therapies of digoxin along with chemotherapy and radiation may be 
necessary for complete regression. 
3.1.5.2 Uncoupling proteins 
 
For oxidative phosphorylation to occur properly, collaboration between electron transfer and 
proton pumping is a necessity. A disturbance in the ‘coupling’ of electrons to protons would lead 
to increased futile proton current, decreased ATP production, and diminished ROS levels. In the 
context of immune cell mitochondrial dysfunction, such as in Alzheimer’s and diabetes, an 
interruption of oxidative phosphorylation may be beneficial for reduction of ROS byproducts. 
Endogenously, certain proteins exist to manifest this disruption. Uncoupling proteins (UCP) are 
known proton uniporters that, in the context of a proper activator, can uncouple mitochondrial 
respiration in a controlled way (549; 550). Such processes are used for thermogenesis from 
brown adipose tissue (551) and for reducing the production of free radicals from mitochondria 
(552). UCP2 has been suggested to decrease pyruvate entry into the TCA cycle (553; 554), 
overall limiting ROS production and age-related damage (555-558). Overexpression of UCP3 in 
a high-fat diet fed mouse was able to rescue insulin signaling (493) and knockout of UCP2 drives 
persistent NF-κB activation as well as heightened ROS production in immune cells, resulting in 
resistance to certain infections (559; 560). These data reveal UCP2 as a plausible 
immunometabolic therapeutic target. T cells produce high levels of mitochondrial UCP2 
following activation; this has been attributed to the need for rapid proliferation via glycolysis as 
well as the necessity of low level ROS production for adequate gene expression and signaling 
activity (561). In an oxidative stress environment, where interplay between innate immune cells 
and T cells generates high ROS, uncoupling the electron transport chain may be useful in 
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resetting homeostasis. Moreover, UCP2 decreases glucose-stimulated insulin release (562), 
highlighting its potential for preventing the release of self-antigen and thus controlling 
autoreactive T cell responses. To date, uncouplers have not been utilized in the treatment of 
autoreactive T cells. However, chemical uncouplers can reduce oxidative stress. Rottlerin, a 
mitochondrial uncoupler, can reduce apoptosis of alveolar macrophages in a model of systemic 
autoimmune disease (563). A study utilizing a mitochondrial fission inhibitor, which led to 
greater uncoupling, normalized oxidative stress levels in hyperglycemia (564). Another drug, 
2,4-dinitrophenol, leads to uncoupling through dissipation of the proton gradient, resulting in 
decreased hepatic insulin resistance in a non-alcoholic fatty liver disease model (565). 
Furthermore, 2,4-dinitrophenol has been shown to enhance the adhesion phenotype (increased 
collagen and VEGF) for post-peritoneal surgical wound healing (566), a process in which 
macrophages play an important role (567). Uncouplers targeting specific cells, therefore, may be 
a potential therapeutic for immune diseases where oxidative stress is high, whereas uncoupling 
inhibitors may be utilized for some cancers, especially those which are resistant to chemotherapy 
(568; 569). 
3.1.5.3 Nutrient limitation 
 
The immune system is highly dependent on the glucose levels available. Everyday physiological 
nutrient limitation throughout the periphery protects from the over accumulation of naïve T cells, 
allowing for the turnover of older and development of new cells (436). Likewise, the adaptive 
immune response also relies on the availability of sufficient amino acids. Innate immune cells 
can control the supply of amino acids and thus regulate T cell responsiveness. Upon CD40 
ligation or LPS stimulation, APCs can increase their cysteine production and share this with 
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interacting T cells, which cannot make their own (570; 571). Cysteine is critical for T cell 
survival due to its necessity in glutathione production (572; 573). Similarly, indoleamine 2,3-
dioxygenase (IDO) expression by macrophages can reduce levels of extracellular tryptophan, 
which is also needed, but not directly produced, by T cells. A lack of tryptophan will eventually 
cause T cell anergy or apoptosis (574; 575), again suppressing an immune response. 
In a similar manner, environmental nutrient limitation may also affect an immune 
response. Caloric restriction causes greater lipid metabolism, lessening the dependence on 
glucose and thus decreasing an immune response (576). Lipid metabolism is the chief 
mechanism of energy production in immune-privileged sites, such as the eye, brain, and 
placenta. Fatty acid utilization leads to lower costimulatory molecule expression, resistance to 
apoptosis, and less damage by free radicals (576-578), correlating with blunted immune 
responses. In contrast, immune-sensitive areas that depend on glucose metabolism are more 
susceptible to infection and death following an effective immune response (443; 445; 579). 
Notably, saturated and unsaturated fatty acids also differ in their abilities to stimulate an immune 
response. Saturated fatty acids, which are considered more detrimental to health, induce greater 
activation of TLR2 and TLR4 on myeloid cells, whereas unsaturated fatty acids can inhibit TLR 
signaling and NF-κB activation (580-582). In particular, polyunsaturated acids can alter the T 
cell membrane, negatively impacting signaling and activation of lymphocytes (583; 584). 
Moreover, less caloric intake also correlates with better DNA repair, reduced antioxidant decline, 
diminished cancer rates, and an increase in mouse lifespan (585-588). In autoimmunity and 
metabolic syndrome, such constraints may be highly effective in quelling inflammation (589; 
590). Specifically, obesity has been associated with dysfunctional phagocytosis and respiratory 
burst in macrophages (591; 592). Similar to leptin insensitivity in obesity, continuous ingestion 
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of saturated fatty acids eventually will lead to a reduction in innate and adaptive immune 
responses, making an individual more susceptible to cancer and infections (593) and reducing 
wound healing capacity (594; 595). Caloric restriction of obese mice, which were at-risk for 
breast cancer, significantly reduced tumor growth and mimicked mTOR inhibition for regulating 
cell proliferation (596). Nutrient limitation via endogenous and exogenous factors may therefore 
ameloriate a number of immune diseases with metabolic components. 
3.1.5.4 Anti-glycolytics 
 
Because of the high dependence of immune cells on glucose metabolism, anti-glycolytics have 
been implemented to limit immunity and treat disease. One of the most studied drugs is 
rapamycin. Rapamycin is able to inhibit glucose metabolism via blockade of mTOR, 
downstream of PI3K-Akt. Such inhibition leads to decreased T and B cell activation and function 
as well as decreased cellular proliferation. Rapamycin has been studied extensively for treatment 
of advanced cancer (597; 598) and in transplant patients to mitigate rejection and graft-versus-
host disease (599-601). At the immune cell level, rapamycin can affect T cell differentiation and 
memory. Rapamycin treatment enhanced the quality and quantity of CD8 T cell memory 
responses by switching metabolism from glycolysis to oxidative phosphorylation (460). 
Rapamycin can also mimic dietary restriction, increasing life span (602) as shown additionally in 
memory T cells (433; 460). Thus, caloric reduction and fat metabolism discussed above may be 
used as alternatives to rapamycin and may also improve T cell memory (435; 603). In CD4 T 
cells, rapamycin can promote CD4 Treg development (604-606) as well as modulate chemokine 
receptors for mobilizing effector cells out of the periphery and back to the lymphoid organs 
(607). The immunosuppressive effects of rapamycin, however, have been associated with higher 
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infection rates (608; 609) as well as hyperglycemia, due to inhibition of the PI3K-Akt-mTOR 
signaling pathway required for Glut1 expression and translocation to the plasma membrane (610; 
611), making it more suitable as a metabolic treatment for chronic inflammation and organ 
transplantation. 
3-bromopyruvate is another anti-glycolytic drug primarily used for the treatment of 
cancer. During glycolysis, a series of enzymes are necessary for the breakdown of glucose into 
pyruvate. 3-bromopyruvate is able to inhibit the activity of the first enzyme in the glycolytic 
pathway, hexokinase (612). Hexokinase is often overexpressed in tumors and contributes to the 
high glycolytic activity seen in cancerous cells (398; 399). Treatment of tumor cells with 3-
bromopyruvate drains intracellular ATP levels, resulting in cell death (613). Although systemic 
treatment may be detrimental to actively proliferating and cytokine-secreting T cells, intra-
tumoral treatment may allow for the induction of anti-tumor CD8 memory T cells, since a 
reversal of metabolism from glycolysis to oxidative phosphorylation is necessary for the 
maintenance of adaptive memory (434; 463). Additionally, 3-bromopyruvate is quite specific for 
cancer cells, with little to no toxicity of healthy tissue (614; 615). Therefore, eradication of the 
cancerous cell growth with 3-bromopyruvate may diminish the suppressive microenvironment 
surrounding the tumor, allowing for greater infiltration of cytotoxic killer cells and subsequent 
tumor immunity – an area of research that still requires investigation. 
3.1.5.5 Anti-mitochondrial drugs 
 
Blocking different mitochondrial complexes along the electron transport chain can manifest in 
phagocytic defects (616) and NF-κB inactivation (617). These types of treatments are standard in 
lab settings; however, drugs that can be used in the clinic need to be better characterized. 
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Metformin, for example, is an anti-oxidative phosphorylation drug and is predominantly used as 
an anti-diabetic drug. It enhances glucose disposal in muscle and reduces hepatic 
gluconeogenesis. Unlike rapamycin, which directly blocks mTOR, metformin can activate AMP-
activated protein kinase (AMPK), which in turn blocks mTOR function, inhibiting cell 
proliferation (618; 619). AMPK activation induces glucose uptake from the blood, increasing 
glycolysis and lessening the dependence of cells on oxygen (620). Metformin can specifically 
impede complex I of the electron transport chain and inhibit oxygen consumption in cancer cells 
(621; 622). Particularly, metformin usage for cancer therapy has been widely studied in those 
with type 2 diabetes (623; 624), a known risk factor for tumor formation (625). Like the anti-
glycolytics mentioned previously, reductions in cancer cell growth may permit the cytotoxic 
killing of tumor cells by T cells, albeit when treatment is administered directly to the tumor. The 
impact of metformin has also been characterized in a mouse model of cancer vaccination. Upon 
metformin treatment of ova-specific T cells, a significant enhancement of memory CD8 T cells 
was detected along with better tumor regression. These results demonstrate the ability of 
metformin to modulate the immune system outside of its anti-proliferative effects. Additionally, 
in the context of proinflammatory cytokines, metformin is able to block the activation of NF-κB, 
resulting in diminished cytokine-induced endothelial cell adhesion molecule expression (626; 
627). Such an effect may lead to decreases in chronic macrophage infiltration into the adipocytes 
of type 2 diabetics as well as lower the damaging consequences of autoimmunity. Of course, 
better understanding of metformin’s selective effects on the immune system is necessary for 
these types of indications. 
As another approach to metabolic control for immune regulation, antioxidants have been 
utilized in a plethora of disease models, including autoimmunity, infections, neurodegeneration, 
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and cancer (154; 628-631). Although antioxidants do not specifically block oxidative 
phosphorylation, they are important for decreasing ROS produced from the electron transport 
chain during mitochondrial respiration, thus reducing damaging side effects. During aerobic 
respiration, the glutathione transported from the cytosol into the mitochondrial membrane is the 
only antioxidant available for metabolizing H2O2 (632). Therefore, the augmentation of 
antioxidants present in immune cells may alleviate certain cellular dysfunctions. Specifically, 
antioxidants are able to show improvement of immune-mediated disorders, such as lymphocyte 
and macrophage function in the face of aging, septic shock, asthma, and type 1 diabetes (154; 
633-636). The mechanisms by which antioxidants improve immune responses vary greatly. An 
antioxidant present in green tea called epigallocatechin-3-gallate can reduce T cell signaling via 
downregulation of cytokine receptors (637) and ameliorate EAE through an enhancement of 
regulatory T cells (638). Other studies demonstrated the antioxidant ability of resveratrol to 
decrease collagen-induced arthritis by suppressing TH17 responses (639) and to enhance B cell 
lymphoma recognition by CD4+ T cells through upregulation of HLA class II molecules (640). 
Consistently, other antioxidants have shown promise in restricting NF-κB activation (64; 641; 
642), leading to many anti-inflammatory effects. On the metabolic side, a recent study utilizing 
α-tocopherol, the antioxidant component of Vitamin E, demonstrated a reduction in glycolysis in 
lymphoma cells through blockade of lactate dehydrogenase activity (643).  
Our group focuses on the usage of manganese metalloporphyrins as catalytic antioxidants 
for the scavenging of ROS (hydrogen peroxide, superoxide, peryoxynitrite) and the mimicking of 
superoxide dismutase (154; 268). Unlike other antioxidants, the metalloporphyrins are catalytic 
and can repetitively eliminate ROS, resulting in many immunological effects. These antioxidants 
have shown promise in reducing type 1 diabetes incidence through autoreactive TH1 cell 
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modulation (36; 154; 644) and in protecting islets during isolation for transplantation (79; 297).  
Furthermore, NF-κB activation (64) and CD8 T cell effector function (278) are reduced upon 
metalloporphyrin treatment. Inhibition of NF-κB after metalloporphyrin administration has also 
shown promise in decreasing acute central nervous system injury, effectively enhancing 
neurologic function following ischemic stroke (645). Additionally, metalloporphyrins can protect 
lungs from radiation-induced injury (646-648) and kidneys from ischemia/reperfusion injury 
(649). Interestingly, metalloporphyrins display oxidoreductase abilities, where they can act as 
scavengers in the cytoplasm, as in the context of reduced TACE oxidation (644), yet work as 
oxidizers in the nucleus, inhibiting the reduction of the p50 subunit of NF-κB and effectively 
blocking its DNA binding (64). In the context of cancer, metalloporphyrins are also able to block 
HIF-1 activation, decrease hypoxia, reduce tumor-protective cytokine release and ultimately 
suppress tumor growth (650). HIF-1, as mentioned above, is critical for facilitating glycolysis in 
times of low oxygen; moreover, tumor cells rely heavily on glycolysis to survive, making them 
an obvious target of metalloporphyrin-induced regulation. The wide scope of metalloporphyrin 
effectiveness allows for their usage in a range of immunologic diseases, all centered around 
restoring redox balance; yet the effect of metalloporphyrins on fundamental immune cell 
metabolism has yet to be described. In conjunction with the cancer studies, we have observed 
promotion of hyporesponsive T cells after antioxidant treatment (48; 644), which further 
instigated curiosity regarding metabolism. Preliminary studies suggest decreases in both 
glycolysis and oxidative phosphorylation following metalloporphyrin administration. An overall 
metabolic reduction may then decrease T cell differentiation and return cells to stasis or 
quiescence, all while retaining viability, since metalloporphyrins are not toxic (79; 268; 278). If 
T cells are in fact displaying lowered metabolism, the potential for treating chronic inflammatory 
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conditions, such as autoimmunity, is widespread. With frontline therapeutics, such as anti-
metabolites, rapamycin, and antibodies against costimulatory molecules, either failing in the 
clinic or leading to unwanted side effects, agents that modulate immune function, are reversible, 
and show no toxicity are highly desirable. Metalloporphyrins meet all of these demands and 
therefore, may be beneficial for reducing inflammatory disorders/potentiating cancer regression 
and should elicit greater attention in the search for alternative metabolic therapies. 
3.1.6 Summary 
The immune system plays a vital role in maintaining a fine balance in the battle against 
infections and cancer, but requires rigorous control in order to walk the fine line of regulator and 
menace leading to self-reactivity and autoimmunity. Both oxidative phosphorylation and 
glycolysis are critical for fulfilling the metabolic needs of immune cells. In innate immune cells, 
glycolysis is the predominant form of metabolism, whereas adaptive immune cells fluctuate 
between oxidative phosphorylation and glycolysis, depending on their activation status. 
Nonetheless, the heavy reliance of immune cells on glucose utilization makes them good targets 
for immunometabolic therapies. A number of endogenous molecules can be pursued, including 
HIF-1 and UCP2. Alternatively, caloric restriction, anti-glycolytics, and antioxidants all exhibit 
potential in resetting homeostasis in chronic inflammation while possibly enhancing immunity in 
cancer models. Overall, metabolic regulation should be an active line of research for the control 
of immune-mediated disorders. 
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3.2 ABSTRACT 
The immune system is critical for protecting the body against infections and cancer, but needs 
scrupulous regulation to limit self-reactivity and autoimmunity. Our group has utilized a 
metalloporphyrin catalytic antioxidant (CA) as a potential immunoregulatory therapy in the 
context of type 1 diabetes. We have previously reported CA-mediated effects, such as a decrease 
in proinflammatory cytokine production from APCs and T cells as well as reduced diabetes onset 
in NOD mice and upon adoptive transfer of diabetogenic T cells. However, it is unclear whether 
or not CA can promote immunoregulation outside of TH1 cell surface molecules and cytokines. 
Upon CA treatment, TH1 cells do not skew towards a TH2 lineage, based on cytokine profiles. 
Furthermore, CD25+Foxp3+ cells are not enhanced following CA treatment during in vitro 
stimulation of BDC-2.5.TCR.Tg CD4+ T cells. In contrast, adoptive transfer of a mixture of 
control:CA-treated splenocytes does impart extended protection against diabetes onset in 
comparison to CA-treated splenocytes alone, highlighting the possibility of some type of 
regulation following in vivo redox modulation, possibly beyond classical Treg suppresion. The 
reliance of immune cells on specific metabolic pathways during different activation states makes 
them good targets for immunometabolic therapies. Although antioxidants do not specifically 
block oxidative phosphorylation, they are known to decrease ROS produced from the electron 
transport chain during mitochondrial respiration, thus reducing damaging side effects. Therefore, 
the ability of redox modulation to affect the bioenergetics of diabetogenic splenocytes was 
tested. In the context of diabetogenic splenocytes, CA treatment mildly decreases overall 
oxidative phosphorylation. Upon further subdivision of oxidation from two different substrates, 
CA administration demonstrated enhancement of glucose oxidation and reduction of fatty acid 
oxidation; however, these alterations were not due to a decrease in mitochondrial complex and 
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biogenesis molecules. CA also displays anti-Warburg effect characteristics, in which it decreases 
aerobic glycolysis needed for immune cell proliferation, demonstrated by reduced lactate 
production, deactivation of mTOR, and lowered Glut1 expression. Despite this outcome, CA 
does not cause cell death, as the effects of redox modulation are reversible. The reduction in 
aerobic glycolysis-mediated metabolism seen after administration correlates with decreased 
immune cell reactivity and therefore, CA treatment promotes cell stasis or quiescence and can 
impede diabetogenic autoimmune responses.  
3.3 INTRODUCTION 
The control of self-reactivity is critical for prevention and potential reversal of autoimmunity. In 
particular, regulating immune cells in type 1 diabetes can lead to reduced beta cell damage. Both 
the innate and adaptive immune cells should be targeted for complete protection. T cells, 
specifically, can be controlled in many ways. Different T cell subsets have specific functions for 
mediating protection against disease. TH1 cells are known to promote immunity against 
intracellular pathogens, whereas TH2 cells drive allergic and anti-parasitic responses. Notably, 
the cytokines produced from each subset can block the induction of a different subset. For 
example, IL-4 produced by TH2 cells can inhibit Tbet, the transcription factor necessary for the 
TH1 cytokine IFN-γ. This intrinsic regulatory mechanism is important for endogenous control of 
immune responses; however, it can also be exploited for protection against chronic 
inflammation. TH1 cells are the primary subset responsible for type 1 diabetes pathology. 
Although TH1 cells are necessary for progression of disease, the TH2 compartment has been 
credited with a protective role due to its ability to cause a cytokine shift away from the TH1 
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cytokines (172; 651; 652). Strategies to instigate this skewing are sought after and highly 
promising for regulating autoreactive T cell responses. 
In addition to skewing, Treg-mediated suppression is another mechanism for potentially 
inhibiting autoreactive T cell responses. Regulatory T cells are formed endogenously within the 
thymus (natural Tregs) to prevent self-reactive T cell responses (653). Moreover, adaptive Tregs 
can be induced in the periphery during inflammatory processes (204). Despite different origins, 
each class of Tregs has the common ability to downregulate effector function and inflammation. 
The classic phenotypic marker for Tregs is Foxp3, the transcription factor necessary for their 
development. Beyond expression of Foxp3, the diversity of Tregs is substantial. Certain subsets 
can secrete IL-10 and TGF-β (654; 655), whereas others can mediate suppression via a contact-
dependent mechanism, such as cytolysis (656) and CTLA-4 ligation (657). Deficiencies in Treg 
numbers and function have been reported in a number of autoimmune disorders, including type 1 
diabetes (210). A lack of endogenous regulation in collaboration, with genetic HLA 
susceptibility and high oxidative stress, is the perfect storm for a break in tolerance to self-
antigen and autoimmune destruction of beta cells. Treg promotion in the face of type 1 diabetes 
may be beneficial for preventing frank disease and/or the regeneration of beta cells. 
Another mechanism of T cell regulation is the production of indoleamine 2,3-
dioxygenase (IDO) from APCs. IDO is the enzyme responsible for tryptophan catabolism, 
leading to a depletion of this essential amino acid. T cells are reliant on tryptophan for 
proliferation, and thus, IDO has the ability to hinder their expansion (658). Physiologically, IDO 
is produced to help contract an immune response, limiting inflammation and preventing 
bystander damage. IFN-γ is essential for IDO induction (659; 660), illustrating the interplay 
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between APCs and T cells in immune cell regulation and the ability of innate cells to control 
adaptive populations.  
One of the most understudied mechanisms of immune cell control is metabolic 
modification. This type of regulation is relatively unexploited but promising in the context of 
autoreactivity. Both innate and adaptive immune cells depend on specific metabolic pathways for 
survival. Naive and central memory T cells are highly dependent on oxidative phosphorylation, 
and although mitochondrial respiration does increase, glycolysis is the primary metabolic 
pathway utilized during both T cell and APC activation. Resting T cells undergo oxidative 
phosphorylation as they traverse the body, building up reserves of ATP in preparation for an 
upcoming response (410). Cells that have successfully made it through thymic selection wait for 
stimulation by activated APCs. In NOD mice, which spontaneously develop type 1 diabetes, self-
reactive T cells are not efficiently deleted in the thymus, allowing for the escape of autoreactive 
cells into the periphery (661; 662). Thus, self-reactive T cells that target the beta cells might not 
be using oxidative phosphorylation, but instead may switch over to glycolysis, since they have a 
strong enough signal to drive activation without deletion and survive selection. During the 
initiation of an immune response, rapid macromolecule synthesis and cell growth are essential 
for productive effector function. Instead of relying on the slow process of oxidative 
phosphorylation, immune cells use the much faster (100X) glycolytic pathway to meet their 
energy demands (421). Notably, the inhibition of glycolysis through blockade of HIF-1, for 
example, reduces TH17 differentiation (535; 663). Moreover, blocking mTOR via rapamycin 
treatment also elicits glycolytic reduction and can augment Treg development (604; 606). On the 
innate cell side, DCs upregulate glycolysis upon TLR stimulation (427), and proinflammatory 
macrophages require glycolysis for cytokine production (428; 429). The metabolic demands of 
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immune cells highlight the importance of both glycolysis and oxidative phosphorylation in 
activation and survival.   
An imbalance of immunological and/or metabolic function can often lead to diseases, 
such as autoimmunity. In previous studies, we demonstrated the ability of a metalloporphyrin 
catalytic antioxidant (CA) to prevent T cell activation through the inhibition of LAG-3 cleavage, 
a negative regulator of T cell function (644). Furthermore, CA can block the activation of NF-
κB, decreasing proinflammatory cytokine production (64). Both of these effects contribute to the 
prevention of spontaneous diabetes onset in the NOD mouse and disease progression upon 
adoptive transfer diabetogenic T cells (36; 644). Other groups have demonstrated the ability of 
antioxidants to suppress TH17-mediated arthritis (639), enhance Treg for the resolution of EAE 
(638), and reduce cancer cell glycolysis and growth (643). However, it is unknown whether CA 
treatment causes: A) a skewing of diabetogenic TH1 cells to a different subset; B) an increase in 
immunoregulatory functions; or C) immune cell metabolic quiescence. In this study, each of 
these possibilities is addressed in the context of redox modulation, ultimately contributing to the 
prevention of an autoimmune response. 
3.4 RESEARCH DESIGN AND METHODS 
3.4.1 Materials 
NOD.BDC-2.5.TCR.Tg and NOD.scid mice were bred and housed under specific pathogen-free 
conditions in the Animal Facility of Rangos Research Center at Children’s Hospital of Pittsburgh 
of UPMC (Pittsburgh, PA). Female mice at 4-10 wks of age were used in all experiments. All 
animal experiments were approved by the Institutional Animal Care and Use Committee of the 
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Children’s Hospital of Pittsburgh and were in compliance with the laws of the United States of 
America. Foxp3-FITC (eBioscience, San Diego, CA), Rat IgG2α isotype-FITC, Fc Block, CD4-
PE, and CD25-APC (BD Biosciences, San Diego, CA) were used for flow cytometry. Anti-CD3 
and anti-CD28 (BD Biosciences) were utilized for T cell stimulation. Mouse anti-mMitoProfile 
Total OXPHOS Rodent Antibody Cocktail, rabbit anti-mGlut1 (Abcam, Cambridge, MA), rabbit 
anti-mphospho-mTOR (Ser2448), rabbit anti-mmTOR (Cell Signaling, Danvers, MA) were used 
for Western blots. Primary antibodies rat anti-mIFN-γ (BioLegend, San Diego, CA) and mouse 
anti-mIDO (EMD Millipore, Billerica, MA) and secondary antibodies goat anti-rIgG-Cy3 and 
goat anti-mIgG-FITC (Sigma, St. Louis, MO) were used for confocal microscropy. Antibody 
pairs for IFN-γ, IL-10, IL-4 and IL-2 ELISAs were purchased from BD Biosciences; mouse 
Duoset for IL-17 ELISAs were purchased from R&D Systems (Minneapolis, MN).  L-Lactate 
Assay Kit was purchased from Abcam. MnTE-2 catalytic antioxidant (CA) was a generous gift 
from James Crapo, MD at National Jewish Health. CA was prepared as previously described (48) 
and used at 10 mg/kg in all in vivo experiments and at 68 µM in all in vitro experiments. 
3.4.2 In vitro T cell assay 
BDC-2.5.TCR.Tg splenocytes were seeded in 96-well round-bottom plates with 0.5 µM of BDC-
2.5 mimotope (M) (EKAHRPIWARMDAKK) in supplemented DMEM (48) (Invitrogen Life 
Technologies). At 48-96h post-stimulation, all cells were counted with a hemocytometer, and 
supernatants were harvested for ELISA. 
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3.4.3 Cytokine measurements by ELISA 
IFN-γ, IL-4, IL-10, IL-17, and IL-2 ELISAs were performed according to manufacturer’s 
instructions. All ELISAs were read on a SpectraMax M2 microplate reader (Molecular Devices, 
Sunnyvale, CA), and data was analyzed using SoftMax Pro v5.4.2 (Molecular Devices). 
 
3.4.4 In vitro Treg phenotype assessment 
BDC-2.5.TCR.Tg CD4+ T cells were isolated from mouse spleen via MACS CD4+ T cell 
Isolation Kit (Miltenyi Biotec, Auburn, CA). Cells were plated at 1x10
5
 in supplemented DMEM 
and stimulated +/- CA with anti-CD28 (1 µg/ml) and a titration of pre-coated anti-CD3 (0.1-1 
µg/ml). After 5 days of incubation, cells were collected, surface stained for CD4 and CD25, and 
intracellular stained for Foxp3 or isotype to determine Treg phenotype by flow cytometry. 
Supernatants were used for IFN-γ ELISA. 
3.4.5 Surface/intracellular staining and flow cytometric analysis 
Cells were surface stained as previously described (278). For intracellular Foxp3 staining, FC 
block (BD Biosciences) was first applied to the cells. Cells were then surface stained followed by 
fixation/permeabilization using BD Cytofix/Cytoperm (BD Biosciences). Intracellular Foxp3 or 
isotype staining was then conducted in BD PermWash. Fluorescence was measured on a 
FACSAria (BD Biosciences). Flow cytometric analysis was done using FlowJo Software v6.4 
(Tree Star, Ashland, OR). All samples were gated on CD4+ cells. 
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3.4.6 In vivo 7 day treatment 
BDC-2.5.TCR.Tg mice were treated with CA or HBSS (10 mg/kg) intraperitoneally for 7 days. 
On day 8, spleens were collected for further analysis, described below. 
 
3.4.7 Adoptive transfer of diabetogenic splenocytes 
Following 7 day in vivo treatment, splenocytes were isolated from control or CA-treated mice. A 
total of 1x10
7
 splenocytes was then adoptively transferred intravenously into NOD.scid mice; 
transfers included control alone, CA alone, and control:CA ratios of 1:6, 1:4, and 1:1. Diabetes 
was monitored starting at 10 days post-transfer. Overt diabetes was measured by a positive 
glucosuria test followed by two consecutive blood glucose readings of ≥ 300 mg/dL. 
3.4.8 Confocal microscopy 
Following 7 day in vivo treatment, splenocytes were isolated and plated in 96-well glass-bottom 
plates (MatTek Corporation, Ashland, MA) at the same ratios as mentioned above (excluding 
1:1). Cells were stimulated with 5000 NOD.scid islet cells for 24h. After stimulation, cells were 
fixed in 4% paraformaldehyde for 15 min at RT, permeabilized in 0.5% Triton-X-100 in PBS for 
10’, and washed with PBS in between all steps. Plates were stored at 4oC O/N. On the second 
day, cells were stained with IDO (1:50) and IFN-γ (1:50) in BD PermWash for 1h at 37oC. 
Secondary antibodies were then used alone or with double-stained cells: goat anti-mouse-IgG-
FITC (1:64) and goat anti-rat-IgG-Cy3 (1:250). Cells were visualized via an Olympus Fluoview 
FV1000 confocal microscope (Olympus Imaging, Center Valley, PA). Digital images (n=3-4) 
were acquired from each well using a 40X objective. Staining was quantified via MetaMorph 
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(Molecular Devices, Sunnyvale, CA). Results are expressed as number of positively stained cells 
per nuclei per image. 
 
3.4.9 Splenocyte respiration rates 
On day 8 post CA or HBSS treatment, splenocytes were harvested, and 2x10
7
 cells were 
measured by an Oroboros High Resolution Respirometer (Innsbruck, Austria) in a stirred 2 mL 
chamber in supplemented DMEM. Oxygen sensor was calibrated at each experiment according 
to the manufacturer's instructions. Calculations of respiratory rates were performed by software 
built into the instrument. Basal oxygen consumption was measured followed by 1) oligomycin (1 
µM), to inhibit ATP production by blocking complex V (ATPase) of the electron transport chain; 
2) at least 8 additions of 1 µM FCCP, to uncouple oxidative phosphorylation; and 3) rotenone (1 
µM), to measure non-mitochondrial oxygen consumption via inhibition of complex I in the 
electron transport chain.  
3.4.10 Preparation of cell lysates and western blotting 
BDC-2.5.TCR.Tg splenocytes were harvested after 7 days of in vivo treatment. Whole cell 
lysates were prepared as described (337). Protein concentration of all lysates was determined by 
BCA protein assay (Thermo Fisher, Rockford, IL). Protein lysates were separated on 4-20% 
SDS–PAGE gels. Western blots were performed as described (64) (with the exception of no 
boiling, 150 mAmp transfer for 1.5h, and blocking O/N in 5% non-fat dry milk in PBS for those 
samples probed with MitoOXPHOS antibody) with antibodies to MitoOXPHOS (1:250) (Santa 
Cruz), Glut1 (1 µg/ml) (Abcam), mTOR (1:1000), phospho-mTOR (1:1000), phospho-S6K 
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(1:1000), phospho-PHAS (1:1000) (Cell Signaling) and β-actin (1:10,000). All primary 
antibodies were diluted in 5% BSA in TBST, except for MitoOXPHOS in 1% non-fat dry milk 
in PBS. Secondary antibodies were from Jackson ImmunoResearch, West Grove, PA.  
Chemiluminescence was detected using ECL Plus reagent (Amersham Pharmacia Biotech, 
Buckinghamshire, UK). Blots were analyzed using Fujifilm LAS-4000 imager and Multi Gauge 
software (Fujifilm Life Science, Tokyo, Japan). 
3.4.11 Mitochondrial mRNA quantification 
BDC-2.5.TCR.Tg splenocytes were isolated after 7 days of in vivo treatment. Cells were 
collected, pelleted, and used for RNA isolation. RNA was isolated via the RNAeasy Kit 
(Quiagen, Valencia, CA), followed by cDNA synthesis using the SuperScript III First-Strand 
Synthesis System (Invitrogen, Carlsbad, CA). The qRT-PCR was performed using the following 
primer pair: PCG-1 (forward) 5’-ACCCACAGGATCAGAACAAACCCT-3’, (reverse) 5’-
TGGTGTGAGGAGGGTCATCGTTT-3’; TFAM (forward) 5’-
AGTCTTGGGAAGAGCAGATGGCT-3’, (reverse) 5’-AGACCTAACTGGTTTCTTGGGCCT-
3’; Nrf1 (forward) 5’-AACGGAAACGGCCTCATGTGTTTG-3’, (reverse) 5’-
GAGTACAATCGCTTGCTGTCCCA-3’; Complex I (NDUFB8) (forward) 5’-
TTCGGCTTTGTGGCTTTCATGGT-3’; (reverse) 5’-AAAGCCCATCAAGCCTCCTCAGAT-
’; Complex II (SDHB) (forward) 5’-AATGCAGACGTACGAGGTGGATCT-3’; (reverse) 5’-
TTGCCTCCGTTGATGTTCATGGC-3’; Complex III (UQCRC2) (forward) 5’-
ATCGGCTTGTTCGTTAAAGCAGGC-3’; (reverse) 5’-
TGCCTTCTACAGTGTACGCCATGT-3’; Complex IV (COX1) (forward) 5’-
CTCACAGTGCGGTCCAAC-3’; (reverse) 5’-CCAGCACCTGGTACTTAAG-3’; Complex V 
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(ATP5A) (forward) 5’-GGGCGTGTGTTAAGCATTGGTGAT-3’; (reverse) 5’-
ATTGTCGGGTTCCAAGTTCAGGGA-3’; GAPDH (forward) 5’-
GCATCCTGCACCACCAACT-3’, (reverse) 5’-CTGGCATGGCCTTCCGTGTT-3’. 
Quantitative RT-PCR was performed using a Light Cycler 2.0 (Roche, Indianapolis, IN). The 
reaction mixtures containing SYBR Green were generated following the manufacturer’s 
protocol. The cycling program was: initial denaturation at 95°C for 10 min, 40 cycles of 
amplification with a denaturation step at 95°C for 5 sec, an annealing temperature of 60°C for 15 
sec, and an extension step at 72°C for 20 sec. All samples were normalized to GAPDH, and CA-
treated samples were compared to control samples arbitrarily set to 1. 
3.4.12 Glucose and palmitate uptake assay 
BDC-2.5.TCR.Tg splenocytes were isolated after 7 days of in vivo CA treatment. Glucose 
oxidation was determined as described previously (664). Briefly, 1µCi of D-[6-
14
C] glucose and 
2.5 µM cold glucose in 0.2% BSA-Hanks buffer was added to splenocytes. Tubes were 
incubated at 37
o
C in water bath with rotation for 1 hour. To terminate metabolic reactions, 200 
µl 2 N HCl was added and 500 µl Hyamine (PerkinElmer Life Sciences) was added. 
14
CO2 
generated was then detected using a beta counter. Palmitate oxidation was measured as described 
previously (665). Briefly, splenocytes were resuspended in sucrose/Tris/EDTA buffer and 
incubated for 1 hour in reaction mixture (pH 8.0) containing [1-
14
C] palmitic acid. Measurements 
of acid-soluble metabolites and trapped CO2 were then detected. 
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3.4.13 ATP determination 
ATP determination kit was used following the manufacturer’s instructions (Invitrogen Life 
Technologies). Spleens were collected on day 8 following 7 days of in vivo treatment, weighed, 
homogenized in 1X reaction buffer, and centrifuged. 1 ml boiling water was added to each cell 
pellet, vortexed, centrifuged at 12,000 rpm for 5 min at 4
o
C, and supernatants were utilized in the 
assay. Background was measured for each standard and sample and subtracted accordingly. 
Luciferase was measured on a Victor
3
 Multilabel Counter 1420 (PerkinElmer, Waltham, MA) 
and ATP values were normalized to spleen weight. 
3.4.14 Lactate assay 
L-Lactate Assay Kit was used following the manufacturer’s instructions (Abcam). Spleens were 
collected on day 8 following 7 days of in vivo treatment, weighed, sonicated in lactate assay 
buffer, and diluted 1:5 in buffer.  
3.4.15 Statistical analysis 
The difference between mean values was assessed by Student’s t test, with p<0.05 considered 
significant. All experiments were performed at least three times. Data are mean ± SEM. Survival 
analysis
 
was done using the product-limit (Kaplan-Meier) method with the endpoint defined as 
disease. Data on
 
animals that did not develop type 1 diabetes were censored. The p values were 
determined by Log-Rank
 
test. 
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3.5 RESULTS 
3.5.1 Redox modulation does not skew T cells to the TH2 or TH17 subset 
Diabetogenic T cells stimulated in the presence of CA were previously demonstrated to have 
significantly decreased IFN-γ production, in comparison to control cells (644). Therefore, we 
wanted to determine whether or not cells were being skewed to a different T helper cell subset 
following redox modulation. BDC-2.5.TCR.Tg splenocytes were treated with M +/- CA for 72h, 
and supernatants were analyzed for IL-4, IL-10, IL-17 and IL-2 by ELISA. All cytokines were 
reduced in the presence of CA, except for IL-2, which is actually increased and necessary for T 
cell proliferation (Figure 29). CA has been previously reported to diminish expansion (644) yet 
keep cells alive (278; 304), suggesting a delayed usage of IL-2, which may attribute to its 
elevation after treatment. These data indicate that diabetogenic cells are not driven to a TH2 or 
TH17 subset following redox modulation. 
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Figure 29: CA administration decreases TH17 and TH2 subset cytokines. BDC-2.5.TCR.Tg 
splenocytes were left untreated or stimulated with M +/- CA for 72h. Cells were counted and 
supernatants were utilized in IL-4, IL-10, IL-17, and IL-2 ELISAs. Cytokine per cell = ng 
cytokine/# of total cells after 72h stimulation. n=3 independent experiments performed in 
triplicate, *p<0.05, ***p<0.0005. 
 
3.5.2 CA treatment does not enhance a regulatory T cell phenotype in vitro 
With no push towards a different T helper cell subset, we next wanted to determine if CA could 
promote regulatory T cell differentiation in vitro. Utilizing BDC-2.5.TCR.Tg isolated CD4+ T 
cells, CD25+Foxp3+ phenotype was measured following static anti-CD28 and a range of anti-
CD3 concentrations +/- CA. After 5 days of stimulation, CA-treated cells did not demonstrate a 
significant increase in regulatory T cell phenotype through a range of anti-CD3 concentrations 
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(Figure 30A). However, CA was still able to significantly decrease IFN-γ production at anti-
CD3 concentrations of 0.1-0.2 µg/ml (Figure 30B). Despite the reduction in TH1 phenotype, 
stimulating diabetogenic T cells under non-polarizing conditions in the presence of CA did not 
enhance a regulatory T cell phenotype in vitro. 
Figure 30: CA treatment does not increase Treg phenotype of CD4+ diabetogenic T cells. 
BDC-2.5.TCR.Tg CD4+ T cells were isolated from spleens. Cells were stimulated with pre-
coated titration of anti-CD3 and soluble anti-CD28 (1.0 µg/ml) +/- CA. (A) After 5 days of 
incubation, cells were collected and stained for CD4, CD25, and Foxp3. Samples gated on 
CD4+CD25+ cells by flow cytometry. n=3 independent experiments. (B) Supernatants from 
cultures were used in an IFN-γ ELISA. n=3 independent experiments, *p<0.05. 
3.5.3 Redox modulation of donor mice delays diabetes transfer 
Although no skewing to a different T helper cell subset and no enhancement of Treg phenotype 
was demonstrated following CA addition in vitro, we conducted an in vivo suppression assay 
with varying ratios of control and CA-treated cells. CA or HBSS (control) was administered to 
BDC-2.5.TCR.Tg mice for 7 days, and on day 8 cells were transferred alone or in control:CA 
ratios of 1:1, 1:4, and 1:6 into NOD.scid recipients. Control transfers succumbed to diabetes by 
day 10, consistent with historical data (36; 644), whereas CA transfers exhibited significantly 
delayed diabetogenic potential (p<0.0005) (Figure 31A). Strikingly, the majority of the 1:6 
adoptive transfer ratios surpassed the diabetes onset point of the CA transfers (>23 days), 
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illustrating in vivo cross-regulation between the two populations (Figure 31B). Conversely, 
ratios of 1:4 and 1:1 did not display reduced diabetogenic potential, with 1:1 actually 
accelerating disease (Figure 31C, D), indicating a need for higher numbers of CA:Control cells 
to alter diabetogenic potential. The contribution of the CA-treated cells within the 1:6 ratio 
transfers is therefore enough to prevent the autoimmune attack of diabetogenic BDC-2.5.TCR.Tg 
splenocytes up to the end of the study, ~40 days post-transfer. 
 
Figure 31: CA treatment of donor mice leads to in vivo regulation of diabetogenic potential 
upon adoptive transfer. BDC-2.5.TCR.Tg mice were treated for 7 days i.p. with CA or HBSS 
at 10 mg/kg. On day 8, splenocytes were harvested and adoptively transferred i.v. into NOD.scid 
recipients. Mice were monitored by glucosuria for the onset of type 1 diabetes and considered 
diabetic after two consecutive blood glucose readings of >300 mg/dL. (A) Control vs. CA, 
***p<0.0001; (B) Control vs. 1:6, ***p<0.0001; (C) Control vs. 1:4, no significance, CA vs. 
1:4, ***p<0.0001; (D) Control vs. 1:1, *p<0.05, CA vs. 1:1, ***p<0.0001. n=3 mice/transfer. 
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3.5.4 IDO induction correlates with diabetogenic potential of adoptive transfer ratios 
To elucidate the mechanism responsible for the delay in diabetes after 1:6 control:CA adoptive 
transfers, splenocytes were plated in vitro in the presence of islets. IDO and IFN-γ induction 
were visualized via confocal microscropy. CA-treated cells demonstrated dramatically increased 
levels of IDO in comparison to control cells (p=0.0588) (Figure 32). The 1:6 ratio also showed 
moderately increased IDO production in comparison to control cells (p=0.061); however, the 
IFN-γ detected in the 1:6 ratio was trending higher (p=0.2007) than the levels in CA-treated 
cells. This difference in IFN-γ secretion may be important for the longer diabetes delay in the 1:6 
transferred mice, as IFN-γ is necessary for IDO induction (659; 660). 
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Figure 32: IDO induction correlates with decreased diabetogenic potential. Following 7 day 
CA or HBSS in vivo treatment, splenocytes were harvested and plated as control alone, CA 
alone, or control:CA ratios of 1:6 and 1:4. Cells were then stimulated with islets for 24h. 
Following stimulation, cells were immunostained for IDO and IFNγ. Confocal images were 
obtained at a 40X objective and quantified. IDO and IFN-γ per cell were calculated by dividing 
by the nuclei (Hoescht) per image. A total of 3 images/condition was averaged ± SEM. 
 
3.5.5 Redox modulation mildly decreases overall oxygen consumption of diabetogenic 
splenocytes 
In addition to the 1:6 extension in diabetes onset delay, we also wanted to further deduce why 
CA treatment alone failed to afford durable protection against disease onset past 20 days post-
transfer. Based on previous studies, redox modulation can inhibit TH1 effector function and block 
immune cell NF-κB activation (48; 64; 644). These effects are important for preventing disease, 
but may not be the sole mechanisms for reducing immune cell activity. Because CA can 
scavenge ROS, which are a constant byproduct of cellular respiration, another level of regulation 
may be contributing to the delayed but eventual beta cell destruction (Figure 31A). Therefore, 
we wanted to determine if CA-treated autoreactive cells also displayed a reduced metabolic 
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signature, thus regulating their ability to generate enough energy to push toward effector 
function. To study this, we first calculated respiration by measuring overall oxygen consumption 
in control versus CA-treated splenocytes (Figure 33A). Although uncoupling respiration from 
ATP synthesis with FCCP titration elicited statistically significant decreases following CA 
treatment, redox modulation did not significantly reduce respiration at baseline (Basal), during 
maximal uncoupling (FCCP 8.0 µM), or from non-mitochondrial oxygen consumption sources 
(Rot), the major indicators of oxidative phosphorylation (Figure 33B). Therefore, overall 
oxidative phosphorylation was only mildly affected upon CA treatment. 
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Figure 33: Respiration is reduced following in vivo redox modulation. BDC-2.5.TCR.Tg 
mice were treated for 7 days i.p. with CA or HBSS at 10 mg/kg. On day 8, splenocytes were 
harvested and analyzed in an Oroboros Respirometer. Oxygen consumption was measured as 
pmol/second/million cells (pmol/(s*Mill)). (A) Respiration was determined at basal conditions 
and after the addition of mitochondrial inhibitors, oligomycin (Oligo) and rotenone (Rot), and 
additive amounts of the mitochondrial uncoupler FCCP. (B) n=5 independent experiments, 
*p<0.05, **p<0.005.   
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3.5.6 CA treatment does not significantly alter mitochondrial complex/biogenesis 
 molecules 
Based on the minor decrease in respiration, we hypothesized that mitochondrial biogenesis may 
be unchanged after CA treatment. To first assess this possibility, we measured all mitochondrial 
complexes (666) from whole cell splenocyte lysates via western blot, using an antibody cocktail, 
after 7 days of in vivo treatment. The cocktail contains antibodies to complex subunits that are 
labile if not assembled properly; therefore, an accurate depiction of the mitochondrial complexes 
should be feasible with this probe. In general, mitochondrial complex proteins are not 
significantly decreased after CA treatment (Figure 34A, B). Furthermore, mRNA levels of these 
same complexes are similarly unaltered (Figure 34C). Lastly, mitochondrial biogenesis 
transcription factors, which regulate the production of the mitochondrial complexes, were also 
measured by qRT-PCR. Pgc-1 and Tfam were not statistically different following CA treatment 
(Figure 34D). PGC-1 stimulates mitochondrial biogenesis through regulation of nuclear 
respiratory factor 1 (Nrf1) (667). Together, PGC-1 and Nrf1 can initiate mitochondrial 
transcription factor A (TFAM), which activates mitochondrial DNA replication and transcription 
(668). These results indicate similar mitochondrial abundance in control versus CA-treated 
splenocytes, despite the slight reduction in oxygen consumption. However, redox modulation did 
significantly decrease Nrf1 mRNA (Figure 34D). Nrf1 not only contributes to mitochondrial 
biogenesis, but it also plays roles in a wide range of cells, including binding to the antioxidant 
response element (ARE) for gene transcription during times of oxidative stress (669). Reduced 
Nrf1 after redox modulation may therefore correlate with a reduced need for antioxidant 
transcription, as CA acts as an effective scavenger of ROS and reduces oxidative stress on its 
own. 
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Figure 34: CA treatment does not significantly alter mitochondrial complex and biogenesis 
molecules. BDC-2.5.TCR.Tg mice were treated for 7 days i.p. with CA or HBSS at 10 mg/kg. 
On day 8, splenocytes were harvested for protein lysates and mRNA isolation. (A) Whole cell 
lysates were probed for MitoOXPHOS antibody cocktail by western blot. Actin was probed as a 
loading control. Each complex is indicated based on its molecular weight. Data are 
representative of 3 independent experiments. (B) Densitometry was quantified for each complex 
by normalizing control and CA-treated cells to actin. Fold induction of complex protein from 3 
independent experiments. (C-D) Relative mitochondrial complex or biogenesis mRNA levels 
were measured by qRT-PCR. The fold change of control samples were set arbitrarily to 1 and 
compared to CA treatment. All samples were normalized to the endogenous GAPDH control. 
n=4-5 independent experiments. 
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3.5.7 Redox modulation decreases aerobic glycolysis of diabetogenic splenocytes 
Activated immune cells undergo aerobic glycolysis as their main form of metabolism (421; 423; 
424). Based on the results indicating a non-significant decrease in oxidative phosphorylation 
(Figure 33), we next wanted to ascertain the level of glycolysis following CA treatment. To 
determine glycolytic dominance, we measured lactate production in mouse spleens after 7 days 
of in vivo treatment (Figure 35A). Lactate levels were significantly decreased in CA-treated 
spleens (p<0.05). Based on these data, aerobic glycolysis is not enhanced as compensation for 
the observed mild decrease in oxidative phosphorylation; instead, aerobic glycolysis is 
significantly reduced, which may contribute to immune cell quiescence and stunted diabetogenic 
potential. 
3.5.8 CA treatment induces more efficient glucose oxidation while reducing fatty acid 
 oxidation 
Glucose utilization via aerobic glycolysis is the standard pathway for activation of immune cells. 
However, glucose and other substrates can be used for the TCA cycle and oxidative 
phosphorylation. To parse out differences in substrate oxidation, in contrast to overall oxygen 
consumption (Figure 33), glucose and the fatty acid palmitate were used in an uptake assay. In 
CA-treated splenocytes, glucose oxidation, as measured by radiolabeled CO2 production, was 
significantly enhanced (p<0.005) in comparison to control cells (Figure 35B). Conversely, fatty 
acid oxidation, which would increase in the absence of sufficient glucose oxidation, was 
decreased following redox modulation (Figure 35C). Moreover, spleen ATP levels remain 
unchanged between the groups (Figure 35D), suggesting an augmentation of TCA cycle 
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efficiency after CA administration, resulting in more glucose oxidation but less aerobic 
glycolysis necessary for driving activation of diabetogenic splenocytes. 
Figure 35: Glucose oxidation efficiency is enhanced after redox modulation. BDC-
2.5.TCR.Tg mice were treated for 7 days i.p. with CA or HBSS at 10 mg/kg. On day 8, spleens 
were harvested. (A) Spleens were weighed, homogenized, and used in a lactate assay. Lactate 
(nmol) was quantified per mg of spleen. (B) Isolated splenocytes were given D-[6-
14
C] glucose 
and 2.5 µM cold glucose, incubated for 1 hour, and 
14
CO2 was measured. (C) Isolated 
splenocytes were given [1-
14
C] palmitic acid, incubated for 1 hour, and 
14
CO2 was measured. (D) 
Spleens were weighed, homogenized, boiled and used in an ATP determination assay. ATP (nM) 
was quantified per mg of spleen. n=3 mice/group for all assays. *p<0.05, **p<0.005. 
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3.5.9 Redox modulation leads to less mTOR activity and Glut1 expression 
In accordance with the decrease in lactate production, we sought to determine CA-mediated 
aerobic glycolytic signaling effects, specifically through mTOR and Glut1 expression. mTOR 
activation is essential  for driving cell cycle. Decreased activation of mTOR blocks expansion of 
cells, especially in times of starvation or when glycolysis is low. After CA treatment, mTOR 
phosphorylation is increased (Figure 36A), which has conflicting interpretations. 
Phosphorylation at serine 2448 can activate mTOR (670); however, removal of serines 2448-
2450 can actually enhance mTOR activity, suggesting that serine 2448 is part of a repressor 
domain (671), indicating a potential reduction in glycolysis and a blockade in splenocyte 
expansion. To further investigate mTOR activity, downstream signaling targets, S6 kinase and 
PHAS were measured. Upon CA treatment, phosphorylation of both S6 and PHAS is decreased 
(Figure 36B), indicating a reduction in mTOR activity and confirming previously reported data 
(644), where CD4+ T cell proliferation was also blunted by redox modulation. Additionally, 
Glut1 protein was assessed in whole cell splenocyte lysates. Glut1 is a glucose transporter 
protein upregulated by cytokines and glycolytic enzymes. Redox modulation can decrease 
cytokine production from both innate and adaptive immune cells (48; 64; 644). Glut1 expression 
is decreased following CA administration (Figure 36C), suggesting diminished glycolysis in 
response to lowered cytokine stimulation. These data along with those showing reduced aerobic 
glycolysis together highlight the potential of CA treatment to lower immune cell bioenergetics, 
which most likely contributes to decreased activation and delayed diabetes onset upon transfer.  
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Figure 36: Redox modulation leads to increased phospho-mTOR and decreased Glut1 
expression. BDC-2.5.TCR.Tg mice were treated for 7 days i.p. with CA or HBSS at 10 mg/kg. 
On day 8, splenocytes were harvested for protein lysates. (A) Whole cell lysates were probed for 
(A) phospho-mTOR and mTOR (B) phospho-p70s6K and phosphor-PHAS and (C) Glut1 by 
western blot. Actin was probed as a loading control for both panels. Data are representative of 
(A, C) 3-4 independent experiments, (B) 1-2 independent experiments. 
 
3.5.10 CA-mediated immunomodulatory alterations are reversible 
CA treatment affects both immune and metabolic functions of diabetogenic immune cells. 
Although both of these parameters clearly contribute to the reduction in diabetogenic potential of 
autoreactive splenocytes, determining the reversibility of these effects, as seen during the 
adoptive transfer in which CA-treated autoreactive cells eventually cause disease (Figure 31A), 
is important for establishing redox modulation as a potential clinical agent. Therefore, we 
measured the reversibility of CA administration in an immunological ELISA assay. Following 7 
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days of in vivo treatment, transgenic autoreactive splenocytes were stimulated in vitro with 
cognate peptide. By day 4 post-stimulation, CA-treated IFN-γ production returned to control 
levels (Figure 37). Although this reversal, i.e. towards a control cell phenotype, demonstrates the 
inability of CA treatment to chronically block diabetogenic function, explaining the eventual 
diabetes onset after adoptive transfer, it demonstrates no global immunosuppression after 
treatment has ceased, resulting in a lack of long-term, unwanted side effects. 
Figure 37: Diabetogenic immune function blockade is reversible after ending CA 
treatment. BDC-2.5.TCR.Tg mice were treated for 7 days i.p. with CA or HBSS at 10 mg/kg. 
On day 8, splenocytes were harvested for in vitro stimulation with M +/- CA. At 48-96h, 
supernatants were collected and used in an IFN-γ ELISA, n=5 independent experiments 
performed in triplicate, *p<0.05. 
3.6 DISCUSSION 
The alteration of undesired immune responses can be beneficial in the context of a plethora of 
diseases, including autoimmunity. Unlike cancer and infections, controlling self-reactivity 
requires a reduction in innate and adaptive immune cell activities. A number of endogenous 
pathways exist to directly or indirectly adjust immune responses. Such modifications of T cells 
 133 
include skewing towards a different T helper subset, Treg-mediated suppression, and APC-
derived IDO induction for the inhibition of T cell proliferation and survival. Feed-forward 
mechanisms and interplay between the two arms of the immune response will extend these T cell 
adjustments to eventually downregulate innate cell functions (672), thus widely alleviating any 
aberrant responses. Besides strictly immunological mechanisms, another means of immune cell 
regulation is metabolic restraint. This type of control can theoretically affect both innate and 
adaptive immune cells. Anti-glycolytics and treatments to inhibit oxidative phosphorylation have 
been utilized in cancer, transplantation, and neurodegenerative diseases (547; 597; 600; 613; 
629). In autoimmunity, for example, HIF-1 blockade leads to decreased glycolysis, resulting in 
diminished TH17-mediated murine EAE (535). Similarly, antioxidant treatments, which 
effectively lower oxidative stress propelled by mitochondrial respiration, can relieve TH17-
mediated murine arthritis (639) and induce regulatory T cells (673; 674). In previous studies, we 
demonstrated reduced type 1 diabetes through antioxidant treatment; however, the experiments 
were limited to TH1 response measurements (644). We therefore wanted to determine whether 
CA treatment affected the specific regulators of T cell function listed above and/or if redox 
modulation could influence immune cell metabolism.  
CA treatment is known to decrease TH1 responses via reductions in IFN-γ (48; 278; 644). 
Through detection of cytokine secretion, we investigated whether CA administration skews 
diabetogenic T cells to a different T helper subset, such as TH17 or TH2 cells. The induction of 
TH2 cells can inhibit TH1 cell responses, successfully biasing the autoreactive T cell pool away 
from beta cell destruction (172; 675; 676). Cytokines were measured on a per-cell basis to 
exclude any differences that may be acquired from overall decreased cell proliferation upon in 
vitro stimulation in the presence of CA, shown previously using BDC-2.5.TCR.Tg splenocytes 
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(644). In the present studies, we conclude that CA treatment does not skew TH1 cells towards 
another T helper subset, as cytokine decreases were detected for IL-17, IL-4, and IL-10. 
Next, we measured the ability of CA treatment to promote Treg differentiation. 
Regulatory T cells are important for suppressing autoreactive T cells that have escaped thymic 
selection. Moreover, generation of Tregs may afford long-term tolerance to self-antigen and/or 
reversal of immune-mediated tissue damage. After CA administration in vitro, we did not 
observe an enhancement of Treg differentiation following anti-CD3/CD28 stimulation under 
non-polarizing conditions. Low anti-CD3 concentrations are known to drive 
CD4+Foxp3+CD25+ Tregs in vitro (677); CA treatment, even with the lowest dose of anti-CD3, 
does not significantly increase Treg development over control cells. However, polarizing 
conditions may have to be implemented in future studies in order to rule out this possibility 
completely. 
Despite these data, adoptive transfers of CA-treated diabetogenic splenocytes yielded in 
vivo suppression of autoreactive responses. Transfer of CA-treated cells alone caused a 
significant delay in diabetes onset; however, the control:CA ratio of 1:6 was able to extend this 
delay of diabetes onset, suggesting regulatory interactions between the two populations. Notably, 
CA-treated cell transfers ultimately succumbed to disease at day 23, whereas the 1:6 ratio 
remained diabetes free until the end of the study (40 days). This difference between the transfers 
was particularly interesting on two levels: 1) the mechanism in play between the two cell 
populations in the 1:6 ratio transfer and 2) the eventual disease manifestation after CA-treated 
cell transfer.  
IDO induction in APCs causes the catabolism of tryptophan, an essential amino acid for 
T cell proliferation and survival. The enzymatic activity of IDO is useful for contraction of an 
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immune response and has been exploited in the setting of transplantation. IDO released from 
DCs can inhibit alloreactive T cells, blocking transplant rejection (678; 679). In autoimmunity, 
IDO can potentially have a similar effect, restraining autoreactive T cell responses (680). 
Utilizing the 1:6 transfer ratio in vitro, we detected an increase in IDO levels in comparison to 
control, CA-treated, and 1:4 transfer ratios. IDO production has been postulated to follow 
ligation of LAG-3 on T cells to MHC class II on DCs (204; 371; 681). In our previous study, CA 
enhanced the frequency of LAG-3+ T cells and also decreased its cleavage from the cell surface 
(644), suggesting a possible mechanism for this study’s results. Moreover, IDO is controlled by 
IFN-γ; IFN-γ can bind to its receptor on APCs and signal through JAK/STAT pathways to 
initiate IDO expression (682). Because CA can decrease IFN-γ production (48; 278; 644), it is 
possible that redox modulation alone may lower the TH1 cytokine level too much, not allowing 
for sufficient IDO activity and resulting in the eventual onset of type 1 diabetes after adoptive 
transfer. CA treatment during islet transplantations likewise results in too little IFN-γ, and in the 
absence of any other immunosuppression, transplants are eventually rejected (unpublished data). 
A delicate balance of IFN-γ levels is thus necessary for reducing diabetogenic potential, and the 
contribution between both control and CA-treated cells in the 1:6 ratio may be sufficient for 
inducing IDO, restraining disease onset. 
With the ability of CA to scavenge ROS produced during cellular respiration (64; 683), it 
is plausible for redox modulation to extend beyond immunological control. Adoptive transfers of 
CA-treated diabetogenic splenocytes significantly impede type 1 diabetes in comparison to 
control cells. However, the loss of regulation around 23 days post-transfer led us to test whether 
or not immune cell metabolism is restrained by redox modulation until the amount of CA 
troughs, consequently reversing self-reactive control. Adequate bioenergetics levels are crucial 
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for directing activation and expansion of immune cells. Resting and memory T cells rely 
primarily on oxidative phosphorylation, whereas activated T cells depend on mainly on 
glycolysis. Innate cells, on the other hand, predominately utilize glycolysis during all activation 
states (423; 424). Oxidative phosphorylation is important for ATP storage in immune cells, 
preparing them for efficient function upon activation and some increases are detected upon 
activation (410). Conversely, the macromolecule synthesis necessary for immune cell expansion 
is a result of the quicker metabolic route of glycolysis (421). In general, both metabolic pathways 
are necessary for priming and activating autoreactive immune cells. Redox modulation 
demonstrated only a mild reduction in overall oxygen consumption of diabetogenic splenocytes. 
This effect on mitochondrial respiration was not due to an alteration in primary mitochondrial 
biogenesis or complexes of the electron transport chain. However, Nrf1, a transcription factor 
important for biogenesis as well as activating the ARE, was significantly decreased after CA 
treatment. This result is potentially because of the antioxidant actions of CA. The need for more 
antioxidant genes to be transcribed following Nrf1 binding to the ARE is likely lowered in the 
presence of redox modulation. Moreover, scavenging of ROS by CA reduces oxidative stress, 
which is known to upregulate Nrf1 gene transcription (684; 685). The significant reduction in 
Nrf1 may therefore be related to the stress level of the cell and not necessarily an impact on 
mitochondrial abundance. 
We next measured lactate production and signaling molecule activation to determine if 
compensatory increases in aerobic glycolysis resulted from the slight decrease in respiration after 
CA treatment. During times of dominant glycolysis, the metabolic intermediate pyruvate is 
fermented to lactate, producing NAD+ for macromolecule synthesis and for the continuation of 
glycolysis. Lactate levels increase during T cell activation (409; 447), again illustrating how 
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immune cells rely heavily on aerobic glycolysis to transition from a resting state. Lactate levels 
in the spleen, a secondary lymphoid organ, were significantly lowered in CA-treated mice, 
suggesting that aerobic glycolysis is decreased upon redox modulation. 
In addition to lactate levels, we also measured the glycolytic signaling molecules 
phospho-mTOR and Glut1. mTOR is activated downstream of the PI3K-Akt pathway, which is 
stimulated during T cell activation and hence, glycolysis (409). For efficient cell cycle 
progression and proliferation, mTOR is activated, allowing for the activation of downstream 
signaling targets p70s6K and phospho-PHAS1 (480; 686), which drive ribosome biogenesis and 
translation initiation, respectively. During times of starvation or low glycolysis, phosphorylated 
mTOR is decreased, repressing its own catalytic activity and promoting hyporesponsive T cells 
(485; 671), yet protecting against apoptosis (687). Furthermore, dephosphorylated mTOR has 
been postulated to augment the function of p21 and p27 cyclin-dependent kinase inhibitors (688), 
effectively blocking cell cycle progression. CA treatment boosted the amount of phosphorylated 
mTOR in comparison to control splenocytes, highlighting conflicting interpretations. Serine 
2448 phosphorylation may both activate mTOR (670) yet contribute to an mTOR repressor 
domain (671). Further studies on several phosphorylation sites within mTOR will need to be 
conducted to definitively interpret our results. However, reductions in phosphorylation of s6K 
and PHAS indicate a potential reduction in glycolysis and a blockade in splenocyte expansion 
due to mTOR inactivation. This result also positively correlates with previous studies displaying 
decreased CD4+ T cell proliferation following redox modulation (644) and provides more 
evidence of reduced aerobic glycolysis.  
Glut1, the only glucose transporter expressed on immune cells (406), was also measured. 
CA-treated splenocytes showed lower Glut1 levels than in control cells. Glucose uptake through 
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Glut1 is critical for metabolic processes; reduced Glut1 levels are indicative of an environment 
lacking the growth factors/cytokines necessary for perpetuating PI3K-Akt signaling pathways 
necessary for Glut1 expression (409; 475). CA can decrease cytokine levels from T cells and 
APCs (64; 278; 644); this lack of cytokine production may also act to reduce Glut1 expression. 
CA-treated cells do, however, remain viable (278), and therefore, the reduction in Glut1 is not 
harmful to splenocyte health. Indeed, regulation of Glut1 expression is actually essential for 
controlling hyperresponsive lymphocytes so as not to cause pathology (475). Additionally, HIF-
1, a molecule especially critical for glycolysis during both aerobic and anaerobic respiration, can 
control the induction of Glut1 (414). With the reduction in Glut1 expression, CA may be 
downregulating HIF-1. In a radiation-induced pulmonary injury model, HIF-1 activation is 
decreased after CA treatment (646). Similarly, HIF-1 deactivation via redox modulation can 
enhance tumor radiosensitivity (689). These data demonstrate the importance of glycolysis for 
immune responsiveness and support our experiments depicting reduced Glut1 and decreased 
mTOR activity after CA administration. 
Aerobic glycolysis is primarily used during tumor cell proliferation, a phenomenon 
known as the Warburg effect. This metabolic pathway is critical for effectively synthesizing new 
macromolecules for cell expansion and is characterized by HIF-1 activation, Glut1 expression, 
and lactate production. Although CA treatment only mildy decreased overall oxidative 
phosphorylation and reduced aerobic glycolysis, we parsed out different oxidation substrate 
pathways (glucose and palmitate) to determine any differences. Glucose oxidation efficiency is 
enhanced following CA administration, whereas fatty acid oxidation is decreased. While 
glucose-driven oxidative phosphorylation is necessary for preparing the cell for activation (410), 
fatty acid oxidation is critical for driving chronic inflammation, as in the case of EAE (690). 
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Furthermore, overall ATP production within the spleen is unchanged between control and CA 
treatment. These results do not necessarily mean that glucose is oxidized faster or more than 
control cells, but may instead indicate better TCA cycle function and possibly better coupling in 
the electron transport chain. ROS produced during the electron transport chain are able to 
damage TCA enzymes, such as aconitase (691; 692). When these enzymes are harmed by ROS, 
their activity is decreased (693), resulting in less efficient glucose oxidation. Importantly, 
reduced fatty acid oxidation may indicate less autoimmune-mediated chronic activation, further 
controlling self-reactivity. Overall, redox modulation leads to better glucose breakdown, yet 
reduced immune cell activation via aerobic glycolysis.  
With the current antibodies and immunosuppressive agents in the clinic, negative side 
effects are almost always a cause for concern. For example, blocking immune cell activation for 
prevention of transplantation rejection usually requires long-term drug usage, which often 
instigates unavoidable damage. On the other hand, for treatment of autoimmunity, certain 
immunosuppressive agents may be too toxic or result in bystander injury that only worsens the 
disease. Cyclosporine A, for example, can block T cell activation and has been used outside of 
transplantation in severe cases of rheumatoid arthritis and psoriasis (694; 695). However, 
hepatotoxicity and nephrotoxicity are common side effects of this drug, which can lead to 
chronic organ disease or failure (666; 696; 697). A new class of small molecule agents is needed 
to better control autoreactivity yet protect against lasting side effects. Unlike certain 
immunosuppressants, antioxidant treatment can benefit autoimmunity as well as preserve organ 
function (79; 304), with little to no toxicity at the recommended amount. The toxic dose of the 
CA is 9-times the effective dose used in our studies (698), illustrating its bioavailability and low 
risk of injury. Importantly, CA treatment is reversible, as measured by the return of IFN-γ after 
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clearance of the agent, confirming the maintenance of cell viability following administration. 
The reversibility of redox modulation could especially be useful for acute illnesses or for tumor 
therapies. Furthermore, CA treatment could serve as a means to reset the threshold of 
hyperresponsive immune cells. This would then allow for subsequent administration of a more 
targeted immunotherapy, such as an antibody that specifically affects T cells, to effectively 
prevent or reverse autoimmunity.   
In conclusion, redox modulation does not promote skewing of T helper subsets or 
induction of classical Treg cells. IDO production may be the mechanism behind the extension of 
diabetes delay in competitive adoptive transfers; however, the 1:6 ratio of control:CA-treated 
cells is not physiologically relevant, unless only subsets of cells could be targeted during 
systemic CA administration. Therefore, metabolic control by redox modulation may be 
attributable to the reduction in diabetogenic potential, highlighting this agent as not only 
immunomodulatory and cytoprotective, but also reversible, with anti-Warburg effect 
characteristics, overall promoting immune cell quiescence. Bioenergetic regulation is thus a 
possible therapeutic option for controlling self-reactivity and may hold promise for prevention or 
reversal of type 1 diabetes. 
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4.0  REDOX MODULATION IMPROVES INSULIN SENSITIVITY AND 
INFLAMMATION IN A HIGH-FAT DIET-INDUCED TYPE 2 DIABETES MODEL 
4.1 ABSTRACT 
In type 2 diabetes, a collaboration of impaired insulin signaling and decreased insulin secretion 
leads to hyperglycemia and long-term health complications. Insulin resistance is further 
exaggerated through chronic dietary fat intake and inflammation. The liver and adipose tissue are 
two sites of abnormal fat deposition and immune cell infiltrate upon obesity-induced diabetes. 
Through utilization of a metalloporphyrin catalytic antioxidant (CA), we sought to determine 
whether redox modulation could assuage liver and adipose complications as well as enhance 
insulin sensitivity and glucose tolerance in a high-fat diet-induced mouse model of type 2 
diabetes. In addition to scavenging reactive oxygen species and mimicking superoxide 
dismutase, CA can decrease proinflammatory cytokine secretion through inhibition of NF-κB 
activation. Moreover, CA is not toxic and can preserve beta cell function. In the present study, 
CA delayed weight gain, reduced serum leptin and insulin levels, alleviated hepatic steatosis, 
decreased adipose immune cell infiltrate, and enhanced the acute phase IL-6 response for tissue 
repair. Overall, CA treatment is a potential therapeutic strategy for impeding type 2 diabetes 
pathogenesis and reducing chronic diabetic side effects. 
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4.2 INTRODUCTION 
Unlike type 1 diabetes, in which a loss of beta cells contributes to the absence of insulin, type 2 
diabetes is not autoimmune-mediated, but instead induces poor glucose tolerance as a result of 
insulin resistance. Insulin is important for regulating energy metabolism by facilitating glucose 
uptake in skeletal muscle, while reducing gluconeogenesis in the liver and lipolysis in the 
adipose tissue. As the amount of blood glucose and lipid metabolites tips into excess in the 
context of obesity, the liver, muscle, and adipose are unable to compensate and become the 
targets of fat deposition and inflammatory cell infiltrate. In particular, global insulin receptor 
signaling becomes desensitized, resulting in abnormal translocation of glucose transporters and 
impaired glucose metabolism (699). The pancreatic beta cells attempt to restore glucose 
tolerance by secreting more insulin; however, as peripheral insulin resistance increases, the beta 
cell secretory capacity is unable to re-establish insulin sensitivity (700; 701). Type 2 diabetes 
manifests when loss of glucose tolerance supersedes insulin resistance.  
Control of blood glucose levels is critical. A combination of hyperglycemia, obesity and 
insulin resistance can enhance oxidative stress and lead to chronic complications. In type 2 
diabetes, long-term complications include cardiovascular disease, hypertension, dyslipidemia, 
and poor circulation, together termed ‘metabolic syndrome’ (702; 703). Unlike type 1 diabetes, 
type 2 diabetes often can be treated through caloric restraint and exercise (704; 705). However, 
with approximately 2/3 of U.S. adults considered overweight or obese, type 2 diabetes is a 
prevalent epidemic and requires further inquiry into alternative treatment options for the initial 
disease and the costly diabetic complications (706). 
The mechanisms leading to insulin resistance and complications are highly dependent on 
oxidative stress and inflammation. Hyperglycemia and lipotoxicity can lead to abundant ROS 
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generation and inflammation (707). Rodent models of type 2 diabetes and human patients display 
high ROS in the islets (708). Islets, in comparison to other tissues, have low antioxidant levels 
(91), making them extremely susceptible to oxidative stress and hyperglycemia (709). High 
glucose levels can impair glucose-stimulated insulin secretion, whereas H2O2, a potent oxidizer, 
can damage glucose metabolism, together resulting in dysfunctional insulin release (95; 710). 
Defects in glucose metabolism lead to deficient ATP production, further lending to diminished 
glucose-stimulated insulin secretion (711). For this reason, insulin resistance and beta cell 
mitochondrial dysfunction are both thought to play a role in type 2 diabetes.  
In addition to hyperglycemia, an overall increase in dietary fat leads to an energy surplus, 
overworking islet mitochondria and generating an abundance of ROS (712). Mitochondria 
derived ROS have been implicated in enhancing the expression of insulin signaling inhibitors, 
leading to less glucose uptake. Specifically, ROS can directly inhibit insulin signaling through 
activation of stress kinases like JNK and p38 MAPK (713; 714), leading to serine/threonine 
phosphorylation of insulin receptor substrate 1 (IRS1), and inhibition of PI3K activation 
downstream of insulin ligation. In the context of inactivated PI3K, the glucose transporter Glut4 
in skeletal muscle does not translocate to the plasma membrane and glucose uptake is reduced 
(713). Moreover, H2O2 can directly inhibit Akt and glucose transporter activity (715) as well as 
reduce IRS1 and IRS2 protein levels after chronic exposure (716). These ROS-mediated 
modifications can augment insulin resistance and play critical roles in promoting disease 
complications. 
As a result of heightened ROS levels, redox-dependent transcription factors such as NF-
κB further exacerbate type 2 diabetes via proinflammatory cytokine secretion. Activation of NF-
κB leads to the production of MCP-1, IL-1β, IL-6, and TNFα, all of which are detrimental to 
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insulin tolerance if chronically produced (717). During obesity and type 2 diabetes, macrophages 
infiltrate the fat and liver, where they worsen insulin resistance through proinflammatory 
cytokine production (718; 719). In healthy individuals, insulin is able to bind insulin receptor and 
signal through PI3K and Akt to block proinflammatory cytokine production. It does so by 
phosphorylating FOXO proteins (720; 721), removing them from the nucleus and disabling their 
ability to facilitate NF-κB activation. Therefore, insulin acts as an endogenous anti-inflammatory 
agent (722; 723), and improper insulin signaling results in an exaggerated inflammatory 
environment. Aberrant proinflammatory cytokine production positively correlates with insulin 
resistance in type 2 diabetes (724), and anti-inflammatory therapies have shown promise in 
improving insulin sensitivity (725). IL-1R-antagonist or anti-IL-1β can preserve beta cell 
function in type 2 diabetes (726; 727). Furthermore, blockade of NF-κB through resveratrol and 
curcumin administration reduces adipocyte cytokine production, suggesting improved insulin 
sensitivity through anti-inflammatory strategies (728). 
In our previous studies, we utilized a manganese metalloporphyrin catalytic antioxidant 
(CA) to block proinflammatory cytokine production and inhibit type 1 diabetes onset (36; 48; 
278; 644). The CA we used is able to scavenge a broad range of ROS, including superoxide, 
hydrogen peroxide, and peryoxynitrite, and acts a SOD mimetic (269). Importantly, we have 
detected reductions in both oxidative stress and NF-κB activation following administration of 
CA (64). Based on these studies, we wanted to determine whether CA treatment could modulate 
high-fat diet-induced inflammation in the male, C57BL/6J model of type 2 diabetes and if this 
treatment could assuage insulin resistance as well as obesity-induced liver steatosis and 
inflamed-adipose complications. 
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4.3 RESEARCH DESIGN AND METHODS 
4.3.1 Materials 
C57BL/6J mice were purchased from Jackson Labs (Bar Harbor, MN) and housed under specific 
pathogen-free conditions in the Animal Facility of Rangos Research Center at Children’s 
Hospital of Pittsburgh of UPMC (Pittsburgh, PA). Male mice at 6-8 wks of age were used in all 
experiments. All animal experiments were approved by the Institutional Animal Care and Use 
Committee of the Children’s Hospital of Pittsburgh and were in compliance with the laws of the 
United States of America. High-fat diet (HFD) chow was purchased from Research Diets, Inc 
(New Brunswick, NJ). Mice were placed on either standard chow diet (n=12) or HFD chow 
consisting of 60% kCal fat (n=22) for 12 weeks. Mice were weighed weekly until the end of the 
experiment. MnTE-2 catalytic antioxidant (CA) was a generous gift from James Crapo, MD at 
National Jewish Health. CA was prepared as previously described (48) and used at 5 mg/kg 
subcutaneously every 3 days in all in vivo experiments.  
4.3.2 Comprehensive diagnostic panel 
At 12 weeks of chow, blood samples were collected from each mouse for toxicity profiling using 
a VetScan Comprehensive Diagnostic Profile with a VetScan Chemistry Analyzer (Abaxis, 
Union City, CA). Liver, kidney, and pancreatic dysfunction were tested through evaluation of 
alanine aminotransferase (ALT), albumin (ALB), alkaline phosphatase (431), amylase (649), 
calcium (Ca), creatinine, globulin (GLOB), phosphorus, potassium, sodium (Na), total bilirubin, 
total serum protein (TP), and blood urea nitrogen levels. 
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4.3.3 10-week IPGTT 
A 20% glucose solution (2.0 g/kg) was intraperitoneally administered to fasted mice at 10 weeks 
of HFD feeding. Blood samples were collected at 0, 30, 60, 90 and 120 min after glucose 
injection. Blood glucose levels were measured using a glucometer (Ascensia Breeze 2, Bayer). 
4.3.4 Serum adipokine measurement 
Fasting serum insulin and leptin was evaluated at 5 weeks, 10 weeks, and 12 weeks. Blood 
samples were collected and serum adipokines were determined by a Milliplex Mouse Serum 
Adipokine Panel, according to manufacturer’s instructions (Millipore, Billerica, MA). 
4.3.5 Liver and fat histology 
Liver and adipose tissue of sacrificed animals were harvested, fixed in 10% formalin, and 
embedded in paraffin. Cut paraffin sections were stained with hematoxylin, eosin, an IL-6 
antibody or an F4/80 antibody (Abcam, Cambridge, MA). Sections were visualized via an 
Axioplan 2 microscope (Zeiss). Digital images (n=3-4) were acquired from each slide using a 
20X objective with at least 3 mice/group. Staining was quantified via MetaMorph (Molecular 
Devices, Sunnyvale, CA). Results are expressed as percent of positively stained area/total 
measured area. 
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4.3.6 Statistical analysis 
The difference between mean values was assessed by Student’s t test, with p<0.05 considered 
significant. All experiments were performed on at least 6 mice/group. Outliers were excluded 
from final result calculations. Data are mean ± SEM.  
4.4 RESULTS 
4.4.1 Redox modulation delays early weight gain in HFD-fed mice 
Historically, high-fat diet fed mice gain weight exponentially over time (729), making this a 
good model for studying type 2 diabetes. HFD mice did gain weight as expected; however, at 
early time points (5 weeks) following the onset of HFD chow, CA treatment significantly 
reduced weight gain (Figure 38A). Standard chow fed mice, termed ‘Lean’ and ‘Lean+CA’, 
exhibited no difference in weight gain, but remained lighter than their HFD fed counterparts. 
Weight gain past 5 weeks did not vary between HFD and HFD+CA treated mice or Lean and 
Lean+CA treated mice (data not shown). By the end of the study after 12 weeks of chow, no 
significant differences were detected in the weights of HFD and HFD+CA treated mice (Figure 
38B). These data indicate that early onset of obesity is delayed upon redox modulation; however, 
elongated high calorie intake and subsequent weight gain are not altered with CA treatment. 
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Figure 38: CA treatment delays early-onset obesity in HFD-fed mice. (A) Over 5 weeks of 
chow administration, weights were measured for HFD, HFD+CA, Lean, and Lean+CA treated 
mice. n=6-11 mice/group. *p<0.05, **p<0.005. (B) At the conclusion of the study (12 weeks), 
mice were weighed. Data from n=5-6 mice/group are displayed as averages +/- SEM. p values 
less than 0.05 are considered significant. NS = not significant. 
4.4.2 Redox modulation does not promote hepatotoxicity, nephrotoxicity, or pancreatic 
 toxicity 
To confirm that CA treatment does not harm liver, kidney, or pancreatic health during HFD 
administration, a comprehensive diagnostic profile was conducted on each mouse group. All 
mice were measured for each analyte, but only those demonstrating significant differences are 
listed in Table 1. No differences were seen amongst all groups in phosphorus, potassium, total 
bilirubin, creatinine and blood urea nitrogen levels. Overall, HFD chow enhanced the amount of 
each analyte tested in comparison to Lean mice. However, CA treatment did not augment HFD-
mediated levels or impart toxicity in either group. The only analyte significantly increased after 
HFD+CA treatment was sodium (Na); however, the escalation was not substantial in comparison 
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to Lean or Lean+CA sodium levels (data not shown), indicating that metalloporphyrin in 
conjunction with high fat may affect salt concentration. CA administration also significantly 
increased albumin in Lean+CA treated mice compared to Lean mice, although the values of 
albumin did not exceed those detected in HFD fed mice. Moreover, redox modulation enhanced 
alkaline phosphatase levels in Lean+CA treated mice compared to Lean mice. HFD+CA treated 
mice also displayed increased alkaline phosphatase levels compared to HFD mice, though they 
did not reach statistical significance and have not been included in this table. CA may be 
elevating ALP in the blood by unknown mechanisms, but treatment did not consistently increase 
ALT or total bilirubin, which are often used as secondary tests for monitoring liver dysfunction. 
Therefore, HFD chow did boost levels of analytes to levels typically detected in obesity, but CA 
treatment did not synergize to cause major hepatotoxicity, nephrotoxicity, or pancreatic toxicity, 
making it a safe therapeutic strategy in the HFD model. We are confident that the delay in weight 
gain from CA treatment (Figure 38A) in the HFD+CA group was not a result of toxicity, but 
instead a true effect of therapeutic efficacy. 
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Table 1: CA treatment does not cause toxicity. Blood was collected from each mouse at the 
end of 12 weeks of chow administration. Blood was utilized in a comprehensive diagnostic 
profile using a VetScan Chemistry Analyzer. Data table includes only those values 
demonstrating significant differences. ALB = albumin, ALP = alkaline phosphatase, ALT = 
alanine aminotransferase, AMY = amylase, Ca = calcium, Na = sodium, TP = serum total 
protein, GLOB = immunoglobulin. g/dL = grams/deciliter; U/L = units/liter; mg/dL = 
milligrams/deciliter; mmol/L = millimoles/liter. n=5-6 mice/group. p values less than 0.05 are 
considered significant. 
4.4.3 CA treatment reduces fasting blood glucose levels, but does not improve 
 postprandial glucose tolerance 
After 10 weeks of HFD chow, fasting blood glucose levels were measured for all mouse groups. 
HFD+CA treatment statistically decreased fasting blood sugar in comparison to HFD mice 
(p<0.05) (Figure 39A). Lean mice with or without treatment did not vary in their blood glucose 
levels, whereas both HFD fed groups exhibited higher blood glucose levels in comparison to 
Lean and Lean+CA treated mice. Although fasting glycemia was reduced after CA treatment, 
redox modulation did not alleviate glucose intolerance in HFD mice during an IPGTT (Figure 
39B). Lean and Lean+CA treated mice normalized blood glucose levels by 120 min post-glucose 
challenge, whereas HFD and HFD+CA treated mice failed to normalize. Therefore, fasting blood 
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glucose is alleviated after redox modulation, but postprandial glucose tolerance does not improve 
after CA treatment. 
 
 
Figure 39: CA treatment improves fasting but not postprandial blood glucose levels. (A) At 
10 weeks of chow administration, mice were fasted overnight, and blood glucose was measured. 
(B) Mice were administered 2.5 g/kg glucose solution intraperitoneally. Every 30 minutes, blood 
glucose was measured until 120 minutes post-glucose challenge. n=3-4 mice/group, *p<0.05, 
***p<0.0005. 
 
4.4.4 Fasting leptin and insulin levels are reduced following CA treatment 
The serum adipokines leptin and insulin were measured after overnight fasting at different time 
points during the 12 week chow comparison. CA treatment significantly reduced fasting leptin 
levels in HFD mice at 5 weeks (Figure 40A). Leptin is an important hormone for regulating 
appetite. Furthermore, leptin resistance has been associated with obesity, resulting in greater 
serum leptin levels and a decreased satiated feeling (730; 731). These observations are consistent 
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with the weight gain delay detected in HFD+CA treated mice (Figure 38A), suggesting that 
lower leptin resistance may obviate polyphagia during early obesity onset. Serum insulin levels 
were also measured after fasting. At 10 and 12 weeks, redox modulation significantly reduced 
insulin levels in comparison to HFD mice (p<0.05) (Figure 40B), indicating improved insulin 
sensitivity despite postprandial glucose intolerance detected above (Figure 39B).  
Figure 40: Adipokine levels were reduced in HFD mice administered CA treatment. Mice 
were fasted overnight at 5, 10, and 12 weeks, and serum was collected from each mouse. (A) 
Leptin and (B) insulin were measured via an adipokine panel. Data obtained in triplicate for n=5-
6 mice/group. *p<0.05, **p<0.005, ***p<0.0005. 
 
4.4.5 CA treatment reduces cellular infiltrate of adipose tissue in HFD mice 
Adipose tissue is a site of insulin-dependent glucose disposal. As adiposity increases, adipokine 
release is also enhanced, attracting macrophages into the adipose tissue. Immune cell infiltration 
leads to greater proinflammatory cytokine production and adipokine release, effectively 
worsening insulin resistance. Despite a lack of difference in weight at the end of the study, 
HFD+CA treated mice displayed a slight reduction in overall visual obesity in comparison to 
HFD mice (Figure 41A). Furthermore, CA treatment was able to reduce infiltration into the 
adipose in comparison to untreated HFD mice (Figure 41B). Accumulation decreases in the 
adipose may contribute to the lower insulin levels detected in HFD+CA mice (Figure 40B). 
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Moreover, CA treatment has previously been reported to significantly reduce MCP-1, IFNγ, and 
TNFα (48; 64; 79; 644), which serve to attract and activate macrophages. In the HFD model of 
type 2 diabetes, similar mechanisms may be occurring following redox modulation. 
Figure 41: CA treatment reduces immune cell infiltration in the adipose tissue. (A) Upon 
sacrifice, mice were photographed to visualize obesity. (B) Visceral fat was removed from each 
mouse, fixed in 10% formalin, and embedded in paraffin. Fat sections were cut at 0.7 µm and 
stained with hematoxylin and eosin (H&E). Sections were visualized with a 20X objective. 
Histology representative of 5-6 mice/group. 
 
4.4.6 Redox modulation reduces liver steatosis in HFD mice 
Liver, the site of gluconeogenesis and glycogen storage, regulates hepatic glucose production. 
Insulin inhibits the release of FFA from adipocytes. In the context of insulin resistance, lipolysis 
from the adipose tissue liberates FFA, which can then be stored in peripheral sites, such as the 
liver, causing steatosis or fatty liver. Immediately after sacrifice, liver was weighed from all 
mouse groups. CA treatment significantly reduced liver weights in comparison to untreated HFD 
mice (Figure 42A). Lean and Lean+CA liver weights were both decreased compared to HFD fed 
mice, although CA treatment also significantly reduced Lean liver weights in comparison to 
untreated Lean mice. Liver sections were also visualized for fat droplets by H&E staining. CA 
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treatment diminished fat accumulation in HFD mouse livers in comparison to untreated HFD 
mice (Figure 42B). Sections of Lean and Lean+CA did not display significant differences in fat 
droplets by microscopy. Instead, lowered liver weights in Lean+CA treated mice suggests that 
redox modulation not only lowers liver steatosis but may also reduce other accessory cell 
infiltrate; however, reduced weight was not due to liver dysfunction or disease, as no toxicity 
was detected in any mouse group (Table 1). 
Figure 42: Liver steatosis is diminished following CA treatment of HFD mice. (A) After 
sacrifice at 12 weeks, livers were removed and weighed. n=3-4 mice/group, *p<0.05, 
**p<0.005, ***p<0.0005. (B) Livers were fixed in 10% formalin, embedded in paraffin, and 0.5 
µm sections were stained with H&E. Sections were visualized with a 20X objective. Histology 
representative of 3-4 mice/group. 
 
4.4.7 CA administration enhances liver IL-6 production coincident with macrophage 
 infiltrate in HFD mice 
IL-6 is thought to contribute to the inflammatory environment that promotes insulin resistance in 
type 2 diabetes, although IL-6 has also been characterized as a necessary cytokine for the acute 
phase response, which helps to resolve tissue damage and assuage insulin resistance (337). After 
12 weeks of HFD administration, CA treatment augmented liver IL-6 production in comparison 
to untreated HFD mice (Figure 43). Notably, IL-6 was also enhanced in Lean+CA treated mice 
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compared to HFD mice. Conversely, no differences were detected in Lean versus Lean+CA 
treated mice. These data indicate a positive role for IL-6 after redox modulation in both HFD and 
Lean mice. IL-6 may correlate with the lower fasting blood glucose, fasting serum insulin, 
adipose infiltrate, and liver steatosis in HFD+CA treated mice. 
Figure 43: Liver IL-6 is augmented in CA treated mice. (A) After sacrifice at 12 weeks, livers 
were fixed in 10% formalin, embedded in paraffin, and 0.5 µm sections were stained with IL-6 
and counterstained with hematoxylin. Sections were visualized with a 20X objective. Histology 
representative of 3-4 mice/group. (B) Quantification of %IL-6/total measured area from n=3 
images/mouse/group. *p<0.05. 
 
 
In correlation with IL-6 levels, macrophage infiltrate into the liver was determined by 
F4/80 histological staining. CA-treated Lean and HFD mice exhibited the highest amounts of 
macrophage infiltrate compared to untreated animals (Figure 44). Macrophages are a known 
source of IL-6 production, making them a plausible candidate for the enhanced IL-6 production 
following CA treatment (Figure 43). Additionally, hepatocytes can also produce IL-6 to instigate 
tissue repair. The contribution of both cell types may synergize to reduce liver steatosis and 
fasting blood glucose levels. 
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Figure 44: Macrophage infiltrate into the liver is enhanced following CA treatment. After 
sacrifice at 12 weeks, livers were fixed in 10% formalin, embedded in paraffin, and 0.5 µm 
sections were stained with F4/80 and counterstained with hematoxylin. Sections were visualized 
with a 20X objective. Histology representative of 3-4 mice/group. 
 
4.5 DISCUSSION 
Obesity-induced type 2 diabetes and its complications are a widespread problem amongst U.S. 
individuals as well as a cost burden on the healthcare economy. Treatment options to reduce the 
risk of insulin resistance and/or diabetic complications are of major importance. During the 
course of chronic high fat intake, glycemic control may fail as a result of compounded peripheral 
insulin resistance. The mechanisms triggering insulin resistance include oxidative stress and 
inflammatory-mediated cellular infiltrate, signaling defects, and reduced glucose uptake. 
Specifically, the liver and adipose tissue are two sights of abnormal lipid deposition and immune 
cell infiltrate. We sought to determine whether redox modulation using a metalloporphyrin 
catalytic antioxidant could assuage liver and adipose complications as well as enhance insulin 
sensitivity and glucose tolerance. 
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Early in the course of HFD chow administration, CA treatment was able to delay weight 
gain in comparison to untreated mice. This result was not due to toxicity of the CA, as multiple 
diagnostic parameters displayed no hepatoxicity, nephrotoxicity, or pancreatic toxicity. 
However, leptin levels were also reduced in redox modulated HFD mice after 5 weeks of chow. 
In order to signal to the body that satiety has been met, leptin signals through leptin receptor on 
neuronal tissues, regulating appetite and body weight. In obesity-induced type 2 diabetes, leptin 
signaling is thought to be defective, mimicking what occurs with insulin resistance. Specifically, 
leptin signals through PI3K, like insulin, and oxidative stress-mediated inhibition of this pathway 
may contribute to leptin resistance (732). Additionally, ROS can decrease IRS protein levels 
after chronic exposure (716), and deletion of IRS2 resulted in leptin resistance in a mouse model 
(733). Under fasting conditions, elevated serum leptin levels are proportional to the mass of 
adipose tissue and indicate obesity-induced leptin resistance (734; 735). Therefore, our treatment 
can delay weight gain early after chow administration, potentially as a result of lowered leptin 
concentrations.  
Notably, redox modulation was able to reduce fasting blood glucose levels, but could not 
alter glucose intolerance during an IPGTT. This result is in line with early type 2 diabetes 
development, where normoglycemia is detected under fasting conditions, but postprandial 
hyperglycemia manifests (700). Although the IPGTT was conducted at 10 weeks post chow 
administration, a delay in type 2 diabetes is likely based on the delay in weight gain and leptin 
resistance detected early in the course of CA treatment. Additionally, fasting serum insulin levels 
were significantly decreased in CA-treated HFD mice at both 10 and 12 weeks. Despite the 
failed glucose tolerance test, redox modulation was able to maintain insulin sensitivity in HFD 
mice. This regulation may be due to (A) an inhibition of stress kinases such as JNK, which 
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would improve insulin signaling; (B) a reduction in proinflammatory cytokine production; and/or 
(C) a decrease in beta cell mitochondrial dysfunction. We previously demonstrated that CA 
diminishes TNFα, and MCP-1 levels through the inactivation of NF-κB (48; 64; 79). 
Furthermore, CA can improve glucose metabolism (Figure 34) by reducing ROS damage of 
mitochondrial enzymes and thereby enhance the efficiency of the TCA cycle. All of these 
improvements would allow for both healthier beta cell function and better insulin signaling, 
ultimately lowering hyperinsulinemia in HFD mice. 
The generation of greater adipose tissue causes the secretion of more proinflammatory 
adipokines, and macrophage infiltration into the adipose tissue increases with the severity of 
obesity (736). MCP-1, for example, is significantly increased in adipose and in circulation 
following HFD-induced obesity (737). This chemokine serves to attract macrophages into the 
adipose and under conditions of adipocyte stress and necrosis, macrophages display a ‘crown’ 
arrangement surrounding fat cells, suggesting increased phagocytic activity towards dying cells 
(738). Moreover, depletion of TH1 CD4+ cells or CD8+ cells ameloriates systemic insulin 
resistance by decreasing macrophage infiltration into adipose tissue (503; 505). CA has 
previously been shown to not only decrease MCP-1, but also reduce CD4 T cell proliferation and 
IFNγ secretion (644), which is known to trigger macrophage activation. The reduction of 
infiltrate detected in the fat of HFD+CA treated mice may therefore result from diminished 
chemoattractant and/or accessory cell-mediated macrophage localization and activation. 
As adipose expands, an increase in FFA release can instigate peripheral accumulation in 
the liver. In correlation with reduced infiltrate into the adipose, CA treatment may reduce the 
stress and MCP-1 secretion from the adipose, which in turn, would diminish lipolysis and hepatic 
steatosis in comparison to untreated HFD mice (737). Fat deposition in the liver can be attributed 
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to several mechanisms. One known regulator liver triglycerides is sirtuin 6 (SIRT6). In human 
fatty livers, SIRT6 levels are low (739), indicating a need for this molecule to decrease fat 
accumulation. Similarly, signaling through JNK1 is able to protect against liver steatosis (740). 
An accretion of long-chain polyunsaturated fatty acids within the liver is known to regulate the 
metabolism of lipids, and in steatosis, these beneficial fatty acids are also down, causing a 
reduction in beta oxidation as well as Glut4 receptor expression (741). Hepatic SREBP-1c is 
responsible for lipogenesis, and in both mouse models of obesity and human patients, SREBP-1c 
expression is increased (742; 743). Additionally, the buildup of FFA in the liver, through either 
lipogenesis or adipocyte lipolysis, stimulates ROS production and mitochondrial dysfunction, 
further promoting systemic insulin resistance (744). All of these factors are possible targets of 
redox modulation and delineating their involvement in reducing steatosis will be investigated in 
future studies. 
Our most intriguing observation in this study was the augmentation of IL-6 production in 
CA-treated HFD and Lean mice. Although IL-6 is thought to be detrimental by feeding in to the 
inflammatory environment during insulin resistance, other studies also indicate a beneficial role 
for the cytokine. IL-6-/- mice, for example, spontaneously become obese (496), and ablation of 
IL-6 in the liver exacerbates obesity-induced insulin resistance (745). As a possible mechanism 
of these results and our observations, IL-6 contributes to the acute phase response (746) for 
wound healing (746). NF-κB-dependent cytokines, such as IL-1β, IL-6, and TNFα, constitute the 
APR (747), which helps to resolve inflammation by driving tissue repair as well as hepatocyte 
growth factor (HGF) production. HGF mimics insulin signaling through PI3K-Akt activation and 
suppresses NF-κB activation through GSK3β inactivation (748; 749). HGF is therefore a potent 
anti-inflammatory molecule. Our group has demonstrated that IL-6 can induce HGF for 
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resolution of inflammation (337), suggesting its protective role for liver repair after 
hyperglycemia and lipid accumulation in type 2 diabetes. Moreover, IL-6 is thought to regulate 
secretion of glucagon-like peptide-1 (GLP-1), a digestive protein necessary for stimulating beta 
cell insulin secretion. In obesity, IL-6 enhances GLP-1, which in turn augments insulin secretion 
to try and prevent diabetes onset (750). A fine balance of IL-6 can therefore suppress hepatic 
inflammation and improve systemic insulin sensitivity. The relative production of IL-6 from both 
hepatocytes and F4/80+ macrophages will need to be further investigated to determine the 
dominant source in CA-treated HFD livers. IL-6 elevation upon redox modulation of HFD fed 
mice may then correlate with the early acute phase response, essentially attempting to restore 
liver functionality and delaying fulminant diabetes onset.  
Antioxidant administration is warranted as a means of reducing inflammation and 
secondary oxidative stress for control of type 2 diabetes pathology and complications. 
Regulating inflammation is thought to benefit insulin-stimulated glucose uptake at peripheral 
sites. High-density lipoprotein (HDL) (“good cholesterol”) and glutathione, both of which have 
inherent antioxidant properties, are impaired in type 2 diabetes (751-754). These results highlight 
the importance of reinstating antioxidant levels for control of blood glucose and prevention of 
diabetic complications. Antioxidants such as resveratrol, inhibit NF-κB activation in adipocytes, 
whereas epigallocatechin gallate, an antioxidant found in green tea, enhances glucose uptake in 
adipose tissue (755). Moreover, salsalate treatment, a form of salicylate, improves glucose 
tolerance, and reduces circulating FFA through inhibition of NF-κB (756). Antioxidant 
administration can not only improve insulin sensitivity, but can also delay or decrease diabetic 
complications. HDL, as mentioned above, can act as an antioxidant and anti-inflammatory, 
preventing diabetes-induced atherosclerosis (752). Indirect elevation of HDL, through the usage 
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of statins, is a potential therapy for reducing risk of long-term complications (757). Similarly, 
administration of exogenous glutathione was able to reduce ICAM-1 levels, an important 
endothelial marker of inflammation, and subsequently, lower vascular complications (758). 
Evidence suggests that scavenging ROS, through the usage of Vitamin E for example, is not 
potent enough to impede diabetic complications; instead, SOD and/or catalase mimics hold more 
potential for improving mitochondrial function and lowering DNA damage in the context of type 
2 diabetes (759), justifying the use of CA treatment.  
 Through redox modulation of HFD mice, we observed delayed obesity and reductions in 
fasting blood glucose, insulin, and leptin levels. Furthermore, liver and adipose lipid 
accumulation and cellular infiltrate, respectively, were also decreased after CA treatment, 
indicating greater systemic insulin sensitivity and lowered inflammation. Augmented IL-6 
production in the liver is a potential mechanism of redox-modulated steatosis prevention and 
may be a direct consequence of the acute phase response. CA treatment is therefore a potential 
therapeutic strategy for impeding type 2 diabetes pathogenesis and reducing chronic diabetic side 
effects. 
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5.0  CONCLUSIONS AND FUTURE DIRECTIONS 
5.1 CONCLUSIONS 
An imbalance of ROS and antioxidant levels generates oxidative stress. In autoimmune type 1 
diabetes and obesity-induced type 2 diabetes, high ROS triggers heightened proinflammatory 
responses, which can manifest into beta cell dysfunction or ablation. To first test whether control 
of ROS can overcome self-reactivity, a catalytic antioxidant was used in diabetogenic murine 
models. Specifically, CA was able to delay type 1 diabetes onset through blocking TH1 
responses. The mechanism of CA-mediated regulation involved reducing activation of TACE, a 
redox-dependent metalloprotease found in immune cells. Subsequently, the TACE ligand, LAG-
3, displayed decreased shedding from CD4+ T cells. As a negative regulator of T cell activation, 
the retention of LAG-3 was then able to inhibit autoreactive T cell stimulation and effector 
function, contributing to the delayed diabetes observation. Moreover, soluble LAG-3 can be 
utilized as a serum biomarker of diabetes progression in mice. Soluble LAG-3 may also serve as 
a biomarker of disease risk in first-degree relatives of type 1 diabetes patients a priori of 
autoantibody detection.  
The effects of CA on immune cell metabolism were next assessed to identify a second 
layer of autoreactive regulation and to better understand the limitation of redox modulation. CA 
treatment prevented uncoupled respiration of diabetogenic splenocytes, resulting in lowered 
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experimental oxidative phosphorylation. Additionally, aerobic glycolysis, often utilized by tumor 
cells and termed the ‘Warburg effect’, was also reduced following CA treatment. These 
observations suggested improved metabolic efficiency, yet no enhancement of autoreactive 
immune cell activation, contributing to weakened diabetogenic potential. Importantly, CA 
treatment does not impart long-term side effects, as the inactivation of immune cells was 
reversible.  
The ability of CA to affect metabolism led to a deviation from autoimmunity and 
experimentation in a high-fat diet model of type 2 diabetes. As a final objective, redox 
modulation of obesity-induced inflammation, insulin resistance, and diabetic complications was 
characterized. CA treatment delayed early weight gain in correlation with reduced serum leptin 
levels. Additionally, CA effectively lowered fasting insulin and blood glucose levels throughout 
the course of the study; however, this effect was not sustained postprandially. Redox modulation 
did decrease liver steatosis and immune cell infiltrate into adipose tissue. Notably, IL-6 was 
enhanced in the liver after CA treatment. This result is likely attributed to an increase in the acute 
phase response for liver repair, suggesting an overall delay in the chronic damage observed with 
a loss of glucose tolerance. 
Overall, CA can impair autoreactive immune cell activation through (1) reduced 
metalloprotease-dependent shedding of LAG-3; (2) decreased bioenergetics and subsequent 
metabolic quiescence; and (3) from previous studies, inhibition of NF-κB activation. Effects on 
oxidative stress and inflammation in autoimmunity transcend into alleviation of insulin 
resistance and glucose tolerance in non-autoimmune type 2 diabetes. Therefore, redox 
modulation can affect cellular function through immunomodulatory, anti-inflammatory, and 
cytoprotective pathways, which culminate with negative regulation of Warburg effect 
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characteristics. This opens up redox modulation as a potential therapeutic for those pathological 
conditions that have an inflammatory component, such as type 1 and type 2 diabetes. 
5.2 FUTURE DIRECTIONS 
Several future studies will need to be conducted in order to further develop the work of this 
thesis project. As a follow-up to Chapter 2, the importance of LAG-3 signaling in T cells and on 
APC activation will be deduced. LAG-3-/- mice are currently housed at the University of 
Pittsburgh animal facility. As expected, in vitro stimulation of these splenocytes and in vivo 
immunization of these mice results in enhanced TH1 responses (Figure 45). Delineation of the 
signaling cascade downstream of LAG-3 will enable a better understanding of the molecule’s 
role in prevention of T cell activation and will allow for establishment of targeted molecular 
agonists (or antagonists, for chronic infection and cancer). Moreover, the importance of soluble 
LAG-3 in APC activation is also currently undefined. Surface LAG-3 interaction with MHC 
class II will stimulate ERK-mediated SHP-1 recruitment and inhibit DC activation (371). 
However, studies using non-physiological sLAG-3, such as recombinant fusion sLAG-3 or 
LAG-3-Ig, demonstrate activation of DCs (760-762). Therefore, delineating the physiological 
role of sLAG-3 is necessary. Experiments utilizing bone marrow-derived macrophages and 
dendritic cells in transwell cocultures with LAG-3-/- or WT T cells may facilitate greater 
comprehension of this biological mechanism. To definitively assess the ability of soluble LAG-3 
to serve as a biomarker for type 1 diabetes risk in first-degree relatives, greater numbers of 
human serum samples need to be obtained and tested. Furthermore, correlations between the 
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number of autoantibodies and soluble LAG-3 levels must be concretely established in a larger 
sampling population. 
For the metabolic studies in Chapter 3, more work needs to be done to verify the 
enhanced efficiency of the TCA cycle following CA treatment. Enzymes important for glucose 
metabolism, such as aconitase, may first be measured. NADPH and glutathione levels can also 
be quantified to determine any deviation towards the pentose phosphate pathway after CA 
administration. Other experiments that should be incorporated into this project are a full-body 
glucose uptake study using a PET scan, for assessing global glucose metabolism efficiency, and 
measurement of ATP levels, to characterize final energy output. These studies would augment 
evidence of metabolic quiescence. Reversal of the effects imparted by CA treatment was 
demonstrated by both a recovery of IFNγ secretion and diabetes onset after CA administration 
was stopped. Short-term CA treatment may thus reset immune cell homeostasis, necessitating 
long-term use of the agent or a combinatorial therapy approach for complete autoreactive 
prevention. A range of other agents, such as rapamycin, will be administered along with CA to 
define appropriate kinetics, duration, and long-term outcomes in protection from type 1 diabetes. 
The high-fat diet study reported in Chapter 4 requires the most persistence to confirm the 
mechanisms behind the observed results. First, the enhanced IL-6 after CA treatment needs to be 
attributed to the hepatocytes and/or macrophages. Co-immunostaining will be conducted on liver 
sections. Liver lysates must also be tested for: 1) anti-inflammatory HGF levels, as IL-6 is 
known to increase HGF for tissue repair, reconciling the contradictory cytokine augmentation 
and 2) the PI3K-Akt pathway constituents, as insulin signaling and sensitivity relies on these 
specific molecules. In addition, another HFD vs. HFD+CA study is currently underway, and the 
same outputs will be measured as above. However, several other experiments will also be 
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performed prior to and after sacrifice. Most importantly, IPGTTs and an insulin tolerance test 
will be conducted. Although the IPGTT from Chapter 4 showed no improvement of glucose 
tolerance after CA treatment, a caveat exists in the measurement technique. Mice were initially 
injected with 2.0 g/kg of a glucose solution, causing a spike in blood glucose that was out of 
range (>600) of the glucometer. As a means of bypassing this restriction, glucose will be 
administered at a lower dose (1.0 g/kg). At 5 weeks of HFD chow, the new dose of glucose 
exhibited measurable differences in HFD vs. HFD+CA mice (Figure 46), which correlates better 
with the reduced fasting blood glucose and insulin observed in Chapter 4. Moreover, an insulin 
tolerance test will be conducted to confirm enhanced insulin sensitivity after treatment. Before 
sacrifice, the difference in lean and fat mass will also be measured in these animals, as the total 
weight gain did not vary between groups in the reported findings. Total HDL (“good 
cholesterol”) will also be assessed from serum. Finally, insulin signaling with or without CA 
treatment will be studied more in-depth using HepG2 cells in culture. These experiments should 
illuminate observations and provide further support for the use of CA in type 2 diabetes 
treatment.  
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Figure 45: LAG-3-/- mice exhibit enhanced TH1 responses. (A) Whole cell lysates from B6 
WT vs. KO splenocytes stimulated with 1.0 µg/ml ConA for 72h were probed for LAG-3. (B) 
Splenocytes were stimulated with 1.0 µg/ml ConA, and supernatants were collected at 48-96h. 
IFNγ was measured by ELISA. n=2 independent experiments. (C) Spleens were harvested at 
homeostasis and cells were quantified by trypan blue exclusion. (D-E) Mice were immunized s.c. 
at the base of the tail with HEL in CFA. Draining inguinal lymph node cells were quantified and 
titrated in an IFNγ recall ELISPOT assay at 8 days post-immunization. n=3 mice/group. 
*p<0.05, ***p<0.0005. 
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Figure 46: Glucose tolerance is improved after CA treatment. An IPGTT was conducted on 
mice fed HFD or HFD+CA for 5 weeks. Mice were fasted overnight beforehand and serum was 
obtained at t=0 for basal glucose levels. Glucose was injected at a dose of 1.0 g/kg and blood 
glucose was measured every 30 min until 120 min post-glucose challenge. n=4 mice/group. 
*p<0.05, ***p<0.005. 
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